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Summary
G protein-coupled receptors (GPCRs) are a versatile family of eukaryotic membrane
spanning proteins that initiate cellular signal transduction. Usually, external ligands
of various types are binding to a GPCR and activating it. Thereby, the receptor can in-
tegrate external stimuli in a ligand-dependent manner such that multiple signal
transduction pathways are activated with different efficacies. This phenomenon
called ligand biased signaling is known for many receptors of the GPCR family. It re-
mains to be clarified to what extend the receptor contributes to signaling bias, and
which role the signaling network plays in its propagation and modification. As
GPCRs are targets of many established drugs, the knowledge of biased signaling is
promising to lead to the development of improved drugs.
In this study, I investigated the onset and propagation of biased signaling with theo-
retical and experimental approaches. A mathematical model was established based
on the recent understanding that ligand binding stabilizes distinct receptor conforma-
tions and thereby introduces bias in signaling. The model suggests that ligand bias
can occur due to conformation-dependent ligand binding efficacies and that
modifiers acting on allosteric binding sites additionally influence the ratio of these re-
ceptor conformations. Further experimental investigations of the onset of ligand bias
were conducted with a cell line stably expressing the human external calcium sensing
receptor (CaSR), that is known for its multifarious ligand binding and signaling. Us-
ing a FRET sensor of the intracellular G protein Gq, we observed its direct activation
upon CaSR stimulation with various ligands, a read-out at the very beginning of the
signaling cascade. In our real-time measurements we found several ligands initiating
G protein activity that closely resembles downstream signaling read-outs that were
described in literature about CaSR biased signaling. However, some ligands did not
show bias in our assays in contradiction to published results of downstream
read-outs. This indicates a modifying role of the signaling network downstream of
the receptor. We conducted simultaneous measurements of G protein activation and
intracellular calcium release in order to assess the dynamic co-activation of these two
signaling events. In these results, the Gq activity and intracellular calcium mobiliza-
tion show similar trends, but the precise co-variation of the signaling events depends
on the ligand combinations used. These observations indicate that biased signaling
results both from the receptor level and the downstream signaling network.
In summary, in this work advanced experimental tools and theoretical considerations
were combined to investigate the onset and propagation of ligand biased signaling.
This is a first step towards a deeper, network-level understanding of signal bias
which might enable the targeted design and application of biasing drugs in future.
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Nederlandse sammenvatting
G-eiwit gekoppelde receptoren (GPCR’s) zijn een veelzijdige familie van eukaryote
membraanoverspannende eiwitten die cellulaire signal transductie initieren.
Gewoonlijk binden liganden van verschillende type zich aan de GPCR en activeren
het. Bovendien kan de receptor, afhankelijk van de ligand, verscheidene externe stim-
uli integreren, zodat meerdere signal transductie routes worden geactiveerd met
verschillende doeltreffendheden. Dit fenomeen, dat vertekende ligand signalering ge-
noemd wordt, is bekend voor vele receptoren uit de GPCR familie. Desalnietemin
blijft het onduidelijk in hoeverre de receptor bijdraagt aan de signalerings verteken-
ing en welke rol het signalerings netwerk speelt in de vermeerdering en verandering
van de vertekening.
Omdat GPRC’s doelwitten zijn van vele gevestigde geneesmiddelen, is de kennis van
vertekende signalering veelbelovend voor de ontwikkeling van verbeterde medicij-
nen.
Ik heb in dit onderzoek gekeken naar de start en voortplanting van vertekende signa-
lering met zowel experimentele als theoretische technieken. Er is een wiskundig
model ontwikkeld, gebaseerd op de huidige kennis dat ligand binding verschillende
receptor configuraties stabiliseert en daarmee een vertekening introduceert in signa-
lering. Het model suggereert dat ligand vertekende signalering kan ontstaan door de
configuratie-specifieke ligand doeltreffendheden. Bovendien wordt de ratio van deze
configuraties beinvloed door modificeerders, die binden op de allosterische bindings
locaties.
Verder is er experimenteel onderzoek gedaan naar de start van de vertekende ligand
signalering met een cellijn die de menselijke externe calcium sensor receptor (CaSR)
stabiel tot expressie had. CaSR is bekend om zijn verscheidenheid betreffende ligand
binding en signalering. Gebruik makend van de FRET sensor van het tussencellulaire
G eiwit Gq, observeerden we dat het eiwit direct geactiveerd werd na CaSR stimuler-
ing met verschillende ligands. Dit is een read-out in het begin van de signaliserings
cascade.
In onze real-time metingen vonden we verschillende liganden die G eiwit activiteit
initieerden dat erg leek op stroomafwaardse read-outs die waren beschreven in de lit-
eratuur over vertekende CaSR signalering. Sommige ligands echter, in tegenstelling
met gepubliceerde resultaten, vertoonden geen vertekening in onze experimenten.
Dit geeft een indicatie dat het netwerk, stroomafwaards van de receptor, een modifi-
cerende rol heeft.
We deden simultane meetingen van G-eiwit activatie en tussen-cellulaire calcium
afgifte om de dynamische co-activatie van deze twee signaleringsgebeurtenissen te
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onderzoeken. In onze resultaten vertonen de Gq activatie en de tussen cellulaire cal-
cium mobilizatie vergelijkbare trends. De precieze co-variatie van de signaliserings
gebeurtenissen echter, hangt af van de gebruikte combinatie van ligands. Deze obser-
vaties indiceren dat vertekende signalering wordt veroorzaakt op zowel het receptor
niveau als in het stroomafwaardse signalerings netwerk.
Samenvattend werden voor dit werk geavanceerde experminentele technieken en
theoretische overwegingen gecombineerd om de start en voortplanting van vertek-
ende ligand signalering te onderzoeken. Dit is een eerste stap naar een dieper begrip
van vertekende ligand signalering op het niveau van het netwerk. Eventueel zal dit
in de toekomst het doelgerichte ontwerp en toepassing van medicijnen, die gebruik
maken van de vertekende ligand signalering, mogelijk maken.
vii
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CHAPTER1
General Introduction
1
1.1 G protein-coupled receptors are environmental
signal integrators
"No man is an island" is a famous quote of the 17th century poet John Donne. It ex-
presses the connections that every person encounters with his or her social environ-
ment. In a broader biological sense, we can adapt this quote to "no living organism
(or cell) is an island": a multitude of mechanisms have evolved that enable all organ-
isms – unicellulars and multicellulars alike – to communicate with their environment.
Such response mechanisms evolved because an appropriate reaction of an organism
to its surroundings is essential for its survival.
For us, humans, information about the environment is encoded in stimuli such as
sounds, light, temperature, tastes or smells. On a cellular scale, information is mostly
transmitted in chemical form - e.g. as hormones. Molecular processes facilitate
this exchange within and between cells. A cell carries out ‘signal transduction’
which includes the perception and integration of signals to initiate a reaction to the
cell’s current environment. Signal transduction describes how cells in multicellular
organisms exchange information and coordinate tasks. Signal transduction is realized
by interacting proteins, forming huge protein-protein interaction networks. Proteins
communicate with each other via a limited set of (dynamic) mechanisms, involving
complex formation and protein modification. The complexity of signal transduction,
therefore, emerges from the almost unlimited number of protein-protein interaction
combinations that are possible, given the fact that the signaling network of a human
easily involves hundreds to thousands of proteins [1].
Transmembrane proteins, receptors or channels, connect the outside of a cell with its
interior. Some of them are activated by external signals that induce changes in their
3D structure, a mechanism that triggers activation of intracellular proteins. Intracellu-
lar proteins then activate each other in sequences, involving branches, loops, and
feedbacks: networks. These activities are meant when we speak about ‘signal trans-
duction’, ‘signal integration’ or ‘signal processing’ of perceived signals. Finally, the
signals cause activation of downstream ‘response’ molecules, such as transcription
factors that regulate gene activity, ultimately controlling cellular functions, such as
motility, differentiation, proliferation or death [2]. In figure 1.1, such a ‘core’ signaling
pathway is depicted.
Characteristics of the GPCR family
For eukaryotes, one important class of membrane-spanning receptors is the family of
G protein-coupled receptors (GPCRs). A GPCR is characterized by a core structure
of seven trans-membrane α-helices (TMs) and interaction with heterotrimeric G
proteins. GPCRs can be activated by a plethora of signals, ranging from single
2
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Figure 1.1: Scheme of the core signaling pathway. A membrane spanning receptor acts as a sensor
for extracellular stimuli. Agonist binding induces its activation and the subsequent signal trans-
duction. In GPCR signaling, heterotrimeric G proteins or β-arrestins act as signal transducers. The
signal is amplified or modified in signal transduction cascades. Effector molecules, such as kinases or
transcription factors, finally induce the cellular responses. Adapted from [2].
photons, small molecules (like ions or amino acids) to larger peptides (like hormones
or neurotransmitters). The human genome encodes about 800 GPCRs [3]. Due to their
versatility, GPCRs play important roles in physiology [4]. Their diversity, ubiquitous
expression and function in physiology make them attractive for the pharmaceutical
industry; estimations of approved drugs that target GPCRs range from 25 - 30% [4, 5]
and the potential for drug discovery in this class of receptors is tremendous [6].
Human GPCRs can be classified in five main families according to their structure and
ligand binding characteristics [6]: Rhodopsin, Secretin, Adhesion, Glutamate and
Frizzled/Taste2. Members of these receptor families differ in the amino acid se-
quences of their extracellular N- and cytosolic C-termini. The cytosolic sites contain
docking sites for intracellular molecules and sites for modifications, such as phospho-
rylation. The N-termini are involved in extracellular ligand binding. Most
rhodopsin-like GPCRs have a short N-terminus and agonists bind to extracellular
loops of the transmembrane (TM) domain. The N-termini of the adhesion GPCRs are
however very long and diverse, with several binding domains for extracellular ma-
trix molecules. The extracellular domains of the secretin and glutamate-like receptors
are long as well and crucial for ligand interaction and receptor activation.
Glutamate-like receptors have a N-terminus that is folded into two domains, forming
a ligand binding cavity, called the Venus Flytrap (VFT) domain, due to its resem-
blance to the carnivorous plant. The ligand binding pocket in the VFT domain is
conserved within this family of GPCRs. The transmembrane domains contain the
binding sites that allow interaction with allosteric ligands [7].
Despite these differences, the shared structural motif of GPCRs is their core of seven
transmembrane helices. In addition, they show conserved sequence motifs across all
families [3, 8] and crystallographic investigations have revealed common conforma-
tional changes upon activation [9]. Conserved cysteine residues are thought to form
stabilizing disulfide bridges [3].
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It is now well established that GPCRs from the glutamate family are obligate dimers,
covalently linked by disulfide bridges in the VFT domain and by those close to
the TM domain [10]. Evidence exists that also receptors from other families form
functional dimers. Whether they do so in vivo is still highly debated [9, 11, 12];
especially since studies with truncated glutamate-like receptors indicate that a GPCR
monomer is sufficient to activate G proteins [13, 14]. Recent studies, largely based
on fluorescence and bioluminescence techniques, investigated GPCR dimerization
[12, 15–18]. Crystallographic studies discovered potential dimer interfaces in the
TM domains of chemokine and opioid receptors [19], supporting the evidence that
GPCRs form functional dimers [20]. Indeed, single molecule imaging revealed a
dynamic equilibrium between GPCR monomers and dimers [21, 22], displaying the
average lifetime of a rhodopsin-like GPCR dimer as well as the dimer-formation
kinetics. Receptor dimerization may impact the functions of a GPCRs, for example its
coupling to different G proteins [23, 24], and its signaling specificity, efficiency and
allosteric regulation[25–28]. To make things even more complex, heterodimers have
been shown to exist, suggesting GPCR crosstalk [27, 29].
Beyond ligand binding: receptor activation and G protein interaction
Recent advances in crystallography and of Förster Resonance Energy Transfer (FRET)
studies in live cells allow detailed insight into the receptor structure and kinetics of
ligand binding, receptor-G protein interaction and activation. Ligand binding appears
to induce conformational rearrangements of the transmembrane helices relative to
each other; as found by intramolecular FRET and by comparison of crystal structures
of ligand bound versus free receptors [30–34]. These studies also revealed that GPCRs
adopt multiple conformations, mainly in response to different agonists [35–38]. It is
thought that ligand binding influences the energy landscape of the receptor, as well
as its conformational variability at the intracellular side [39, 40].
On the cytoplasmic surface of rhodopsin-like GPCRs, an ‘ionic lock’ (formed by the
highly conserved E/DRY motif on transmembrane helix 3 (TM3) and a glutamate
residue on TM6) is ruptured during GPCR activation [34, 41]. This causes TM6 to
move closer to TM5, opening a cavity for G protein binding [33, 34]. These shifts from
inactive to active receptor conformations are fast, as determined by intramolecular
FRET studies, ranging from several tenths of milliseconds for the β1 adrenergic
receptor to about one second for the parathyroid hormone receptor (PTHR) [30, 31,
42]. The time constants for receptor activation are therefore receptor-type specific and
are even influenced by the ligand binding. For example, biphasic ligand binding has
been observed for the PTHR with a first, very fast interaction and a slower second
binding step, interpreted as binding to the N-terminus and to the receptor core,
respectively [43].
Serine/Threonine residues in the cytosolic C-terminus of GPCRs can be phosphory-
lated by protein kinase A and C (PKA and PKC, respectively) or G protein-coupled
4
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receptor kinases (GRKs). This modification recruits β-arrestins to the receptor [4].
Arrestin binding was believed to uncouple the receptor from G protein signaling, in-
duce receptor internalization, and subsequent signal desensitization. It has been
shown, however, that β-arrestins induce signal transduction themselves by acting as
scaffolds for other, G protein independent signaling molecules [44]. These alternative
signaling routes add up to the multifunctionality and interconnectivity of GPCR
signaling.
The hallmark of GPCRs is their ability to activate heterotrimeric G proteins with
the intracellular loops of their TM domains. G proteins have diverse functions
but a conserved structure, consisting of α- and βγ-subunits. The C-terminus of Gα
interacts with the binding pocket that is exposed by an active GPCR [33]. Other
structural features have also been identified as important for receptor-G protein
coupling and selectivity; for example, the intracellular loop 2 of the receptor [45–47].
Receptor-G protein interaction kinetics is very fast and occurs on a similar timescale
as receptor activation [48]. Whether G proteins ‘pre couple’ to receptors has not been
demonstrated unambiguously [32].
In an inactive heterotrimeric G protein, the subunits are in close proximity and the Gα
subunit is bound to GDP. Interactions with an active receptor induce conformational
changes in the C-terminus of Gα, resulting in a rotation of its α-helical domain and
the subsequent opening of the guanine binding pocket [33]. This causes the release
of the bound GDP and its replacement by GTP. Thus, the GPCR acts as a guanine
exchange factor (GEF). Next, the GTP-bound, active α-subunit and the βγ subunits
change conformations, or even dissociate. Activation timescales of several hundred
milliseconds were determined for Gs and Gi activation [4]. Both subunits are now
able to activate downstream signaling pathways. Finally, a Gα protein can return to
its inactive state when its GTP is hydrolyzed by a GTPase. When reassembled with
Gβγ subunits, it is ready for a new activation cycle.
The external calcium sensing receptor (CaSR)
In the early 1990s, a GPCR has been identified that functions as a key regulator
of whole-body, calcium homeostasis [49]. Termed after its primary physiological
target, extracellular calcium, (Ca2+)o, the calcium sensing receptor (CaSR) is primarily
expressed within the chief cells of the parathyroid glands. It gets activated at high
concentrations of (Ca2+)o and suppresses the secretion of the calcium-retaining,
parathyroid hormone (PTH), thereby maintaining the calcium concentrations in the
physiological range of 1.1 - 1.3 mM [50].
The CaSR belongs to the family of metabotropic glutamate receptors [49]; it is an
obligate dimer, coupled by cysteine residues of each monomer [51] and has large
extracellular domains that form VFT-like structures. At least three to five (Ca2+)o
binding sites are estimated by computational prediction studies, explaining the high
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cooperativity with Hill coefficients between 2 to 4 observed in various responses to
(Ca2+)o exposure [52].
Further studies revealed the expression of the CaSR in various tissues, some of those
are related to calcium regulation, e.g. kidney and intestines, and some not, e.g. liver,
blood vessels and breast [53, 54]. The CaSR is a multifaceted receptor, activated
by a broad range of ligands besides (Ca2+)o. External calcium-independent CaSR
activity is induced by di- and trivalent ions (Mg 2+, Sr2+, Gd3+), polyvalent cations
like poly-L-lysine, polyamines, and aminoclycoside antibiotics [54–56]. Allosteric
ligands can modify the affinity of the receptor for (Ca2+)o, examples are amino acids
and synthetic modifiers (calcimimetics and calcilytics). The CaSR therefore integrates
several metabolic signals [57–59].
Three families of heterotrimeric G proteins couple to the CaSR: Gαq, Gαi and
Gα12/13,[55]. Accordingly, signal transduction through different pathways occurs.
CaSR-induced Gαq activity results in the activation of the membrane-bound phospho-
lipase C (PLC), which in turn hydrolyses phosphoinositides into 1,4,5-tris-phosphate
(IP3) and diacyl glycerol, resulting in intracellular calcium (Ca2+)i mobilization, and
activation of protein kinase C (PKC) [60, 61]. Therefore, (Ca2+)i mobilization and IP3
accumulation are common signaling read-outs in CaSR activity studies.
PKC induces the phosphorylation of the threonine residue 888 (T888) in the cytoplas-
mic tail of the CaSR, thereby uncoupling the receptor from Gαq signaling [62]. It has
been shown that T888 phosphorylation is essential for the physiological CaSR func-
tion and influencing the dynamics of intracellular calcium oscillations[63, 64].
Another well-studied CaSR read-out is the phosphorylation of the extracellular-
signal-regulated kinase (ERK) 1/2. The underlying mitogen-activated protein kinase
cascade is induced presumably by converging Gαi and Gαq signaling [50], whereas it is
hypothesized that signaling through Gα12/13 influences the (Ca2+)i oscillation-pattern
in the presence of amino acids [65]. Cellular shape changes have been observed
after CaSR stimulation, termed ‘membrane ruffling’ [66], probably caused by Gα12/13-
mediated Rho GTPases and kinases that lead to rearrangements of the cytoskeleton
and formation of actin stress fibers [61].
The most common diseases associated with the CaSR are the hereditary familial
hypocalciuric hypercalcemia (FHH) and autosomal dominant hypocalcemia (ADH),
caused by loss- and gain-of-function mutations in the receptor, respectively [67]. Nev-
ertheless, reduced CaSR expression has been reported in parathyroid and colorectal
cancer, resulting in the loss of the growth-suppressing effects of high (Ca2+)o concen-
trations [50]. In breast cancer, however, the reverse is observed: an increased
expression and a switch in G protein coupling, from Gαi to Gαs. This switch results in
an elevated secretion of parathyroid hormone-related peptide (PTHrP), which is con-
sidered as a driving factor of metastasis [50]. Thus, the CaSR seems to play both
ontogenic and tumor suppressor roles, depending on its expression level in the target
tissue.
6
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1.2 Ligand biased signaling of GPCRs
The early view that GPCRs exist solely in an "on" or "off" state has been succeeded
by the current view that the receptors are in a dynamic equilibrium of different con-
formations [68, 69]. In this recent concept, ligands induce shifts in the conformation
equilibria and stabilize particular receptor conformations [36, 70–73]. Hereby, biases
in signal transduction correspond to the activation of downstream pathways to differ-
ent degrees in a ligand-combination dependent manner (figure A). This ‘ligand bias’
has been documented for several GPCRs, including the CaSR [70, 74–78].
The dynamic conformation-equilibrium concepts suggests that ‘biasing drugs’ can
improve efficacy and reduce side effects if they can specifically target the signaling
pathways associated to disease [79, 80]. Thus, understanding how ligand-ligand in-
teractions at the level of a GPCR bring about biased signaling has been recognized
as a major challenge in the search for novel drugs [81–83]. Agonist screenings have
revealed the biasing effects of clinically relevant compounds [84, 85], and pharmaco-
logic active compounds with modulated biasing effects were developed [86, 87].
Ligand bias is viewed as an intrinsic property of the receptor-ligand complex and has
been associated to the free energy landscape of a receptor, indicating the stabilization
of particular receptor conformations [88, 89]. Whether signal transduction bias is
solely attributable to a single GPCR is not clear however, perhaps some of the biases
are introduced downstream of GPCRs in the signaling cascade.
Intracellularly binding peptides and nanobodies can, in addition to external signals,
affect the coupling of GPCRs to signaling molecules (reviewed in [86]), indicating
that the intracellular state may be involved in ‘priming’ the cell to specific signaling
pathways and can modulate the biasing effects of extracellular ligands. Ligand bias is
therefore a complicated concept that we do not yet fully understand. With this thesis,
I hope to contribute to an improved understanding of the mechanisms associated
with ligand bias.
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Figure 1.2: Scheme of biased signaling exemplified for the activation of Gα and β-arrestin. A) A
neutral agonist induces GPCR-induced signaling to Gα and β-arrestin to similar degrees. Biasing
agonists, depicted in blue and in red, result in the preferred activation of one of the signal transducers.
B) Dose-response curves (left) and bias plots (right) are often used to compare and quantify the
biasing effects of different ligands.
1.3 Studying ligand biased signaling
In most studies, ligand bias is observed at the level of read-outs downstream of a
GPCR, such as the generation of second messengers, phosphorylation of signaling
proteins, changes in the cellular structure or receptor internalization [66, 90–92]. Thus,
the biasing effect of ligands is deduced from shifts in dose-response curves of these
signaling responses [80, 93, 94], for instance from bias plots [78] (figure 1.2B) .
Downstream read-outs are measured with various biochemical techniques, ranging
from enzyme and immunoassays to luminescence-based assays and fluorescent sen-
sors [95]. These methods are well established and applicable to a broad range of
cellular systems. However, the limitation is that these read-outs are located down-
stream in the signaling cascade. Therefore, they are influenced by intertwining
signaling pathways and do not solely reflect the bias induced at the initial signaling
steps, at the level of a single GPCR, but they rather report the integrated bias of the
interacting signaling network, including the receptor.
Imaging methods allow for the study of real-time signaling responses in single,
living cells [96]. This is advantageous for determining dynamic signaling events, for
example for oscillations and other temporal processes, such as transient activations or
subpopulation behaviors – that occur asynchronously across individual cells. These
responses are generally averaged out in population-based assays, and are therefore no
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longer observable when studying cell populations. Since "seeing is believing" ∗, these
optical techniques allow the direct study of protein-protein interactions, processes
occurring during receptor activation or downstream signal transduction. With current
techniques it is therefore possible to study responses to ligand binding directly at
the receptor, at the level of G protein activation or further downstream [31, 32, 48,
97, 98]. Time-resolved measurements additionally inform us about the kinetics of
(de-)activation processes in signaling and lifetimes of active signaling components;
important information needed to understand the underlying biological mechanisms
of signal transduction [99, 100].
Most of the above mentioned studies with single, living cells exploit Förster Reso-
nance Energy Transfer (FRET) based sensors. Described by Förster in the early
1950ies [101], FRET is nowadays an established, frequently-used tool in cell biology
[102]. The underlying concept of FRET is a non-radiative energy transfer from a
donor fluorophore to an acceptor fluorophore; this requires a close proximity (<10 Å)
of two fluorophores and labeling of the protein(-s) of interest [97, 103]. Since the exci-
tation spectrum of the acceptor overlaps with the emission spectrum of the donor
fluorophore, the acceptor emits light when it is excited by a donor via FRET [102,
103]. FRET is typically quantified by the ratio of acceptor and donor fluorescence [97].
With the development of fluorescent proteins with various excitation and emission
spectra, a palette of FRET-pairs with improved photophysical effects is available to-
day. Most commonly used variants rely on cyan and yellow fluorescent protein pairs
(CFP and YFP) [104, 105].
Stimulus-induced association and dissociation of signaling proteins can be studied by
FRET techniques, e.g. ligand-receptor interactions or G protein-receptor interactions
by intermolecular FRET [42, 43, 48]. Conformational changes in GPCRs or G proteins
upon activation can also be measured with (intramolecular) FRET [30, 31, 106, 107].
Therefore, we can assess biased signaling at various nodes throughout the signaling
network in single, living cells.
1.4 How mathematical models help in understanding
signal transduction
The study of cellular signal transduction has for a long time been limited to the iden-
tification and description of the associated molecules and processes; the emphasis
has not been on how they together give rise to functionality of the signaling
networks. The identification and descriptive approach was, and remains, very suc-
cessful: it brought us the knowledge about the connectivity of signaling networks
that we have today [1]. The resulting network diagrams are static, however, whereas
∗The title of a symposium of the European Molecular Biology Laboratories (EMBL), Heidelberg, in
October 2015.
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signal transduction is a highly dynamic process, consisting of temporal protein inter-
actions. The qualitative description of signaling molecules is therefore not sufficient
to understand dynamic signaling mechanisms. Similarly, we do not understand how
a radio is working by just naming its components [108]: likewise, biological systems
are clearly more than the sum of their parts [1].
Systems biology is shifting the focus towards an understanding of the behavior
of molecular systems over time, including the underlying mechanisms, and relies
heavily on mathematical models [109]. Systems biology is ideally suited to study the
dynamics of signaling networks in terms of interacting signaling proteins [110].
A mathematical model, based on established biological knowledge and tailored to
the research question of interest, can make predictions about the system behavior,
given specific conditions (in silico experiments), and aid in the design of new experi-
ments [111]. Ideally, quantitative, experimental data is then used to test if the model
represents the biology adequately. In a repetitive cycle, knowledge gained from the
experiments are ideally used to improve the predictive power of the model (see fig-
ure 1.3)[111]. Thereby, the mechanisms, involving protein-protein interactions, that
underlie system behavior, such as dynamic signal transduction by a specific pathway,
can be understood, including the effects of mutated proteins and external perturba-
tions, such as drugs, growth factors, cytokines, etc. More conceptual mathematical
models, in the absence of experimental data, can also provide insights into whether a
particular hypothesis is realistic or which system behavior can be expected.
Technological advances, for example in fluorescence microscopy, have made the
generation of time-resolved, quantitative data in the GPCR field feasible. Combined
with a systems approach, new insights into the complexity of GPCR signaling and
crosstalk can be gained, as illustrated by several examples, e.g.[112–114], indicating
the enormous potential for adjusted therapy and specified drugs on the basis of the
systems-biological understanding of biological processes [115, 116].
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Figure 1.3: Iterative cycle between experimental and theoretical approaches in systems biology.
By an iterative cycle of quantitative data generation, mathematical modeling, in silico predictions,
experimental validation and the design of new experiments, new insights into biological questions
and contradictory hypotheses are obtained. Important prerequisite is a close collaboration between
experimenters and theoreticians. Adapted from [111] by the department ‘Systems biology of signal
transduction’ of Prof. Dr. U. Klingmüller, DKFZ, Heidelberg, Germany.
1.5 Aim of this thesis
I have introduced GPCRs as versatile membrane receptors that are capable of signal
integration. Their multifarious ligand binding and different signaling conformations
allow for a variable activation of the downstream signaling pathways that they
connect to, known as ligand bias. Recent experimental techniques do allow for the
study of ligand bias and are believed to have great potential in the design of ‘biasing
drugs’. The limitation of those studies is that the measured signaling read-outs are
generally (far) downstream of the GPCRs of interest. It therefore remains unclear,
in most cases, whether the observed ligand bias of downstream signaling read-outs
can be attributed to the GPCR or, in addition or exclusively, to downstream signaling
processes. This is a complication when one thinks about designing biasing drugs for
GPCRs; perhaps those drugs should target downstream processes instead?
In this thesis, I report my studies on the occurrence of ligand bias at the level of a
GPCR, as well as downstream, with theoretical and experimental approaches. Part of
my work is motivated by recent results from crystallographic and kinetic studies
indicating that GPCRs can adopt several active, signaling conformations that are sta-
bilized by specific ligand combinations. I will show that a conformation-equilibrium
model of a GPCR can explain ligand bias at the level of the receptor (Chapter 2). I
used the CaSR, which is known to show biased signaling when exposed to different
agonists, to study ligand bias experimentally. Using advanced fluorescent mi-
croscopy techniques, I will show the biasing influence of several (allosteric) agonists
on CaSR-induced Gαq activation in single, living cells (Chapter 3). Gαq directly cou-
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ples to the CaSR and is therefore one of the closest read-outs of receptor activity that
one can use. My data shows similarities as well as differences to the biasing effects of
those CASR ligands described in literature that were observed in downstream
read-outs. To differentiate between CASR-induced and network-induced bias, I mea-
sured the propagation of signaling bias from Gαq activation to intracellular calcium
mobilization, using a second fluorescent reporter, R-GECO1 (Chapter 4). By simulta-
neously measuring these fluorescent read-outs, I found evidence that both the CASR
and the downstream signaling network determine ligand bias. I also review recent
systems biology approaches to signal transduction and how those can be applicable
in the GPCR field (Chapter 5), since in the GPCR field systems biology is not yet used
frequently. Finally, I discuss my findings in a broader context and propose that we
should view a single GPCR as a signaling network by itself (Chapter 6). I hope that
my thesis helps to further strengthen the concept of ligand bias by GPCR-activated
signaling network by offering a systems biology perspective.
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CHAPTER2
A conformation-equilibrium model captures ligand ligand
interactions and ligand biased signaling by G protein-coupled
receptors
In collaboration with:
Frank J. Bruggeman
Adapted from: FEBS Journal (2014), 281(20):4659-71
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Abstract
G protein-coupled receptors (GPCRs) are a versatile, important class of cell-surface
receptors. GPCRs occur in different conformations that exist in a dynamic ligand sen-
sitive equilibrium. These conformations vary in their affinities for intracellular sig-
naling proteins and initiate signaling via different intracellular routes. The binding
of extracellular ligands and allosteric ligand ligand interactions shift conformation
equilibria to cause biased signaling. Here, we present a mathematical model that de-
scribes the effects of ligands on the conformation equilibria of GPCRs. Our extended
Monod-Wyman-Changeux model describes the receptor as shifting between active
and inactive receptor conformations under the influence of extracellular ligands. For
each receptor conformation, the intracellular domain of the receptor can attain alter-
native domain conformations that differ in their affinity for intracellular signaling
proteins. At the extracellular domain, the model can accommodate different mecha-
nisms for allosteric ligand ligand interactions that induce shifts in receptor and do-
main conformation equilibria. We use the model to study ligand biased signaling and
how ligand affinity, ligand sensitivity, and maximal signaling output depend on al-
losteric ligand ligand interactions.
Keywords: G protein-coupled receptors; ligand biased signaling; MWC model; coop-
erativity; allostery
2.1 Introduction
Structural [117–119] and kinetic [120–122] studies indicate that GPCRs exist in an
equilibrium of different conformational states. Different intracellular signaling pro-
teins are activated by dedicated receptor conformations [119, 123]. Changes in
receptor-conformation abundances are triggered by the binding of extracellular lig-
ands. Conformation changes involve rearrangement of transmembrane helices [124,
125] that sensitise the cytoplasmic domain of the receptor for specific intracellular sig-
naling proteins. In this manner, bias is introduced to particular signaling routes [126–
128] by the binding of different ligands, their combinations, and allosteric
interactions [126, 129, 130].
The extracellular domains and ligand-binding pockets of GPCRs show a large vari-
ability in sequence and structure [131] indicating the great ligand variety across the
family of GPCRs. In contrast, the transmembrane domain and intracellular domain of
GPCRs is more conserved [132]. This suggests that the structural rearrangements in
the transmembrane and cytoplasmic domain during receptor activation likely follow
similar mechanisms across the family of GPCRs [133]. Therefore, a general model ex-
plaining ligand-induced conformational changes of GPCRs is a relevant problem to
address.
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Whether functional GPCRs occur in the plasma membrane as monomers, (hetero-
or homo-) dimers or even oligomers has been under discussion for a long time
[134]. Several studies support the view that functional GPCRs exist either as homo- or
heterodimers [135, 136] and that two GPCR monomers together form a binding pocket
for intracellular signaling proteins [137]. The binding of extracellular ligands and their
allosteric interactions can then induce conformational changes in the receptor that
trigger cooperative, (de-)stabilising monomer-monomer interactions or sensitisation
of the dimer to particular intracellular signaling proteins [137, 138].
The study of the kinetic properties of cooperative, oligomeric proteins, which exist in
different conformations and function at thermodynamic equilibrium, has a long his-
tory in biochemistry [139–142]. Such models are ideally suited to study signaling
receptors, such as GPCRs, that display shifts in conformation equilibria upon ligand
binding and that do not rely on free-energy input to display conformation changes
[141]; in contrast to, for instance, receptor tyrosine kinases and many transcription
factors that change to an active conformation upon phosphorylation. In the GPCR
field, mathematical models have been used to fit experimental data to assess ligand
affinity and allosteric ligand ligand interactions [143–145]. Those models are gener-
ally simplified representations of the conformation equilibria of GPCRs; the GPCRs
are not considered as dimers with different (global) receptor conformations and (lo-
cal) intracellular domain conformations. As a result, those models are of limited
applicability when used in combination with experimental methods that address the
relation between receptor structure, conformation dynamics, and function, such as is
currently done using NMR and crystallography [118, 146]. Thus,
conformation-equilibria models of GPCRs based on a more mechanistic description
of receptor-ligand interactions and shifts in conformation equilibria are becoming
more relevant.
Here we present a general model of the ligand-induced conformational changes of
GPCRs; it is an extension of the Monod-Wyman-Changeux (MWC) model [139]. The
model considers the GPCR as a dimer that exists in an equilibrium between global re-
ceptor conformations and local intracellular binding domain conformations. These
equilibria are influenced by ligand binding and allosteric ligand ligand interactions.
The model we present can accommodate a great variety of monomers that differ in
the number of ligand binding sites and allosteric ligand ligand and ligand-modifier
interactions. We study how this model accounts for ligand bias of active signaling
conformations in terms of their ligand affinity, ligand sensitivity, and maximal signal-
ing output.
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2.2 Results
A conformation-equilibria based mechanism of GPCR activity
Figure 2.1 shows the basic GPCR mechanism that we study in this paper. The GPCRs
are considered as homodimers. The model can be extended to deal with het-
erodimers, or even oligomers, but we do not consider this here. Each monomer has
an extracellular ligand-binding domain and an intracellular binding domain for
downstream signaling proteins. The extracellular binding domain can accommodate
binding of multiple identical or different ligands, with or without allosteric interac-
tions. The exact details depend on the GPCR of interest, but in principle the model
can accommodate all possible allosteric interaction diagrams. The intracellular do-
main is only functional if the monomer interacts with another monomer in a dimeric
complex. Accordingly, we limit this study to dimers. The intracellular binding do-
main of the dimer binds intracellular proteins, such as G-proteins or β-arrestins,
provided it is in the correct conformation.
G protein 
1
G protein 
2
extracellular space
cell membrane
cytosol
extracellular 
domain,
R-state
intracellular 
domain
monomer
dimer
ligand binding
domain
extracellular 
domain,
T-state
intracellular 
domain
Figure 2.1: A mechanism for GPCR-dimer activity. GPCRs can exist in various conformations that
differ in their affinity for downstream signaling proteins. We distinguish receptor conformations
(rectangular vs oval) of the entire GPCR dimer and domain conformations of the intracellular domain
(blue; circle or square). The domain conformations can occur for each receptor conformation and at
different relative concentrations. One of the receptor conformations is typically considered inactive,
the "tensed" T-state, such that all its domain conformations are not activating intracellular signaling
proteins. Whether G-proteins can bind to these conformations (as shown in the diagram) to give rise
to so-called "pre-complex formation" is unclear from existing experimental data. The other receptor
conformation, the "relaxed" R-state, is considered active with domain conformations that activate
different intracellular signaling routes (ligand biased signaling). Ligand-binding at the extracellular
binding domain introduces shifts in receptor and domain conformation equilibria to initiate and
modulate intracellular signaling, which is the basis of our model.
In the model, signaling by the receptor occurs because the binding of extracellular
ligands induces changes in the equilibria that exist between different active receptor
conformations. As a consequence, one or several conformation states increase in
abundance upon the binding of one ligand (at the expense of others). Subsequently,
the intracellular signaling proteins that have a high affinity for those states bind
preferentially and signaling is biased to the downstream networks that they connect to.
Thus, this mechanism naturally leads to ligand bias. Other ligands can subsequently
introduce an additional shift in the conformation equilibria; for instance, via allosteric
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interactions to modulate ligand biased signaling.
The model that we consider distinguishes two kinds of conformation changes of the
GPCR. Receptor conformation changes concern changes in the conformation of the
entire dimer, whereas domain conformation changes apply only to intracellular bind-
ing domain changes. The latter can occur while the global conformation stays the
same. Thus, at each (global) receptor conformation state, the (local) domain confor-
mation can have various states that differ in their binding affinities for intracellular
signaling proteins. This is the mechanism in this model that leads to ligand bias. Ex-
tracellular ligands can shift both the receptor and domain equilibria. This is where
this model differs from existing models of cooperative proteins based on the MWC
model, and of GPCRs in particular [143–145]. These models do not consider
conformations of the intracellular binding domain in addition to global receptor con-
formations.
We distinguish between receptor and domain conformations to be able to capture a
condition that is typically observed in experiments. In the absence of any ligands,
there typically exists no, or very little, basal signaling activity. This situation we de-
scribe as the receptor occupying an inactive (global) receptor conformation state.
Following the MWC terminology, this state corresponds to the "tensed" T state of the
receptor. As a result, all the (local) domain conformations of the T state are not active.
To allow for ligand bias, we require an active (global) receptor conformation – the "re-
laxed" R state – for which the (local) domain conformations can each activate another
intracellular signaling route. This is why we introduce the concept of different do-
main conformations for the intracellular binding domain of the receptor. The actions
of ligands introduce shifts in the receptor conformations from R to T and vice versa,
as well as in the conformations equilibria of the intracellular domain conformations.
From a thermodynamic perspective, we consider the GPCR at a state of thermody-
namic equilibrium (i.e. in the absence of any sustained free-energy input). GPCRs
operate in a state of thermodynamic equilibrium or close to it. In contrast to, for
instance, receptor tyrosine kinases, where free energy input, e.g. through ATP hydrol-
ysis, is used to drive conformation changes. We assume intra-receptor dynamics to be
fast, relative to changes in extracellular ligand and intracellular target protein concen-
trations, such that on the time scales of appreciable ligand and target-protein
concentration changes the receptor instantaneously relaxes to equilibrium concentra-
tions of its conformations.
Different approaches exist to describe oligomeric proteins that exist in such
quasi-equilibrium conformation states: the most famous approaches, which differ in
their simplifying assumptions for the conformation change transitions, are the
Adair-Klotz model [147, 148], the Koshland-Nemethy-Filmer (KNF) model [142], and
the Monod-Wyman-Changeux [139] (MWC) model. In addition to the KNF and
MWC model, which both simplify the conformation equilibria transitions, a model
without those simplifying assumptions can also be considered [149]. We limit this
study to the MWC model, but the mechanism outlined in Figure 1 can also be cap-
tured by the other modeling approaches. We focus on the MWC model because this
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model contains a limited number of kinetic parameters and only concerns inactive
versus active receptor conformations, and not on intermediate conformations in con-
trast to the KNF model. The latter is relevant because experimentally the signaling
activity of alternative (active) receptor conformations is very hard to distinguish.
+S +S
R1 R2 T1 T2
+S +S
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R-states T-states
orthosteric ligand S
LR
R1S1 R2S1
R1S4 R2S4
T
T1S1 T2S1
T1S4 T2S4
Figure 2.2: A particular model of a GPCR following the mechanism outlined in Figure 2.1. Two
receptor conformations, R and T, are distinguished. Two domain conformations can occur at the
different receptor states (i.e. R1, R2 for R vs T1 and T2 for T). We consider an extracellular binding
domain with two binding sites for a ligand, S (yellow circles). In the main text, we describe how the
fractions of the different GPCR states can be expressed in terms of the ligand concentration, ligand
affinity, and the conformation-equilibrium constants (`T , `R, and L).
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Translation of the GPCR conformation-equilibria mechanism into a mathematical
model
In Figure 2.2, the GPCR mechanism is shown that we consider, and will be extended
in various directions, in the next sections. The GPCR has two global receptor confor-
mations, R and T, and two local domain conformations that can occur regardless of
the global receptor conformations. The domain states for the R states are denoted by
R1 and R2 and for T we have T1 and T2. We consider the T states as inactive. We be-
lieve this to be a relevant scenario for most GPCRs. Specific GPCRs may then differ
in the number of receptor and domain conformations, which can be considered as
model extensions, but the essence remains the same: global active versus inactive re-
ceptor conformations and local domain conformations that are intracellular signaling
protein specific.
A specific receptor state is characterized by three features: its global receptor confor-
mation (R or T), its domain state (if globally in R state then R1 or R2 else T1 or T2),
and the number of ligands S bound, e.g. R2S4, and if two different ligands occur (e.g.
X and Y) then one could have T1X2Y4 for instance. This logic expands without prob-
lems if more receptor conformations or ligands are considered. Note that the MWC
model rules out mixed global conformation states, a dimer with one monomer in the
T state and the other in the R state is excluded. We return to this point later.
In the appendix, we show how the concentration fractions of the receptor states
can be expressed in terms of the concentrations of ligands and modulators, the
equilibrium constants of the conformation equilibria, and the allosteric interactions
between ligands and modulators. There we show that a relevant function to consider
is the so-called partition function of the receptor system defined in equilibrium
statistical physics [150]. A partition function is used to describe the receptor fractions
that occupy different states. We deliberately discern the partition functions of the
monomers from the partition function of the dimerized receptor as this simplifies the
model greatly.
The partition functions of the monomers are dependent on the precise configuration
of their binding sites and allosteric interactions. It can be used to express the
monomer fractions occupying a particular ligand-bound conformation state in terms
of experimentally-accessible kinetic parameters. It contains the dissociation constants
of the different binding sites and the (allosteric) interaction coefficients that modulate
the affinity of particular binding sites when others are occupied; for instance, we can
have for the monomer partition function,
zi,j = 1+
S
K1,i,j
+
S
K2,i,j
+
S2
αi,jK1,i,jK2,i,j
(2.1)
with i = {r, t}, j = {1, 2}. Thus, zr,1 denotes the partition function of the R1 state.
Equation 2.1 indicates that this monomer has two binding sites for the ligand s occur-
ring at concentration S that have an allosteric interaction (see Supplementary
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Information for a quick introduction). In case of zr,1 we obtain the following interpre-
tation; the two binding sites have dissociation constants K1,r,1 and K2,r,1 and αr,1
describes the allosteric interaction between the sites. Positive allostery occurs when
αr,1 < 1 as then the affinity of the monomer for s increases when one of the sites is al-
ready occupied. The fraction of the R1S state (with site 2 occupied) equals
R1S/R1,T = 1zr,1
S
K2,r,1
(see Supplementary Information).
The advantage of our formulation is that the partition function of the entire receptor,
which considers all monomer-monomer interactions and monomer binding states,
can be expressed in terms of partition function of its two interacting monomers. As a
result, we obtain a general description of GPCRs in terms of their monomers (ex-
plained below), regardless of the precise binding properties of these monomers.
Hence, monomers act as modules in our approach, each described by their own parti-
tion function that characterizes their configuration of binding sites. This modularity
requires the following assumptions: i. The monomers only influence each other’s
conformation, and ii. global conformation changes occur in symmetry (the MWC as-
sumption). As a result, the binding affinity of one monomer is only determined by
the occupancies of its own binding states and not by the binding states of its partner
monomer with which it interacts. Then, the monomers can be considered as modules.
This does not mean that the monomers act independently; they do cooperate to give
rise to concerted conformation changes but they do not engage in allosteric signal
(de-)sensitization of their binding sites without the occurrence of a conformation
change. The fact that monomers can be considered as modules makes this descrip-
tion highly attractive and easily extendible to different GPCRs that differ in the
number of extracellular binding sites and allosteric interactions.
To illustrate this modularity, we consider the R1S4 state of Figure 2.2 as an active
signaling state of the receptor; say, it can activate a particular trimeric G-protein of
interest. Using the theory outlined in the appendix, we can express the receptor
fraction of the R1S4 state as,
R2S4
GT
=
(
S2
αK1,r,1K2,r,1
)2
Z
(2.2)
Z = (zr,1)
2 + `R (zr,2)
2 + L
(
(zt,1)
2 + `T (zt,2)
2
)
(2.3)
the zi,j’s are the partition functions of the monomers in receptor conformation
i = {r, t} and domain conformation j = {1, 2}, and GT denotes the total receptor
(dimer) concentration. Equation 2.3, Z, is the partition function of the entire receptor
expressed in terms of equation 2.1, the partition function of any of the monomers.
The L coefficient gives the ratio of the global receptor conformations T/R, the `R
gives the ratio of the domain R conformations, i.e. R2/R1, and `T does the same for
the domain T conformations, T2/T1. The L, `T , and `R constants are equilibrium con-
stants of the conformation equilibria; below we will show that they can be influenced
by ligand binding and allosteric interactions. The modularity is illustrated by the fact
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that Z can be expressed in terms of the zi,j’s, the monomer characterization in terms
of its binding site affinities and the allosteric interactions. In the Figure 2.3, we
outline different monomer binding and allosteric-interaction diagrams.
Description Partition function, Pictogramzi,j , i = {r,t}, j = {1,2}
two identical binding
sites
α < 1 α > 1
α < 1 α > 1 
two identical binding sites 
with allosteric interaction
two signal binding sites 
with a modifier binding 
site
two signal binding sites 
and a modifier binding 
site with allosteric inter-
actions
signal and competitive 
inhibitor binding on two 
binding sites
α < 1, 
η <1 
α > 1, 
η >1 
zi,j =
(
1 +
S
KSi,j
)2(
1 +
M
KMi,j
)
zi,j =
(
1 +
S
KSi,j
)2
zi,j = 1 + 2
S
KSi,j
+
S2
αK2Si,j
zi,j =1 + 2
S
KSi,j
+
S2
αK2Si,j
+ 2
S ·X
KSi,jKX
+ 2
X
KX
+
X2
K2X
zi,j =1 + 2
S
KSi,j
+
S2
αK2Si,j
+
M
KM
+ 2
S ·M
ηi,jKSi,jKM
+
S2 ·M
αηi,jK2Si,jKM
Figure 2.3: Examples of partition functions of monomers that differ in the nature of binding sites.
The monomer partition functions, zi,j, can be substituted in the partition function Z for the entire
GPCR (see main text). S and M denote a signal and a modifier concentration respectively. The α and
η coefficients are (allosteric) interaction coefficients between binding sites. The K coefficients are all
dissociation constants.
So far, we assumed that the conformation changes of the intracellular domain of
receptor display so-called concerted symmetry, i.e. if one of the monomers in a dimer
changes domain conformation then its partner does the same. Accordingly, mixed
local conformations such as R1R2 or T1T2 do not occur, only R1R1 and R2R2. (If we
would have written the partition function as Z = (zr,1 + `Rzr,2)
2 + L
(
(zt,1 + `Tzt,2)
2
)
then we would allow for mixed local states.) The MWC model, by definition, already
excludes mixed global conformation states, i.e. TR and RT.
In the next sections, we show how ligand binding and ligand ligand interactions, as
expressed in the partition functions of the monomers (zi,j’s), induces conformation
changes of the receptor (changes in T/R, R2/R1, and R2S4/R2S1) and how this
provides the mechanism for ligand biased signaling.
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Incorporation of allosteric modifiers
Modifiers, as opposed to signals, are ligands that can bind to the extracellular binding
domain of the GPCR but cannot induce signal transduction without the presence
of another ligand, a "signal". Signals can invoke signaling by themselves. In the
appendix, we show that if modifiers do not show allosteric interactions with signals
or other modifiers that then the partition functions of their binding sites can be
subsumed in the equilibrium constants for the receptor and domain conformations,
respectively L, `R and `T ; for instance,
L′ = L
(
1+ β
1+ γ
)2
(2.4)
`′R = `R
(
1+ βR
1+ γR
)2
(2.5)
`′T = `T
(
1+ βT
1+ γT
)2
(2.6)
Modifiers that affect the conformational equilibria of the receptor can either act as
activators by shifting the equilibrium to particular active states or as inhibitors by
stabilising inactive states. In the equations for the modified equilibrium parameters
L′ and `′, β represents an inhibitor (it pushes the receptor to the global T state) and
γ is an activating modifier with respect to the T1 and R1 local conformations. An
influence on L is an important mechanism to shift the receptor from the inactive T
state, in the absence of a signal, to the active R states when the signals are present.
Since, L = T/R a decrease in L via a modulator or signal would increase the receptor
fraction in the R states. If, in addition, the same, or another, ligand affects the domain
conformation equilibrium constant `R then ligand bias can be introduced. An increase
in `R favors signaling via the R2 state at the expense of signaling via the R1 state.
This again shows the importance of distinguishing between the receptor and domain
conformations in this model of GPCR signaling.
Other than shifting conformation equilibria, modifiers can also affect the binding
properties of the receptor directly through allosteric interactions with signals (al-
losteric modifier) or through competitive binding (competitive modifier). Allosteric
modifiers can either have a stimulating or inhibiting influence on signaling; and even
both if multiple receptor states are active in signaling but respond in an opposite
manner to this modifier. A competitive modifier typically inhibits signaling if it com-
petes with a signal. Such modifier activities can be incorporated into the partition
functions of the monomers (Figure 2.3).
Shifts in global and local conformation equilibria cause ligand bias
The response of a GPCR to the binding of a signal or a modulator involves three
sequential conformation changes. Firstly, the conformation equilibrium between the
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active "R" conformation and the inactive "T" conformation shifts. Indeed in our model
this phenomenon occurs and this is illustrated by the following equation,
total R state concentration
total T state concentration
=
1
L
(zr,1)
2 + `R (zr,2)
2
(zt,1)
2 + `T (zt,2)
2 (2.7)
If the domain conformations have different affinities for the ligands, such that their
partition functions are not the same (i.e. zr,1 6= zr,2 6= zt,1 6= zt,2), then binding of the
signal causes a shift in the ratio of active over inactive conformations. On top of that,
the L and ` coefficients, as well as the ligand dissociation constants, can be functions
of modulators. Thus, also modulators can induce receptor conformation changes.
Secondly, the fractions of the different domain conformations of the active R state can
change in response to ligand binding. In terms of our model, we obtain,
total R1 dimer state concentration
total R2 dimer state concentration
=
1
`R
(zr,1)
2
(zr,2)
2 (2.8)
Also this ratio varies with the signal concentration, provided the domain conforma-
tions have different affinities for the same signal, and with the modifier concentration.
The modifier concentration can influence `R or influence signal affinity via a competi-
tive binding or allosteric interaction with signal binding sites.
Thirdly, the ratio of the active state concentrations can change, indicating a mixed
conformation and affinity effect,
R1S4
R2S4
=
1
`R
(
αr,2K1,r,2K2,r,2
αr,1K1,r,1K2,r,1
)2
(2.9)
We note that this ratio equation is not a function of the signal concentration. As a
consequence, a constant bias occurs when modulator concentrations are held fixed or
if no modulators play a role. Thus, signal bias only occurs due to a modulator that
acts in addition to a signal in our model. This is a consequence of our assumption
that the binding affinities on one monomer are independent of the binding state of its
partner monomer. This is an experimentally testable prediction of our model.
The hierarchy of the three conformation changes is illustrated with a numerical
example in Figure 2.4.
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Figure 2.4: Conformation changes of active states as function of signal and modifier concentra-
tions. A) The dependency of R1S4 on ligand concentration S. The inset depicts the fractions of the
other R1 states R1S0 (blue), R1S1 (purple), R1S2 (yellow), R1S3 (green). B) Fraction of R-state as func-
tion of the total receptor concentration. Blue, solid line: L = 50. The equilibrium between R and
T-states in the absence of ligand can be shifted towards the active conformation by modifying the
L-coefficient, corresponding to a higher basal activity of the receptor (dashed, purple line, L = 1). C),
D) Fraction of R1 and active state R1S4 as function of the total receptor concentration in the R-state,
respectively. E) The ratio of R2S4 to the active conformations can be influenced by a modifier acting
on the equilibrium constant `R. Thus, a switch in local conformations is obtained at high modifier
concentrations, F) R2S4 and R1S4 are depicted in blue and purple, respectively, as function of the
signal concentration. Parameters are listed in the appendix.
Ligand biased signaling illustrated with a bias plot
GPCRs display ligand biased signaling indicating that depending on the identity of
the ligand, or the precise combination of ligands present, the GPCR activates differ-
ent intracellular signaling routes. Ligand bias at the level of the receptor implies that
particular receptor states linked to specific signaling routes are increased in fraction
more than others when particular ligands are added. The influence of biasing modi-
fiers is schematically depicted in figure 2.5A: a modifier can "push" an equilibrium to
a different signaling state as was discussed above (equation 2.9).
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Figure 2.5: Quantification of ligand bias. A) Effect of modifiers on the active states. B) Concept of
the bias plots (a so-called parametric plot). C) Dose-Response curves of the R1S4 and R2S4 states as
fractions of Zdimer . D) Parametric plot of R1S4 and R2S4, the signal concentration S was varied. The
black line has slope
K4R2
K4R1
·`R
indicating that there is no bias towards one of the active states and that
both states reach their maximal values simultaneously. Dotted and dashed line: effect of modifiers β
and γ affecting the `R ratio. E) Ligand bias induced by different KD’s of the receptor states. Solid line:
KR1 = KR2; dashed line: KR1 < KR2; dotted line: KR1 > KR2. F) Parametric plot of R1S4 and R2S4 for
varied concentrations of the allosteric modifier M (red lines) and the competitive inhibitor X (blue
lines). Black line: no modifier present. Red lines: M = 100, blue, lines: X = 3. Remaining parameters
are listed in the appendix.
Typically, bias plots are used to illustrate the signaling bias of one ligand in experi-
ments [126, 151]. The level of one signaling route normalized by its maximal level is
plotted as function of the same measure for an alternative signaling route. We illus-
trate such a plot in Figure 2.5B for the two active states, R1S4 and R2S4, of the GPCR
in our model. In this figure we plot R2S4max(R2S4) as function of
R1S4
max(R1S4)
. The value of
max(R1S4) equals the maximum level of the R1 conformation, which equals
(zr,1)2/Z (and the same for max(R2S4)). In the Supplementary Information, we de-
rive these normalised signaling responses. For instance, in the presence of a modifier
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with concentration m we obtain,
R1S4 + R1S4M
max(R1S4 + R1S4M)
=
(
M·S2
η2r,1αr,1K1,r,1K2,r,1Km,r,1
+ S
2
αr,1K1,r,1K2,r,1
)2
max((zr,1)
2)
zr,1 = 1+
M
Km,r,1
+
S
K1,r,1
+
S
K2,r,1
+
M · S
ηr,1Km,r,1K1,r,1
+
M · S
ηr,1Km,r,1K2,r,1
+
S2
αr,1K1,r,1K2,r,1
+
M · S2
αr,1ηr,1K1,r,1K2,r,1Km,r,1
(2.10)
with ηr,1 as an allosteric interaction coefficient between the binding site of the modifier
and those of the signal. A similar equation for R2S4max(R2S4) is obtained. Typically,
max((zr,1)
2) is obtained at saturating large values of S. However, if the active form
is not any of the saturated forms of receptor, e.g. R1S2 as opposed to R2S4, then the
active concentration may reach its maximum at a sub-saturating concentration of s
and the maximum is not reached at max((zr,1)2); this situation we do not consider.
We investigate signaling bias in Figure 2.5 E, F. In these figures we show that a bias in
the active receptor conformations can be introduced by different binding affinities
of the different states towards the ligand, as shown in Figure 2.5E. Here, a higher
affinity of the conformation to the ligand causes a higher fraction of this ligand-bound
state to be populated, thus a bias occurs. Similarly, an allosteric modifier shifts the
equilibrium of R1S4 and R2S4 due to its allosteric interactions (Figure 2.5F). If there is
a positive allosteric interaction between the modifier and ligand’s binding sites on
the R1 state, i.e. ηR1 < 1, ligand binding to the R1 conformation is enhanced in the
presence of modifier M, leading to a bias towards this receptor conformation. The
same holds true for ηR2 and the R2 state. The same observation can be made for the
competitive modifier, depicted with the blue lines in the same figure. In this case, the
receptor state with lower affinity for the modifier X will have a higher probability to
be fully occupied by the ligand, which subsequently results in a higher fraction of
this state. Thus, the competitive modifier induces an inverse biasing effect.
Ligand bias induced modulation of signal sensitivity, affinity, and
output amplitude
In addition to influencing ligand bias, modulators influence the dependency of the
fraction of active receptor states, e.g. R1S4, on the concentration of their signals, i.e. S.
This dose-response relation of R1S4 with respect to S can be characterized by three
parameters: i. it’s Hill coefficient (sensitivity measure, nH), ii. the signal concentration
at half maximal response (affinity measure; EC50), and iii. the maximal level of the
response (amplitude measure; max(R1S4)). Each of these response properties can be
under the influence of a modulator; modulators can change the qualitative properties
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of the dose-response curve of an active receptor state with respect to a signal. We
illustrate various examples of such modulator influences in Figure 2.6.
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Figure 2.6: Effect of the modifiers on response amplitude, EC50 and Hill coefficient. The allosteric
modifier (M), equilibrium modifier (β,γ) and competitive inhibitor (X) were incorporated into the
receptor model and their effects on the formation of R1S4 were investigated: for its maximum,
EC50 value and hill coefficient, nH . A) Dose-response curve of R1S4 for increasing [M]. B) Effect of
the allosteric modifier M; M was varied between 0 and 10 and max(R1S4) values were calculated
accordingly. Red curve: ηR1 = 0.5, ηR2 = 1.56. Blue curve: ηR1 = 2, ηR2 = 0.64. C) Dose-response curve
of R1S4 in absence or presence of the competitive inhibitor, X. Black line: X = 0; Dark blue: X = 1;
Blue: X = 5, Light Blue: X = 10. D) Dose-response curve of R1S4 for varying β and γ. E) Dependence
of EC50 values of R1S4 on β and γ. β was varied from 0− 10, γ is fixed at 10 (blue curve). Red: γ
varies from 0− 10, β = 1. F) The Hill coefficient, nH , dependence on the modifiers β (blue) and γ
(red). Parameters are listed in the appendix.
Figure 2.6A illustrates the influence of the allosteric modulator M on the response
amplitude of R1S4. For a positive allosteric interaction (ηR1 < 1) an increasing modi-
fier concentrations leads to an increase in max(R1S4). In contrast, a higher modifier
concentrations decreases the amplitude if the allosteric interaction is negative (i.e.
ηR1 > 1). This dependence of modifier influence on whether the allosteric interaction
is positive or negative is also illustrated in Figure 2.6B, where the max(R1S4) is plot-
ted as function of the modifier concentration. A competitive modifier, denoted by X,
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shifts the R1S4 curve to increase the EC50 (Figure 2.6C) while the
conformation-equilibrium modifiers β and γ increase and decrease the receptors
affinity to the ligand, respectively (Figure 2.6D,E). These latter modifiers also influ-
ence the measure for the receptor sensitivity as quantified by the Hill coefficient
(Figure 2.6F).
2.3 Discussion
In this paper, we presented a model of GPCR activation by extracellular signals that
via allosteric interactions and induction of conformation changes bias the receptor
towards conformations that preferentially activate particular downstream proteins.
Hereby, tuneable ligand biased signaling is obtained at the level of the receptor. This
model contains two main features: first, a GPCR is considered to exist in a ligand-
dependent receptor-conformation equilibrium of active and inactive receptor states.
Second, the intracellular domain of the receptor exists in an equilibrium of (domain)
conformations that differ in their affinity for downstream signaling proteins. We used
the concept of allosteric ligand binding developed by Monod, Wyman and Changeux,
however, the ideas behind it can easily be adapted to the more complex KNF model
and generalization thereof. In addition, we illustrated that the ligand biased signaling
of the model involves sensitivity, amplitude and affinity modulation as is found in
experiments [126, 129].
Recent studies relate the structural information of receptors to their function with free
energy landscapes (reviewed in [152]). One view is that a GPCR in the inactive state
visits many different conformations for short times (dynamic disorder) without get-
ting "locked" (i.e. spend a long time) in a few particular states to initiate signaling.
This means that the free energy landscape, defined over all possible receptor struc-
tures, contains no free energy wells in the inactive state; it is essentially flat. Fluctua-
tions in the protein structure by thermal noise then cause the receptor to diffuse over
this free energy landscape and the residence time in active states is short as they do
not occur at potential wells. One perspective on the effect of signal binding is that it
stabilizes particular active receptor conformations and changes the free energy land-
scape to one with wells, where each well corresponds to an alternative active signal-
ing states. We described those alternative signaling states as the local conformations
of the intracellular domain of the receptor. Both for the active and inactive states of
the receptor, we coarse-grained the free energy landscape to one where only a small
number of structures can co-exist in a ligand-dependent equilibrium. In other words,
even though we did not explicitly consider free-energy landscapes, our model that
derive from this perspective.
Our proposal to distinguish between global and local conformations of GPCRs is
supported by several experimental studies. For instance, Nygaard et al [153], reported
the existence of local micro-switches in the intracellular parts of GPCRs, which co-
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occur with global conformational changes of the receptors. This distinction allows
for the consideration of multiple different activity states of the intracellular GPCR
domain, while the entire receptor occupies its active R state, as suggested by Vardy
and Roth [154]. This is also indicated by recent NMR experiments and structural
simulations, which point to the existence of multiple (intracellular) conformations of
GPCRs [118, 128, 154].
It has been suggested that G-proteins bind asymmetrically to GPCR dimers [137,
155]; thus, conformational and signaling structures of the receptors within a dimer
might be asymmetrical. This property would allow for inter-receptor crosstalk and
allosteric interactions between binding sites of different monomers. Experimental
evidence supports this hypothesis. For example, Vilardaga et al. [138] have shown
a direct transinhibition of morphine on α2A-AR conformation and signaling activity
in α2A-AR/MOR heterodimers. Additionally, Han et al. [155], and Jastrebzka et
al. [137] reported asymmetric receptor conformations within dopamine receptor
heterodimers and rhodopsin receptors, respectively. Therefore, our assumption that
allosteric interactions between binding sites of one monomer and sites of its dimer
partner do not occur is likely a simplification. It also has several experimentally
testable consequences. Allosteric interactions between the receptor subunits of the
dimer would lead to an enhanced cooperativity not reproducible by our model. In
such a case, expanding the model to allow for allosteric interactions between the
subunits might be required. The reason why we did not include these interactions
in the first place is that it would increase the number of parameters of the model
and require more experiments for parameter inference. Starting with a simpler
model is our preferred strategy, as it is not clear if the additional parameters are
indeed needed for the model to describe experimental data adequately. We note that
the asymmetric conformations of the dimeric receptors is important especially for
heterodimers [138, 155]. For instance, ligand binding to one receptor can positively
or negatively regulate the signaling activity of its partner receptor. In the model, we
focussed on homodimers. As a result a conformation difference between monomers
is likely of less importance.
The advantage of our model for the fitting of experimental data is that it offers
more mechanistic insight into conformation equilibria of the receptor and how this
is influenced by ligand binding and allosteric interactions. The downside is that
more parameters are to be determined, minimally three more (i.e. L, `R, `T ). In
order to reliably estimate those from experimental data, more experimental data
points and experimental conditions are generally required than what is necessary
for the fitting of, for instance, the extended allosteric two state model proposed by
Hall [145] to experimental data as was done recently [156]. Popular models that are
currently used to quantify effects of allosteric modulators on GPCR signaling are
based on the allosteric two state model proposed by Ehlert [157] or Hall [145] or
variants thereof, e.g. [158]. We derive these models in the Supplementary Information
and discuss their differences to our approach. The main difference is that the existing
models describe the receptor and receptor-ligand interactions in a phenomenological
29
manner with focus on characterizing the nature of the (allosteric) ligands as agonists
or antagonists. In contrast, our model considers a dimer receptor and allows explicitly
for different (global and local) conformations. With this approach, our model is able
to give insights into the conformation dynamics and the receptor mechanism for
ligand biased signaling.
Summarizing, the model we presented considers an equilibrium of different, active-
signaling receptor conformations that is influenced by binding of ligands and modi-
fiers and their allosteric interactions. It can be used to study the effects of modifiers
on pharmacologically important characteristics of GPCR signaling, such as the Hill
coefficient or EC50 values, as well as a tool to study mechanisms leading to biased
signaling at the level of the receptor.
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Supplementary Information
2.A Equilibrium binding models: examples and basic
terminology
Single site binding
We consider a monomer, e, with a single site that binds a ligand, S, i.e.
e + s
 es (2.11)
This reaction is assumed at thermodynamic equilibrium; hence, then it’s rate, v, equals
zero,
v = k+ · e · s− k− · es = k+ · e · s
(
1− es
k+
k− · e · s
)
= 0 (2.12)
Therefore, at equilibrium, when v = 0, we have the following relationship between
the kinetic parameters and the equilibrium concentrations,
es
e · s =
k+
k−
de f
=
1
KD
(2.13)
We note that "
de f
= " means here "define". Here we have identified the dissociation
constant, KD as an equilibrium constant. As any equilibrium constant, the KD can
be expressed in terms of the standard Gibbs free energies of formation of e, s, and es,
which we will not do here.
The total amount of monomer, eT , is conserved and equals the sum of the concentra-
tions of its two states,
eT = e + es = e +
e · s
KD
⇒ eT
e
= 1+
s
KD
de f
= z (2.14)
The "z" is identical to the partition function defined in equilibrium statistical thermo-
dynamics. It will turn out to be a key role in the models we derive. The concentration
of two states of the monomer can now be obtained from the previous equation and
the definition of the dissociation constant,
e = eT
1
KD + s
(2.15)
es = eT
s
KD + s
(2.16)
This indicates a hyperbolic dependency of the concentration of the bound monomer
as function of the ligand concentration. The monomer is for 50 % saturated with the
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ligand when s = KD
de f
= s0.5. We can also express the fractions of the states,
e
eT
=
1
KD + s
=
1
z
(2.17)
es
eT
=
s
KD
1+ sKD
=
s
KD
1
z
(2.18)
In the next section, we consider two binding sites. If those are independent – no
allosteric interaction occurs – then the partition function for this new system equals
(z)2. We will exploit throughout this work the property of partition functions of
independent sites to give rise to the partition function for a system composed out of
several of those sites.
Two sites on one monomer with an allosteric interaction
We consider a monomer, r, with two distinct binding sites; for notational convenience
one is denoted on the left hand side of r, i.e. when occupied we have sr, and the other
on the right hand side of r, i.e. rs,
r + s
1
 sr (2.19)
r + s
2
 rs (2.20)
sr + s
3
 srs (2.21)
rs + s
4
 srs (2.22)
At equilibrium we have the following dissociation constant definitions,
K1 =
r · s
sr
(2.23)
K2 =
r · s
rs
(2.24)
K3 =
sr · s
srs
(2.25)
K4 is related to the other dissociation constant because of the detailed balance condi-
tion: K1K2K3K4 = 1. Again, the total monomer concentration is conserved,
rT = r + sr + rs + srs = r
(
1+
s
K1
+
s
K2
+
s2
αK1K2
)
(2.26)
zr,1,2
de f
=
rT
r
, the partition function (2.27)
Here we have written K3 as αK2 to show that we consider binding to the second
site in such a manner that the occupation of the first site can alter the affinity of the
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second (and vice versa) via allostery. α is sometimes called an (allosteric) interaction
coefficient. If 0 < α < 1 then we have positive allostery (sensitisation), if α > 1
we have negative cooperativity and if α = 1 the sites are independent. In case of
independent binding sites, we have α = 1,
zr,1,2 =
(
1+
s
K1
+
s
K2
+
s2
K1K2
)
=
(
1+
s
K1
)(
1+
s
K2
)
= zr,1zr,2 (2.28)
And if K1 = K2 = K, the partition function of the monomer with the two sites equals
of the product of the individual binding sites (considered in isolation),
zr,1,2 =
(
1+
s
K
)2
= z2 (2.29)
Again the concentration of the monomer states can be derived from the definitions in
this section,
r = rT
1
zr,1,2
(2.30)
sr = rT
s
K1
zr,1,2
(2.31)
rs = rT
s
K2
zr,1,2
(2.32)
srs = rT
s2
αK1K2
zr,1,2
(2.33)
In the next section, we derive an example of a GPCR model and we will show that
the monomer partition function, even in the case of multiple binding per monomer,
e.g. zr,1,2, occurs as independent terms in the GPCR model as long as the monomers
act independently. Then, the GPCR model can be derived as function of the partition
function of the monomers; hence, the monomers act as proper modules in this case.
Example GPCR model
Without modifiers affecting the conformation equilibria
We consider a dimer with two identical monomers that each have two different
binding sites for the ligand S. The monomers within the dimer can be in two global
conformations, denoted by R and T; hence, we can have RR, RT, TR, and TT as
receptor conformation states. The Monod-Wyman-Changeux (MWC) model [139]
assumes that the RT and TR states do not occur due to strong cooperative interactions
between the monomers, called "concerted symmetry". In addition, we assume that
each monomer can have two local domain conformations of their intracellular binding
33
domains regardless of their global state. We denote the local states as a subscript to
the global state, i.e. we have R1, R2, T1, and T2. We also assume concerted symmetry
for local conformations, i.e. R1R2 and T1T2, do not occur, only R1R1, R2R2, T1T1 and
T2T2. For brevity we denote those dimers byR1,R2, T1, and T2. The total amount of
receptor dimer RT is now the sum of the concentrations of all the states,
RT = R1 + 4R1S + 6R1S2 + 4R1S3 +R1S4
+ R2 + 4R2S + 6R2S2 + 4R2S3 +R2S4
+ T1 + 4T1S + 6T1S2 + 4T1S3 + T1S4
+ T2 + 4T2S + 6T2S2 + 4T2S3 + T2S4 (2.34)
Thus we have 4 forms of the states with 1 ligand bound to the dimer, 6 with 2, 4
with 3, 1 with 0, and 1 with 4. If the monomers act independently then the partition
functions of the dimer states are the product of the monomer states. Then, we arrive
at,
RT = R1zR,1 +R2zR,2 + T1zT ,1 + T2zT ,2
= R1 (zr,1)2 +R2 (zr,2)2 + T1 (zt,1)2 + T2 (zt,2)2
= R1
((
(zr,1)
2 +
R2
R1 (zr,2)
2
)
+
T1
R1
(
(zt,1)
2 +
T2
T1 (zt,2)
2
))
de f
= R1
((
(zr,1)
2 + `R (zr,2)
2
)
+ L
(
(zt,1)
2 + `T (zt,2)
2
))
(2.35)
The partition function of the entire receptor system equals RT/R1. The dimer parti-
tion functions are now defined as zR,1 =
R1,T
R1 = (zr,1)
2, zR,2 =
R2,T
R2 = (zr,2)
2, zT ,1 =
T1,T
T1 = (zt,1)
2, and zT ,2 =
T2,T
T2 = (zt,2)
2. (Here the subscript "T" denotes a total con-
centration, corresponding to the four lines in equation 2.34.) With zr,1, zr,2, zt,1, and
zt,2 as the monomer partition function given their intracellular domain binding state;
those could for instance be,
zi,j = 1+
s
K1,i,j
+
s
K2,i,j
+
s2
αi,jK1,i,jK2,i,j
(2.36)
with i = {r, t} and j = {1, 2}. If for instance a modulator m can bind in addition to the
ligand s and in an independent manner then the partition function of the monomer
would become,
zi,j =
(
1+
m
KM,i,j
)(
1+
s
K1,i,j
+
s
K2,i,j
+
s2
αi,jK1,i,jK2,i,j
)
(2.37)
with i = {r, t} and j = {1, 2}. The 1 + mKM,i,j term is the partition function for the
modulator binding site on the monomer.
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Derivation of the allosteric coefficient α
The allosteric coefficient α introduced in our partition functions describes the
occupancy of one site on the ligand affinity of the other site. Thus, α describes the al-
losteric interactions between binding sites on a monomer. We shall now derive the α
coefficient from a MWC approach to show that α can be viewed as deriving from the
occurrence of different monomer conformations. So, suppose that a monomer m is in
equilibrium between two different conformations, denoted by x and y in the
following text,
mx
L
 my. (2.38)
Then, if the binding of ligands stabilizes one of these conformations (x or y), the
equilibrium is shifted towards this state, the classical MWC model. Here, the ratio
my/mx = L describes the equivalent of a L coefficient in the MWC model. The total
concentration of monomer, mT , equals the sum of the concentrations of all its states:
mT = mx + mxs1 + mxs2 + mxs1s2 + my + mys1 + mys2 + mys1s2
= mx +
mxs1
K1,x
+
mxs2
K2,x
+
mxs1s2
K1,xK2,x
+ my +
mys1
K1,y
+
mys2
K2,y
+
mys1s2
K1,yK2,y
= (mx + my)
( mx
mx + my
s1
K1,x
+
mx
mx + my
s2
K2,x
+
mx
mx + my
s1s2
K1,xK2,x
+
my
mx + my
s1
K1,y
+
my
mx + my
s2
K2,y
+
my
mx + my
s1s2
K1,yK2,y
)
(2.39)
The partition function for the monomer that results from this approach is rather
complicated. In order to avoid this, we express the partition function of the monomer
in a more simple format: a so-called Adair model. To achieve this, it is easier to work
with conformation fractions, such as my/(mx + my), than with the L . Let us now
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derive the partition function of the monomer, zm expressed in the Adair formalism,
mtotal
mx + my
def
= zm = 1+ s1
(
mx
mx + my
1
K1,x
+
my
mx + my
1
K1,y
)
︸ ︷︷ ︸
1
K∗1
+ s2
(
mx
mx + my
1
K2,x
+
my
mx + my
1
K2,y
)
︸ ︷︷ ︸
1
K∗2
+ s1s2
(
mx
mx + my
1
K1,xK2,x
+
my
mx + my
1
K1,yK2,y
)
︸ ︷︷ ︸
1
(K1K2)
∗
= 1+
s1
K∗1
+
s2
K∗2
+
s1s2
(K1K2)∗
= 1+
s1
K∗1
+
s2
K∗2
+
s1s2
αK∗1 K
∗
2
⇒ Adair model (2.40)
Here, the K∗’s are the average dissociation constants, considering the fractions of the
monomer in x and y state. The Adair model (equation 2.40) describes the partition
function of the monomer in a concise manner that is less complicated than the un-
derlying MWC model it derives from. An important assumption is that as assume
theL to remain fixed. Summarising, the α coefficient is defined as an allosteric in in-
teraction coefficient deriving from a conformation transition at the monomer level.
The use of Adair model simplifies the structure of the partition function for the whole
receptor (equation 2.43).
Next, we use the partition function of the monomer to derive the partition function
for the dimeric receptor. We have to take into account that the monomers can in the
dimer engage in new conformational changes that lead to the formation of R and T
monomer states. As we assume concerted symmetry for the receptor, the partition
function of the dimer becomes,
Z = (zr)2 + L(zt)2 (2.41)
and additionally including the (local) domain states for the receptor, we end up with
the Z function mentioned in the main text,
Z = (zr,1)2 + `r(zr,2)2 + L((zt,1)2 + `t(zt,2)2). (2.42)
(2.43)
In order to show that this description does not violate thermodynamic equilibrium,
we have to show that this model obeys: i) detailed balance and ii) mass conservation.
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• Detailed balance: Let us now have a closer look on the state transitions in the
full model, now also taking the x and y states into account (Fig. 2.7). Hereby,
we also assume concerted symmetry, so the monomers in a dimer will both be
either in x conformation or both in y, described byRx andRy. The transitions
are now: Rx L−→ Ry
1
L−→ Ty
1
L−→ Tx L−→ Rx . The products of the equilibrium
constants cancel out to one: L · 1L · 1L · L = 1. Thus, detailed balance is not
violated.
• Conservation of mass: We derive the partition functions while we sum over all
the concentrations of the receptor states and assume all binding reactions at
equilibrium. Hence, we account for all mass in the system and mass
conservation is not violated.
Figure 2.7: Equilibrium transitions including additional conformational states. Ri and Ti repre-
senting the different conformations of the receptor dimer. We assume concerted symmetry within the
dimer monomers to reduce the complexity of the scheme. This does not influence the outcome ifL
is fixed.
Incorporating L and ` modulators
In equation 2.37, we added a modulator binding site to each monomer, with a
monomer binding state dependent affinity. It is a custom in MWC models to include
modulators – ligands that do not give rise to protein activity themselves – in the equi-
librium constants for conformations, i.e. in `’s and L. This is straightforward and just
means that in equation 2.35 notR1,R2, T1, and T2 are removed out of the brackets
but those concentrations multiplied with the partition function of the modulator
binding site, e.g. R1
(
1+ mKM,i,j
)2
. This means that the definitions of the equilibrium
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constant for the conformations become,
L = L′
(
1+ mKM,r,1
)2
(
1+ mKM,t,1
)2
`R = `
′
R
(
1+ mKM,r,2
)2
(
1+ mKM,r,1
)2
`T = `
′
T
(
1+ mKM,t,2
)2
(
1+ mKM,t,1
)2 (2.44)
Also in more complicated cases, with additional modulators, the partition functions
will always appear in the numerator and denominator terms.
We note that if the modulators display allosteric interactions with signaling ligands
then the monomer partition functions cannot be written as product of modular and
signaling ligands partition functions – as they do not function independently – and,
as a result, the modulators cannot be subsumed in the definitions of ` and L. This
indicates the somewhat artificial distinction in MWC models between modulators
and signaling ligands.
The signaling state of the receptor
Say thatR1S4 is one of the signaling states of the receptor and we would like to know
how this active conformation changes as function of the concentration of the ligand,
S, then we first need to express the fraction of this state. We would obtain,
R1S4
RT
=
(
s2
αr,1KR,1,1KR,1,2
)2(
(zr,1)
2 + `R (zr,2)
2
)
+ L
(
(zt,1)
2 + `T (zt,2)
2
) (2.45)
The denominator is the partition function of the receptor expressed in terms of the
partition functions of its monomer given their states.
Biased signaling
The concentration of R2S4 equals,
R2S4
RT
=
`R
(
s2
αr,2KR,2,1KR,2,2
)2(
(zr,1)
2 + `R (zr,2)
2
)
+ L
(
(zt,1)
2 + `T (zt,2)
2
) (2.46)
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Hence, the ratio of two local conformation of the active R state equals,
R1S4
R2S4 =
(
s2
αr,1KR,1,1KR,1,2
)2
`R
(
s2
αr,2KR,2,1KR,2,2
)2 = 1`R
(
αr,2KR,2,1KR,2,2
αr,1KR,1,1KR,1,2
)2
(2.47)
This is a constant if no ligand bias occurs; then, we require that no modifier or other
signal influences `R and/or KR,i,j (with i, j = {1, 2}). In the main text, we consider
the situation where the second factor equals 1 and ligand bias can only be induced
via an influence on `R.
A note on the bias plots
In a bias plot, the normalised signaling response of one route, i.e. R2S4max(R2S4) , is plotted
as function of the normalised response of an alternative route, R1S4max(R1S4) . These ratios
are given by the following equations,
R1S4 =
(
s2
αr,1K1,r,1K2,r,1
)2
Z
max(R1S4) =
(
1+ sK1,r,1 +
s
K2,r,1
+ s
2
αr,1K1,r,1K2,r,1
)2
Z
=
(zr,1)
2
Z
0 ≤ R1S4 ≤ max(R1S4)
R1S4
max(R1S4) =
(
s2
αr,1K1,r,1K2,r,1
)2
(
1+ sK1,r,1 +
s
K2,r,1
+ s
2
αr,1K1,r,1K2,r,1
)2 (2.48)
And the same for R2S4 and max(R2S4); note that in this case both terms involve a
multiplication with `R and that therefore `R drops out of the equation. As result,
ligand bias only occurs if the dissociation constants, the K’s, are influenced by modu-
lators via competitive binding or via allosteric interactions between modulator and
signal binding sites. We also note that if a modifier is present the partition function of
the monomers obtain a modifier concentration dependent term (examples can be
found in the box in the main text). Then, multiple active forms could also play role,
e.g. R1S4M in addition to R1S4 (with R1S4M denoting a modifier bound R1S4
state). For instance, one could have,
R1S4 +R1S4M
max(R1S4 +R1S4M) =
(
ms2
βr,1αr,1K1,r,1K2,r,1Km,r,1
+ s
2
αr,1K1,r,1K2,r,1
)2
max((zr,1)
2)
zr,1 = 1+
m
Km,r,1
+
s
K1,r,1
+
s
K2,r,1
+
ms
ηr,1Km,r,1K1,r,1
+
ms
ηr,1Km,r,1K2,r,1
+
s2
αr,1K1,r,1K2,r,1
+
ms2
ηr,1αr,1K1,r,1K2,r,1Km,r,1
(2.49)
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2.B Hill coefficient
One manner to characterise the sensitivity of a cooperative receptor system with al-
losteric interactions between ligands and modulators is to determine its Hill coeffi-
cient with respect to a particular modulator or signaling ligand. Thus, the receptor is
viewed with respect to one concentration, s, i.e. the modulator or ligand of interest,
and this function is approximated by a Hill equation,
y = yT
sn
Kn + sn
(2.50)
Here y is an output of the signaling receptor, e.g. downstream signaling response or
the concentration of a particular receptor state (e.g. R1S4). From this equation the
Hill coefficient n can be determined from,
n = 2
∂ ln y
∂ ln s
∣∣∣
s=s0.5
(2.51)
Here s0.5 denotes the concentration of s where y =
yT
2 given a value for K and n.
2.C Deriving GPCR models
Through the decades, a plethora of concepts have been developed to describe coop-
erativity and allosteric ligand binding in oligomeric proteins. These models differ
in their complexity as well as in the underlying purpose they have been developed
for. Our model includes the dimeric nature of membrane receptors, as well as dif-
ferent conformations of the receptor’s domains (R1, R2). Additionally, we consider
alternative binding sites for the orthosteric ligand and the allosteric modifiers. The
two-state model derived in section 2.C in this Appendix describes the basic assump-
tions underlying our model, whereas the allosteric two-state model proposed by Hall
[145], derived in section 2.C slightly differs in its concept. The α-coefficient in our
model describes an allosteric interaction coefficient and corresponds to γ in the Hall
model, whereas α, β and δ describe changes in ligand affinity to the receptor. Those
are described in our model by different KD values.
The two-state model of receptor activation
The two state model of receptor activation as described by Paul Leff in 1995 [159]
is closely related to the MWC model and describes the very basic concepts of the
receptor model introduced in our article. Notabely, it does not consider domain
conformations. The two-state model assumes a single ligand to bind to an active or
inactive receptor state with different affinities, thereby also shifting the equilibrium
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between the receptor states (L). In MWC terminology, the total receptor can be written
as,
RT = R + RS + T + TS
= R
(
1+
s
KR
)
+ LR
(
1+
s
KT
)
= R
((
1+
s
KR
)
+ L
(
1+
s
KT
))
(2.52)
Consequently, the partition function simplifies to
z =
(
1+
s
KR
)
+ L
(
1+
s
KT
)
(2.53)
The allosteric two-state model
The two-state model derived in the previous section has been extended by David
Hall [145] in order to include the effects of allosteric ligands with a focus on the
characterization of pharmacological ligands. Here, two ligands of different identity
are assumed to bind the receptor states with varying affinities, thereby influencing
both the binding affinity of the other ligand as well as the equilibrium between
inactive and active receptor states.
Hence, the total receptor amount is determined by the inactive and active receptor
states bound to the ligands A and B, and their combination, respectively. Written in
MWC terminology, this leads to
RT = R + RA + RB + RAB + T + TA + TB + TAB
= R
(
1+
αA
KA
+
βB
KB
+
αβγδAB
KAKB
+ L
(
1+
A
KA
+
B
KB
+
γAB
KAKB
))
(2.54)
and
z = 1+
αA
KA
+
βB
KB
+
αβγδAB
KAKB
+ L
(
1+
A
KA
+
B
KB
+
γAB
KAKB
)
(2.55)
with α and β being the affinity of ligand A and B for R and T, respectively, while
γ corresponds to the allosteric interaction coefficient of A and B. δ represents the
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"allosteric activation interaction", the affinity of one ligand to the active state when
the other ligand is already bound, thus, whether it stabilizes the active receptor state
or not. Please note, that the definitions for α, β,γ and δ are adopted from the original
paper, whereas the L coefficient is defined here as TR while in the original text it is the
opposite. For more detailed explanation, see [145].
General approach
In section 2.A we have derived the partition function for a dimeric GPCR with two
ligand binding sites per monomer, and have seen that in this case, the partition
function of one specific conformation equals (zi,j)2, with i = {r, t} and j = {1, 2}.
Subsequently, a partition function of a specific state of a multi-meric GPCR equals
(zi,j)m,with i = {r, t} and j = {1, 2} and m = the number of monomers the receptor
is composed of. The derivation of the partition function can thus be generalized by
making use of the binomial theorem:
(1+ x)n =
n
∑
k=0
(
n
k
)
xk. (2.56)
Here, n is denoting the amount of ligand binding sites in the protein, k denotes the
occupancy status per subunit (ligand bound or not).
Thus, zi,j for a dimer with two distinct ligand binding sites per subunit becomes:
zi,j =
(
1+
s
K1,i,j
+
s
K2,i,j
+
s2
K1,i,jK2,i,j
)2
(2.57)
=
 1∑
k=0
1
∑
l=0
(
1
k
)(
1
l
)(
s
K1,i,j
)k (
s
K2,i,j
)l2 (2.58)
with i = {r, t} and j = {1, 2}, and k and l denoting the occupancy status of the in-
dividual binding sites where the dissociation constant is, say, K1,i,j and K2,i,j, respec-
tively. In the same way, a general partition function can be generated:
zi,j =
 f∑
k=0
· · ·
w
∑
y=0
(
f
k
)
· · ·
(
w
y
)(
s
K1,i,j
)k
· · ·
(
s
Kx,i,j
)yn (2.59)
with i = {r, t} and j = {1, 2}, x = number of different binding sites, f , ..., w = the
number of identical binding sites (i.e. with the same KD) per monomer, k, ..., y the
occupation status of identical binding site f , ..., w, and n = number of monomers. This
approach is only feasible if there are no allosteric interactions between the ligand
binding sites.
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2.D Model parameters
For the figures, different parameter values were chosen. In the following section, the
parameter values are listed that resulted in the figures shown in the main text.
Figure 2.4: Conformation changes of active states as function of sig-
nal and modifier concentrations.
Fig. 2.4A) K1,R1=K2,R1= 1,
αR1= αR2 = 0.1,
K1,R2= K2,R2= 5,
K1,T1=K2,T1= 15,
αT1= αT2 =1,
K1,T2 = K2,T2=25,
`T=`R = 1,
L= 50,X = 0,M= 0;
Fig. 2.4B) solid blue line: L = 50, purple dashed line: L=1; remaining parameters: see
Fig.2.4A).
Fig. 2.4C) see Fig.2.4A)
Fig. 2.4D) see Fig.2.4A)
Fig. 2.4E) see Fig.2.4A)
Fig. 2.4F)`R = (1+ α)
2, α = 100; remaining parameters: see Fig.2.4A).
Figure 2.5: Quantification of ligand bias.
Fig. 2.5C)K1,R1=K2,R1= 0.85,
K1,R2= K2,R2= 1,
K1,T1=K2,T1= 10,
K1,T2 = K2,T2=10,
αR1= αR2 = 0.1,
αT1= αT2 =1,
`T=10, `R = 1,
L= 10,X = 0,M= 0;
Fig. 2.5D) K1,R1=K2,R1= 1,
K1,R2= K2,R2= 1,
`R =
(
1+βR
1+γR
)2
,
solid black line: β= 0, γ=0; dashed line: β= 1, γ=0; dotted line: β= 0, γ=1;
remaining parameters: see Fig.2.5C).
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Fig. 2.5E) black, solid line: K1,R1=K2,R1= 1,K1,R2= K2,R2= 1;
dashed line: K1,R1=K2,R1= 0.3, K1,R2= K2,R2= 1;
dotted line: K1,R1=K2,R1= 3, K1,R2= K2,R2= 1; remaining parameters: see Fig.2.5C)
Fig. 2.5F) black solid line: X=0, M=0;
red, dashed line: X=0, M=100, KM=1, ηR1 = 0.1, ηR2=10, ηT1 = ηT2=1; red, dotted line:
X=0, M=100, KM=1, ηR1 = 10, ηR2=0.1, ηT1 = ηT2=1;
blue, dashed line: X=3, M=0, KX,R1=1, KX,R2=0.1, KX,T1= KX,T1=1;
blue, dotted line: X=3, M=0, KX,R1=0.1, KX,R2=1, KX,T1= KX,T1=1;
remaining parameters: see Fig.2.5C).
Figure 2.6: Effect of the modifiers on response amplitude, EC50 and
Hill coefficient.
Fig. 2.6A) K1,R1=K2,R1= 1,
K1,R2= K2,R2= 1,
K1,T1=K2,T1= 10,
K1,T2 = K2,T2=10,
αR1= αR2 = 0.1,
αT1= αT2 =1,
`T=10, `R = 1,
L= 10,X = 0;
black line: M = 0; dark blue line: M = 0.1, ηR1 = 5, ηR2 = 0.5;
blue line: M = 1, ηR1 = 5, ηR2 = 0.5;
light blue line: M = 10, ηR1 = 5, ηR2 = 0.5;
dark red line: M = 0.1, ηR1 = 0.5, ηR2 = 5;
red line: M = 1, ηR1 = 0.5, ηR2 = 5;
light red line: M = 10, ηR1 = 0.5, ηR2 = 5;
Fig. 2.6B) K1,R1=K2,R1= 0.3,
K1,R2= K2,R2= 1,
K1,T1=K2,T1= 10,
K1,T2 = K2,T2=10,
αR1= αR2 = 1,
αT1= αT2 =1,
`T=10, `R = 1,
L= 1000
(
1+β
1+γ
)2
,X=0, M = 0; black line: β = 50, γ = 20;
dark blue line: β = 60, γ = 20;
blue line: β = 75, γ = 20;
light blue line: β = 90, γ = 20;
dark red line: β = 50, γ = 25;
red line: β = 50, γ = 35;
light red line: β = 50, γ = 45
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Fig. 2.6C) L= 10; blue line: ηR1= 2, ηR2 = 0.64; red line: ηR1= 0.5, ηR2 = 1.56;
remaining parameter: see Fig. 2.6A).
Fig. 2.6D) K1,R1=K2,R1= 0.3,
K1,R2= K2,R2= 1,
K1,T1=K2,T1= 10,
K1,T2 = K2,T2=10,
αR1= αR2 = 1,
αT1= αT2 =1,
`T=10, `R = 2,
L= 100
(
1+β
1+γ
)2
,X=0, M = 0; blue line: β is varied from 0 to 10, γ = 10;
red line: β = 1, γ varies from 0 to 10.
Fig. 2.6E) black, solid line: X=0, dark blue line: X=1, blue line: X=2.5, light blue line:
X= 5; KX,R1 = KX,R2 = 1, αR1= αR2 = 0.88, L = 1000; `R = 1, remaining parameter: see
Fig. 2.6B).
Fig. 2.6F) K1,R1=K2,R1= 0.3,
K1,R2= K2,R2= 1,
K1,T1=K2,T1= 10,
K1,T2 = K2,T2=10,
αR1= αR2 = 0.8,
αT1= αT2 =1,
`T=10, `R = 1,
L= 10
(
1+β
1+γ
)2
, X = 0, M = 0;
blue line: β varied between 0 and 10, γ = 1.4;
red line: β = 3.7, γ varied between 0 and 10.
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Abstract
Background G protein-coupled receptors (GPCRs) generally activate multiple down-
stream signaling pathways, via different G proteins. Which G protein is activated,
and to what extent, depends on which ligands are bound to the receptor. Ligand com-
binations stabilize receptor conformations with particular downstream signaling
biases. Signaling bias is typically inferred from activation of downstream signaling
read-outs. It is therefore not always clear whether bias is caused by the GPCR or by
downstream processes.
Aim Here we study the ligand bias of the extracellular calcium sensing receptor
(CaSR). We measure direct activation of the G protein Gq in response to several direct
activators of CaSR, allosteric modulators and drugs.
Results Using Förster Resonance Energy Transfer (FRET), we monitored the
real-time activation of Gαq by CaSR in single cells. We characterized steady-state sig-
naling, for all considered ligand combinations, in terms of half-maximal activation
(EC50), signal sensitivity (the Hill coefficient) and maximal activation, to assess
ligand-ligand interactions leading to biased signaling by the CaSR.
Conclusion Particular ligand combinations induced biased activation of Gαq. Other
ligand combinations, which were earlier found to give biased activation of down-
stream signaling, did not show biased activation of the Gαq protein, suggesting that,
in those cases, signaling bias does not occur at the CaSR but rather downstream. Bi-
ased activation of outputs of GPCR-networks is therefore caused by concerted bias of
the GPCR and the downstream signaling network.
3.1 Introduction
G protein-coupled receptors (GPCRs) are cell-surface receptors that connect the
signaling machinery of a cell to its extracellular environment. GPCRs are one of the
largest receptor families encoded on the human genome [6] and are involved in a
broad range of different functions. Due to their versatility, they are interesting drug
targets and currently about 30 - 40% of marketed drugs are acting on GPCRs [160,
161].
Once activated, the receptor binds and activates different intracellular signaling
proteins, e.g. heterotrimeric G proteins and β-arrestins, presumably via dedicated
receptor conformations [162], reviewed in [161]. In the inactive state, Gα subunits
are bound to GDP and are coupled to the Gβγ subunit. Binding to an active receptor
induces conformational changes within the G protein, leading to a GDP release and
the binding of GTP in the α subunit. Subsequently, Gα and Gβγ subunits dissociate or
change conformation and activate downstream signaling proteins. A single receptor
can therefore activate multiple intracellular proteins.
Extracellular ligands can introduce biases in intracellular signaling, by stabilizing
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distinct receptor conformations that each activate downstream signaling pathways
to different degrees [69]. Understanding how ligand-ligand interactions at the level
of a GPCR brings about biased signaling has been recognized as a major challenge
in the search for ‘biasing drugs’ [81–83]. Ligand bias, or biased agonism, has been
documented for several GPCRs ([70, 74–77]). In most studies, the biasing effects
of ligands is deduced from shifts in dose-response curves of downstream signaling
responses [80, 93, 94]. Agonist screenings have revealed the biasing effects of clinically
relevant compounds [84, 85], and pharmacologic active compounds with modulated
biasing effects were developed [86, 87]. However, different sources of bias have
been distinguished, ranging from receptor to network contributions [80, 163]. Even
though theory has been used to relate agonist bias to the free energy landscape of a
receptor [88, 89], few experimental studies focus on ligand bias at the level of a GPCR.
Most studies focus on bias observed at output of the signaling network, downstream
of GPRCs. Therefore, whether bias is induced at the receptor level or within the
signaling network is often unknown.
In this work, we use the human extracellular calcium sensing receptor (CaSR), in-
volved in whole-body calcium homeostasis [50, 54]. In addition to calcium, it binds
several other ligands, such as di- and trivalent ions, amino acids, polyamines and an-
tibiotics [55]. It has recently been characterized as an amino-acid sensor [164, 165].
Mutations in this receptor are associated with several diseases, most noticeably famil-
ial hypocalciuric hypercalemia (FHH) and autosomal dominant hypocalcemia
(ADH), induced by a gain-of-function mutation of the CaSR [67, 166].
The CaSR couples to three classes of heterotrimeric Gα subunits (Gq, Gi and G12/13)
and to β-arrestins to activate several downstream signaling pathways [55]. The
biasing influence of several CaSR ligands on signaling-pathway activation has been
investigated using downstream signaling read-outs such as intracellular calcium
release, ERK phosphorylation, membrane ruffling, IP1 accumulation and decrease
in cAMP concentrations [66, 78, 167, 168]. Despite the great interest in ligand-biased
signaling by GPCRs, remarkably few studies focus at the signaling bias introduced
by the GPCR itself. Most studies focus on biases observed at downstream signaling
readouts. It remains therefore unclear to what extent these biases can be attributed to
a GPCR, to its downstream signaling network, or a combination of both. One would
expect that part of the tasks of the cellular signaling network is to integrate signals
and infer the appropriate biases, suggesting that the role of GPCRs are perhaps only
minor.
Here we addressed the contribution of the CaSR to ligand-biased signaling. We
measured real-time, single-cell responses of CaSR-induced Gαq activation to different
ligand combinations, using a Gq FRET sensor.
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3.2 Results
Gq activation as a direct measure of CaSR induced ligand bias
We focus on CaSR-mediated Gq activation to address ligand bias introduced at the
level of the GPCR. HEK293 cells, stably expressing the CaSR (CaSR-HEK cells), were
transfected with a FRET sensor for Gq activation, described previously [169]. This
sensor is a loss-of-FRET sensor; implying that a drop in signal represents an increase
of Gq activity. The fluorescence at different emission wavelengths of the Gq FRET-
construct were recorded during receptor stimulation and their ratio (YFP/CFP) was
used to determine the CaSR-induced Gq activation (Fig. 3.1A). This FRET construct
gives a ratiometric output and therefore corrects for the sensor expression differences
and other sources of concentration fluctuations.
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Figure 3.1: The FRET reporter and the CaSR modulators, used in this study. A) Working principle
of the Gq FRET sensor. Cyan and yellow fluorescent protein (CFP, YFP) are fused to the α and γ
subunit of the heterotrimeric G protein [169, 170] and the sensor is illuminated with light of 420 nm
wavelength. In the inactive state, CFP and YFP are in close proximity and energy transfer from the
CFP donor to the YFP acceptor (FRET) occurs, leading to an emission of light in a 535 nm range. Upon
activation the subunits dissociate, leading to loss of energy transfer. Emission from CFP therefore
increases, accompanied by a drop in YFP fluorescence. This is shown in the time traces. The ratio
between YFP and CFP emission was calculated and taken as a measure of Gq activation. B) HEK293
cells stably expressing the CaSR were transfected with the Gq FRET sensor and exposed to different
stimuli. The stimuli we chose fall into three groups: i. direct activators, ii. allosteric, CaSR specific
drugs and iii. modulators that acted in combination with Ca2+ as main stimulus.
The CaSR ligands considered in this study were chosen from three groups: i. direct
activators (agonists), ii. allosteric, CaSR-specific drugs, and iii. (allosteric) physiologi-
cal modifiers that typically act in combination with Ca2+ as main stimulus (Fig. 3.1B).
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During the experiments, the cells were exposed to increasing doses of agonists, in the
presence or absence of CaSR-drugs or modifiers, unless stated otherwise.
We monitored the responses of single cells to increasing ligand concentrations in real-
time. Figure 3.2 gives an overview of the whole procedure. The Gq activation in in-
dividual cells in response to a step-wise increase in the external calcium concentra-
tion was measured over time. (Later we repeated this experiment with other ligands
and their combinations.) Steady-state Gq activation is reached when the FRET ratio
becomes constant. Steady states were found after each step increase of the calcium
concentration. From the response curves of individual cells, mean traces and stan-
dard errors (SEM) were calculated. The dose-response relation was obtained from
this data, it relates the steady-state values of Gq activation to the varied agonist con-
centration, in the presence or absence of additional ligands.
The consecutive stimulation of the cells with the step-wise increase of calcium con-
centrations resulted in comparable Gq activity as single stimulations with different
calcium concentrations did (figure S3.7). This indicates that dose response curves of
single cells can be obtained by step-wise sequential stimulation.
To test whether the CaSR-expressing HEK293 cells can respond to CaSR stimuli
independent of CaSR, we carried out an experiment with HEK293 wild-type cells,
which do not endogenously express the CaSR [171]. We confirmed that these cells
indeed did not show Gq responses when exposed to CaSR stimuli (panels D in figures
S3.8, S3.9, S3.11 - S3.15).
We note that at low extracellular Ca2+ concentrations, several CaSR-HEK cells re-
sponded to the calcium with a transient overshoot in Gq activation. The Gq activation
signal then increased before it settled to a lower steady-state level. This temporal acti-
vation peak can lead to transient signaling to downstream targets, such as PLC. We
can therefore not exclude that transient downstream signaling events can occur in re-
sponse to external calcium, even when hardly any Gq response is indicated by the
dose-response curve of active steady-state Gq as function of the agonist
concentration.
We found an EC50 value of 3.4 mM Ca2+, which fits perfectly within the range of
reported values (≈ 3 - 4 mM), obtained with intracellular calcium mobilization assays
in CaSR-HEK cells [62, 63, 172, 173]. In similar assays, Hill coefficients (nH) were
found to range from approximately 3 to 6 [52, 66, 172, 174]. Hill coefficients are an
appropriate measure to quantify the sensitivity of a multistep protein-ligand binding
event [175]. A Hill coefficient greater unity indicates that bound ligands make the
receptor more susceptible for binding of further ligand molecules, the reverse for
coefficients below unity. We found a Hill coefficient of 4.2 in this study which fits well
to the earlier findings. The FRET ratio change at maximal stimulus concentration is
26.7% for stimulation with calcium (n=17). This information is summarized for all
treatments in figure 3.6.
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Figure 3.2: Workflow of the experimental data analysis, using an example of CaSR stimulation
with Ca2+. CaSR-HEK cells transfected with the Gq FRET sensor were calcium depleted to a basal
Ca2+ concentration of 0.5 mM prior to stimulation with increasing concentrations of external Ca2+
(0.5 - 7 mM). Dual wavelength fluorescence emission of single cells was recorded in real-time and
FRET ratio (YFP/CFP) was calculated as response to the stimulus (left panels). Breaks in these
fluorescence traces of the single cells result from pipetting in the next stimulus concentration. In
the traces shown here, we eliminated these artifacts intentionally. The mean and standard error of
these time traces was calculated for the individual treatments for n = 17 cells (middle). CFP emission:
cyan; YFP emission: yellow; YFP/CFP ratio: red; the error bars indicate SEM for n = 17. The dose
response curve was obtained from the steady states of Gq activity, adapted to the increased stimulus
concentration in the time course (right). Open circles represent individual cells, filled circles the
average of the YFP/CFP ratio; error bars indicate SEM. The solid line is the fit to equation 4.1.
Gq activation by CaSR agonists
The CaSR can be activated directly by a broad range of agonists in the absence of
calcium, leading to distinct biased activations of downstream signaling readouts,
such as IP1 accumulation, ERK1/2 phosphorylation and cAMP reduction [78]. We
tested whether the biasing effect of different agonists is already established by CaSR
by investigating the occurrence of biased activation of Gq. When no bias at the level
of the receptor and G protein is established, the biased activation of downstream
readouts results from the signaling network beyond the GPCR.
We compare the CaSR-mediated activation of Gq when CaSR is activated by alterna-
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tive agonists – at a basal level of calcium. (We require this basal concentration of Ca2+
to guarantee healthy and coverslide-attached cells.) We have selected direct CaSR ac-
tivators with different traits: i. strontium (Sr2+), a divalent ion, and ii. two
polyamines, spermine and spermidine.
Sr2+ is less potent in Gq activation via CaSR than Ca2+
Even though strontium and calcium are both divalent ions, it is unclear whether
they bind to the same site of the CaSR [176]. We tested Sr2+ concentrations from
0 - 11 mM at a basal calcium concentration of 0.5 mM. We found that Sr2+ is less
potent in activating Gq via CaSR than Ca2+ is. The Gq-vs-Sr2+ dose-response curve
(figure 3.3A) is right shifted compared to the Gq-vs-Ca2+ curve, with an EC50 value
of 5.9 mM and a Hill coefficient of 3.2. The response to 7 mM Sr2+, the maximal
concentration used for calcium treatment, was only about 12.6%, whereas at higher
concentrations the maximal response approached that of calcium. Similar results
have been found in a study of CaSR-HEK cells [177], a lower efficacy was found for
Sr2+, compared to Ca2+, for mobilization of intracellular calcium and accumulation
of inositoles. A study in medullary thyroid carcinoma cells of rats reported that Sr2+
induced biased signaling of the CaSR with respect to the phosphorylation of ERK1/2
[168, 177]. Our data suggests that these biasing effects of Sr2+ are already manifested
at the CaSR-to-Gq level, resulting in a decreased CaSR-induced activation of Gq.
We note that we found a strong covariance between the maximal activation parameter
(β) and the EC50 in the parameter fitting procedure, summarized in figure 3.6. As
a result, we cannot independently estimate those parameters, their ratio we can
however estimate with much higher certainty. The reason is that most of the cells
did not yet reach maximal activity at the maximal strontium concentration of 11 mM,
which explains the large uncertainty in the EC50 values reported in figure 3.6.
Spermine is more potent than spermidine in Gq activation via the CaSR
The polyamines spermine and its precursor molecule, spermidine, are synthesized by
eukaryotes and act as allosteric CaSR agonists [78, 174] with EC50 values for intracel-
lular calcium mobilization of 200 - 500 µM (spermine) and about 4 mM (spermidine)
[174]. We tested a spermine concentration range of 0 - 5 mM and for spermidine we
took 0 - 13 mM. Spermine and spermidine activated Gq, albeit to different extents (fig-
ure 3.3B).
Spermidine has a low efficacy for Gq activation via CaSR; it gave only a maximal ratio
change of about 6.1% at 7 mM (compared to 26.7% in the calcium treatment) and a
high, hard-to-estimate EC50 value. The Hill coefficient of 1.3 suggests noncooperative
binding. Because of the small effects of spermidine on CaSR-mediated Gq activation,
we could not estimate the kinetic parameters very accurately.
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Figure 3.3: Comparison of CaSR agonists with respect to their potential to activate Gq. CaSR-HEK
cells transfected with the Gq FRET sensor were calcium depleted to a basal Ca2+ concentration of 0.5
mM prior to stimulation and fluorescence emission of the Gq sensor was recorded. A) FRET ratio
change comparison between Ca2+ (blue) and Sr2+ (grey). Agonists were added every 90 seconds,
resulting total Ca2+ concentrations were 0.5, 1, 2, 3, 4, 5, and 7 mM; total Sr2+ concentrations were
0, 1, 3, 5, 7, 9, and 11 mM. The curve of the Sr2+ treatment is statistical significant different to the
Ca2+ titration curve with a p-value <0.05 resulting from the inverse lack-of-fit test described in the
section materials and methods. Solid lines: fit to equation 4.1. B) Comparison of CaSR-HEK cells
stimulated with increasing doses of Ca2+ (blue), spermine (orange) and spermidine (purple). Total
Ca2+ concentrations were the same as in A; total spermine and spermidine concentrations were
0, 0.1, 0.25, 0.5, 1, 2, 3, and 5 mM and 0, 1, 3, 4, 7, 9, 11, and 13 mM, respectively. The spermidine
titration curve was significantly different to the Ca2+ titration with a p-value «0.05 resulting from
the inverse lack-of-fit test described in the section materials and methods. Solid lines: fit to equation
4.1. In all plots, error bars indicate SEM. nCa2+ = 17; nSr2+ = 32; nspermine = 35; nspermidine = 16. For
a summary of the statistics of these fits see figure 3.6.
In contrast, spermine has a very high potency in activating the CaSR, even higher
than calcium, as determined by the EC50 value of 1.6 mM, but efficacy is lower (ratio
change at 7 mM = 21.1%).
Our data suggests that the tested polyamines have a lower effect on CaSR-mediated
Gq activation than reported in other studies on responses of downstream signaling
readouts. Nevertheless, we observed a higher potency of spermine than external
calcium to activate Gq, which is qualitatively similar to earlier studies [174]. Spermine
and spermidine, as direct CaSR-activators, have been reported to have a high potency
with respect to intracellular calcium release, at a basal calcium concentration of 0.5
mM in the medium [174]. Comparing these data with our findings on Gq activation
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suggests that the increased intracellular calcium release is either established through
downstream processes within the signaling network, or are induced independently
of Gq.
CaSR drugs bias the Gq response to Ca2+
We used synthetic, allosteric modifiers, so-called CaSR-drugs, in combination with
external calcium to investigate interactions of the modifiers with external calcium at
the level of Gq activation. Cells, pretreated with 1 µM of the allosteric CaSR-inhibitor
(calcilytic) NPS-2143, 90 seconds prior to external calcium addition, showed reduced
Gq activation for all considered calcium doses, resulting in a decreased maximal ratio
change (16.8%; figure 3.4, red and figure 3.6). We found that NPS-2143 causes a right
shift of the Gq-vs-Ca2+ dose response curve (Figure 3.4, red), increasing the EC50
value from 3.4 to 4.7 mM. The sensitivity, quantified with nH, reduced to 3.4 (cf. fig.
3.6). NPS-2143 is documented as a CaSR-specific inhibitor that affects intracellular
calcium mobilization by decreasing the potency of extracellular calcium, resulting in
a right shift of the dose-response curve of the measured intracellular calcium [59, 66].
This is in agreement with our findings.
In contrast to NPS-2143, an allosteric inhibitor, NPS-R568 is a CaSR-specific allosteric
activator (calcimimetic). It potentiates the effect of external calcium stimuli on intra-
cellular calcium release, resulting in a left-shift of the dose-response curve [58, 66].
We added 1 µM R-568 to the cells, again 90 seconds prior to the step-wise stimulation
with external calcium. We observed Gq activation even at basal calcium concentra-
tions of 0.5 mM, which is clearly visible in the dose-response curve (figure 3.4, yel-
low). The dose-response curve is strongly left-shifted, which is reflected by a reduced
EC50 value to about 0.1 mM. Additionally, the maximal response is slightly elevated
(31.0%), compared to stimulation with calcium alone. A near-maximal response was
already established at an external calcium concentration of approximately 3 mM (Fig.
3.4, yellow). Our findings agree with known effects of NPS-R568, as the potentiating
effect has been reported for a stimulus range of 0.5 to 1.5 mM, albeit without influ-
ences on maximal responses [58].
Several allosteric modifiers do not influence Gq activation by CaSR
signaling
Next, we tested whether known allosteric modifiers of CaSR downstream signaling
readouts influence the external calcium mediated response of G_αq upon CaSR
activation. We tested the amino acid L-phenylalanine (PHE) and the polyamines sper-
mine and spermidine. A fixed concentration of these modifiers was added to the
basal calcium concentration of 0.5 mM prior to the stepwise, cumulative increase of
the Ca2+ concentration up to 7 mM.
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Figure 3.4: Effect of the CaSR-drugs on Gq activation. CaSR-HEK cells transfected with the Gq
FRET sensor were calcium depleted to a basal Ca2+ concentration of 0.5 mM prior to stimulation.
During acquisition of fluorescence, 90 seconds before the Ca2+ doses, 1 µM NPS-2143 (red curve) or
1 µM R-568 (yellow curve) was added to the cells and kept constant throughout the experiment. The
presence of the calcimimetic R-568 resulted in a statistically significantly different curve than Ca2+
titration alone, with a p-value «0.05 resulting from the inverse lack-of-fit test described in the section
materials and methods. ncalcium = 17, nNPS−2143 = 11, nNPS−R−568 = 26. Solid lines: fit to equation 4.1;
error bars indicate SEM. For a summary of the statistics of these fits see figure 3.6.
L-phenylalanine as CaSR modifier does not alter Gq activity
The CaSR has been reported to function as a broad range amino acid sensor, with L-
phenylalanine having one of the strongest influences [165]. Millimolar concentrations
of PHE turn sinusoidal oscillations in intracellular calcium into more spike-like
dynamics [65]. Positive cooperativity between Ca2+ and PHE has been reported,
presumably due to the allosteric interactions of their binding sites, increasing both
potency and cooperativity [165, 178]. It has been suggested G12/13 is responsible for
signaling to intracellular calcium oscillations, independent of Gq [179].
We hypothesized that enhanced signaling via G12/13, in response to PHE, should
result in a right shift of the dose-response curve of Gq activity in the presence of PHE,
due to G protein competition. We added 10 mM PHE to the medium prior to the
calcium stimulation and found that, despite the downstream signaling effects reported
in literature, L-phenylalanine did not influence the CaSR in activating Gq. Our data
does therefore agree with the earlier hypotheses that PHE signals independent of Gq,
but we observed no evidence for G protein competition.
The Gq-vs-Ca2+ dose-response curves are not significantly different in the presence
or absence of the amino acid, the dose-response curve characteristics (EC50 = 3.9 mM,
max. response = 24.0% and Hill coefficient = 3.7) are therefore essentially unchanged
(figures 3.5A, 3.6).
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A
B
Figure 3.5: Comparison of CaSR modifiers with respect to their potential to influence Ca2+-
induced Gq activation. CaSR-HEK cells transfected with the Gq FRET sensor were calcium depleted
to a basal Ca2+ concentration of 0.5 mM prior to stimulation. CaSR modulators PHE, spermine and
spermidine were added to the assay 90 seconds before Ca2+ stimulation, and fluorescence emission
of the Gq sensor was recorded. A) Comparison of Gq activity upon Ca2+ stimulation in the presence
(green) and absence of 10 mM PHE (blue). B) Effects of Ca2+ stimulation in the presence of 0.5 mM
spermine (orange), 13 mM spermidine (purple) or in the absence of modifier (blue). In all plots, error
bars indicate SEM. Solid lines are the fit to equation 4.1. nCa2+ = 17, nCa2++PHE = 43, nCa2++spermine =
33, nCa2++spermidine = 25. For a summary of the statistics of these fits see figure 3.6.
Polyamines influence the potency and cooperativity of the Ca2+ induced activation
of Gq by CaSR
Quinn et al. [174] reported that the polyamines spermine and spermidine reduced
the activation threshold of the CaSR for extracellular calcium, resulting in a left-shift
of the dose-response curves measured in intracellular calcium assays.
We held the polyamine concentrations constant to investigate their effect as allosteric
modifiers during the calcium titration experiments. We found that 0.5 mM spermine
(half its EC50 value) and 13 mM spermidine (maximal concentration used in the sper-
midine titration experiment) caused subtle changes in Gq activation by Ca2+. The
presence of the modifiers slightly affected the EC50 concentrations (2.6 mM with sper-
mine, 2.9 mM with spermidine, 3.4 mM without modifier), and reduced the maximal
ratio change to about 19.3 and 23.4 %, compared to 26.7 % without polyamines (fig-
ure 3.5B, 3.6). Interestingly, the Ca2+ cooperativity markedly decreased, indicated by
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Hill coefficients of 2.5 (spermine) and 2.7 (spermidine).
We observed that some cells responded to very low concentrations of calcium with
a transiently peaked Gq activation (figure S3.15, S3.16) in the presence of spermine
and spermidine. Again, we emphasise that this can have a dynamic impact on
downstream signaling.
Summarizing, we see subtle modifying effects of the polyamines on the Ca2+-induced
activation of Gq by CaSR, leading to an altered shape of the dose-response curve.
From these results, we conclude that the presence of the allosteric modifiers influences
CaSR-Gq interactions, presumably by shifting the balance of receptor conformations.
The enhancing effect of the polyamines on intracellular calcium release [174] therefore
appears to result from amplifications of pre-steady state dynamics of Gq activity, not
captured by the dose-response curves, or they are due to a biasing effect of the CaSR
that is independent of Gq activity.
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Figure 3.6 (previous page): Overview of the signaling kinetics for the different CaSR-treatments.
Hill coefficients (nH), and EC50 values of the different CaSR-treatments were obtained by
fitting the dose-response data of the single cells within the different treatments to equation
4.1. Maximum ratio change (YFP/CFP) of the single cells corresponding to 7 mM agonist
was calculated upon the parameter values obtained by the fitting. These characteristic
values are represented with box plots. Upper plot: EC50 values [mM]. Middle: Hill
coefficients. Lower plot: YFP/CFP ratio changes (in %), corresponding to stimulation with
7 mM agonist. Boxes: interquartile range (IR) from the 25th and 75th percentile. White line:
median. Error bars: indicating the most extreme data point within 1.5 · IR distance from
the 25th and 75th percentile. Outliers represent data points with distance of more than 1.5
· IR (black) and 3 · IR (grey). Insets correspond to the calculated median values. The size
of the sample is indicated by n.
3.3 Discussion
Whether ligand bias observed in signaling readouts downstream of GPCRs can be
attributed to GPCRs only or, in addition, to the connecting signaling network is
unclear for most GPCRs. To gain more understanding of the ligand-biasing potential
of a GPCR, we measured the direct activation of Gq by the class C GPCR CaSR. We
will discuss our results, summarized in figure 3.6, in the light of reported biased
activation of downstream signaling readouts by the CaSR.
The kinetic characterisation of activation of Gq by Ca2+ only (figure 3.2 and 3.6) is very
similar to the kinetics reported with intracellular calcium mobilization as downstream
read-out, which is believed to run via Gq [174]. We also found the expected activation
and inhibition effects of the calcimimetic (NPS-R568) and the calcilytic (NPS-2143)
[58, 59], respectively, confirming that we indeed observe CaSR responses. Our Gq
activation responses to strontium are in line with earlier studies as well, indicating
that this agonist is less potent than calcium [78, 168].
The high similarity between classical Ca2+ mobilization data and our new upstream
Gq activation measurements indicate that the relay from Gq to intracellular calcium
(including PLC activation and IP3-induced Ca2+ channel opening at the ER) is highly
linear. Hence, in these cases, Gq is a reliable read-out for assessing downstream
signaling activation.
At the level of Gq activation, we did not observe low concentration effects of the
polyamines (spermine and spermidine), which were observed earlier with intracellu-
lar calcium release data [174]. Also, the polyamides did not function as modifiers,
increasing the receptor sensitivity to extracellular calcium [174]. One explanation for
these discrepancies is that the connecting signaling network, with Gq as input, plays
an important role. For instance, it can in principle attenuate or amplify responses of
Gq to CaSR agonists and modifiers. Transient activity of G proteins can impact down-
stream signaling as well, which are not visible in our steady-state dose-response
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curves. We note that in the spermine and spermidine titration experiments, we did
not observe transient activity at low agonist concentrations (figures S3.10, S3.11).
We cannot rule out that polyamines stabilize receptor conformations that signal
independently of Gq, this would make them true biasing signals. Indeed, we find
indications that spermine is acting as a biasing agonist. In our experiments, increases
in spermine led to a disproportionate fluorescence change of CFP and YFP (figure
S3.10). Whereas we generally observe a comparable quantitative change in CFP and
YFP fluorescence, we measured with spermine a fast increase in CFP fluorescence
that was not reflected by an evenly fast decrease in YFP fluorescence. This effect was
not caused by autofluorescence of the compound (see figure S3.17B). The observed
behavior might be caused by differential coupling of Gαq with Gβγ subunits, or
an altered binding to the receptor, for instance as multimers, suggesting that the
conformation of the CaSR bound to the polyamine influences the CaSR-Gq assembly.
We observed a similar disproportional change in CFP and YFP fluorescence in the
presence of the calcimimetic NPS-R-568 that was also not caused by autofluorescence
(figure S3.13 and S3.17A).
We did not find any effects of the amino acid phenylalanine on Gq activation. This
confirms earlier indirect inferences that Gq is not involved in signaling in response to
amino acids [179]. What we did expect however, but did not see, is any evidence of G
protein competition effects in the Gq signal upon PHE addition. This could be due to
the fact that fluorescent G protein that we use is ectopically expressed (as compared
to G12/13), or it suggests that no pre-coupling of G proteins occurs in the absence of a
signal and, hence, less competition.
Our results show that single-cell based pharmacology has great potential to comple-
ment existing high-throughput analyses. For instance, we were able to trace single
cell responses to different ligands, monitor their (de-)activation responses and obtain
kinetic information. This emphasizes the importance of single-cell, real-time measure-
ments of signaling. Also large cell-to-cell variabilities have been found in cellular sig-
naling [180, 181], indicating that the signaling outcome of the same signal added to
the same type of cells, cultured in the same way, can still be different. This indicates
that in some cases subpopulations of cells, with qualitatively different signaling dy-
namics, should even be distinguished.
Summarizing our observations, we find that ligand bias can be established at the onset
of cellular signaling, at the level of a GPCR and a G protein interaction. This is likely
occurring via the by-now-popular view in the field that distinct GPCR conformations,
signaling via different G proteins, are stabilized by particular ligand combinations. We
therefore find indirect evidence in support of this model. Direct observation of distinct
receptor conformations that signal differently would be a major next achievement in
the field. We also found evidence that the signaling network downstream of a GPCR,
linking a G protein to a downstream signaling readout, can modulate ligand bias.
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We see great potential for experiments that illustrate in single living cells, in real-time,
the decomposition of ligand bias into receptor and downstream-signaling-network
contributions, for instance by using multiple fluorescent reporters in the same cell to
study how their covariations depend on extracellular signal combinations.
3.4 Materials and Methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM) + GlutaMax, calcium free DMEM,
Hank’s Balanced Salt Solution (HBSS), penicillin-streptomycin (pen/strep), Lipofec-
tamine 2000 transfection reagent and Hygromycin B were purchased from Life
Technologies; the allosteric CaSR modulators R-568 and NPS-2143 from Tocris Bio-
sciences. All other chemicals were from Sigma-Aldrich if not stated otherwise.
HEK-293 wild-type cells were obtained from the American Tissue Culture Collection
(ATTCr CRL-1573TM). HEK-293 cells stably expressing the human calcium-sensing
receptor (CaSR-HEK) were a friendly gift from Dr. Donald Ward, The University of
Manchester. The plasmid containing the cDNA encoding human Gαq, Gβ1 and Gγ2
tagged to the fluorescent proteins are described in [169, 170].
Cell Culture & Transfection
HEK-293 cells and CaSR-HEK cells were grown in DMEM + GlutaMax supplied with
10% FCS and 1 % penicilin/streptomycin. In addition, CaSR-HEK cells were under
Hygromycin B selection (200 ¯M/ml). Two days prior to the experiment, the cells were
seeded on fibronectin-coated glass coverlips. Lipofectamine 2000 was used according
to the manufacturer’s instructions to transfect the cells with plasmids encoding the
FRET sensor Gqα-CFP / Gβγ-YFP the day before the experiment.
Wide-Field Fluorescent Microscopy
HEK-293 cells and CaSR-HEK cells grown on coverslips were mounted into an
Attofluor cell chamber and maintained in microscopy medium (20 mM HEPES (pH =
7.4), 137 mM NaCl, 5.4 mM KCl, 0.5 mM CaCl2, 0.8 mM MgCl2 and 20 mM glucose).
They were placed on a Zeiss inverted microscope (Axiovert 200M) equipped with
an oil immersion 40x objective and kept at 37 ◦C . The probes were illuminated
with a Xenon arc lamp with a computer controlled monochomator (bandwidth 30
nm) and excited at 420 nm. Emission of the single cells was detected with a 470/30
bandpass filter and 535/30 bandpass filter by turning the filter wheel for CFP and
YFP fluorescence, respectively. The images were binned (4x4) and recorded with a
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cooled charged coupled device camera (Coolsnap HQ, Roper Scientific, Tucson, AZ,
USA). The illumination time was set to 210 ms for both CFP and YFP.
Experimental Design
Prior to the experiments, the cells were Ca2+-depleted to reduce G protein activity
induced by the CaSR to a minimum. The medium of the cells was changed twice
with serum free DMEM containing 0.5 mM Ca2+ and subsequently incubated in the
low-calcium medium for at least 20 min prior to experiments at 37 ◦C and 5% CO2.
The cells were stimulated with stepwise increasing agonist concentrations every 90
seconds to allow the formation of a new steady state of Gq activity. Direct agonists
used were Ca2+, Sr2+, spermine and spermidine. Dependent on the experimental set
up, CaSR specific drugs and modulators were added to the cells 90 seconds before the
Ca2+ stimulation as follows: 1 ¯M allosteric inhibitor NPS-2143 or 1 ¯M calcimimetic
R-568; 10 mM Phenylalanine, 0.5 mM spermine, or 13 mM spermidine. NPS-2143 and
R-568 were dissolved in DMSO. It was made sure that only a total amount of 0.01 %
DMSO was added to the cells.
Image and data analysis
ImageJ (http://rsbweb.nih.gov/ij/) has been used to analyze the FRET ratio imaging
data: The average fluorescence intensity of individual cells in the CFP and the YFP
channel intensity were obtained by drawing regions of interest (ROI) of the individ-
ual cells. Background intensity was obtained by selecting an ROI outside of cells. The
background data was subtracted from average intensities of the cells and the data
was normalized to the average of the first 20 frames without stimulus. Further, YFP
data was corrected for crosstalk from CFP emission into the YFP channel (55%).
These normalized intensity data were used to calculate the YFP/CFP ratio, which ac-
counted as a measure of Gq activity.
Mean intensities of CFP, YFP and YFP/CFP ratio data and standard error of the mean
(SEM) were calculated from at least 10 cells, obtained in at least 6 independent exper-
iments. For the dose response data, short periods of the steady states intermediat-
ing the stimulus additions have been chosen for which the YFP/CFP ratio is plotted
against the corresponding agonist dose. Same holds true for the RFP fluorescence
emission, whereas steady states were hardly obtained in these measurements and
mean intensities were used for the dose-response curves. YFP/CFP ratios have been
fitted to a distorted Hill equation (equation 4.1)
ymodel = α+
βxh
Kh + xh
(3.1)
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for which x being the agonist concentration and y the normalized fluorescent intensity.
K and h are the dissociation constant and Hill coefficient, respectively with α as the
basal value and β the distortion factor. Fitting of the complete data sets was conducted
by minimizing the objective function, the weighted sum of squares residuals (equation
4.2), whereas the objective of single cell read-outs was the sum of squares residuals
(equation 3.3):
objcomplete =
n
∑
i=1
(ymodel,i − ydata,i)2
σ2data,i
, (3.2)
objindividual =
n
∑
i=1
(ymodel,i − ydata,i)2. (3.3)
Here, ymodel denotes the fluorescent intensity calculated by the model, described in
equation 4.1; ydata are the data points for agonist concentration i. σdata,i is represent-
ing the standard deviation of the data per concentration i.
In order to determine the distribution of EC50 values, Hill coefficients and maximal
responses given the data, the dose-dependent single cell read-outs were fitted indi-
vidually to equation 4.1. Upon these parameters obtained, maximal responses of the
single cells were calculated, corresponding to 7 mM agonist concentration. The ob-
tained signaling characteristica are displayed in Box-and-Whisker plots (Fig. 3.6) in
which the box represents 50 % of the data that lies within the 25th and 75th percentile,
defining the interquartile range (IR). The median is represented as horizontal line
within the box and the whiskers are drawn to the most extreme data points that still
lie within the distance of 1.5 · IR from the drawn percentiles. Outliers are represented
as black and grey dots, if they are ± 1.5 · IR and ± 3 · IR apart from the percentiles,
respectively.
Statistical analysis for the comparison of different CaSR treatments has been per-
formed by an inverse lack-of-fit test. Therefore, all data sets were compared to the
calcium titration data using F-distribution. The sum of squares (SSq) of the two data
sets were calculated as described above for equation 3.3, using the fit of the calcium
titration as ymodel. The random variate X of the F-function was calculated by divid-
ing the SSq of the second data set normalized by its degrees of freedom (d f2) by the
SSq normalized to its degrees of freedom (d fref) of the reference data set (equation
3.4). The d f2 and d fref were:
d f2 = #data points;
d fref = #data points− #parameters of fitting.
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The cumulative distribution function (cdf) of the corresponding F-function was calcu-
lated for the X values and corresponding p-values were determined.
X =
SSq2/d f2
SSqref/d fref
; (3.4)
p = 1− cd f (X)
We used a cutoff-value of 0.05 for the statistical analysis, thus only for p-values less
than 0.05 we considered the curves of the different treatments as statistically different
to the calcium titration curve.
All corrections and analyses, as well as plotting and curve fitting have been carried
out using Wolfram Mathematica version 10.0.
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single dose cumulative addition
A B
Figure 3.7: Comparison of Gq activation by single calcium additions and response to cumulative
additions. CaSR-HEK cells transiently transfected with the Gq FRET sensor were kept in low calcium
medium for 20 minutes before the experiment. A) The cells were stimulated with a single addition of
one of three different calcium concentrations and CFP and YFP emission wavelengths were recorded.
The final calcium concentrations in the medium were: 2.7, 5.2 and 7.2 mM. Mean traces of the time
course data are shown for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars indicate
SEM. B) Comparison of the Gq activity between single doses and cumulative additions (data from
calcium titration experiment, main text) . For the single stimulations, the mean responses were
determined at the steady states of the time curses in A, and error bars indicate the SEM (orange).
The Gq responses during the cumulative stimulation (blue) were determined by the fitting curves
(equation 4.1) of the calcium-titration dose-response curves for the mentioned calcium concentrations.
Error bars indicate SEM.
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Figure 3.8: Calcium titration experiment. CaSR-HEK cells transiently transfected with the Gq FRET
sensor were kept in low calcium medium (0.5 mM) for 20 minutes before the experiment. During the
experiment, the cells were exposed to cumulative increasing calcium concentrations and CFP and
YFP emission wavelengths were recorded. The cells were exposed to calcium concentrations of 0.5,
1, 2, 3, 4, 5 and 7 mM. The period between stimulus addition was 90 seconds. n = 17 cells. A) time
traces of CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual
cells. B) Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red).
Error bars indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP
(upper), YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations.
Empty circles: individual cells. Filled circles: mean values. Error bars indicate SEM. D) Negative
control: HEK293 wild-type cells transfected with the Gq FRET sensor were exposed to the same
experimental setup as described above.
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Figure 3.9: Strontium titration experiment. CaSR-HEK cells transiently transfected with the Gq
FRET sensor were kept in low calcium medium (0.5 mM) for 20 minutes before the experiment.
During the experiment, the cells were exposed to cumulative increasing strontium concentrations
and CFP and YFP emission wavelengths were recorded. The cells were exposed to strontium
concentrations of 0, 1, 3, 5, 7, 9, and 11 mM. The period between stimulus addition was 90 seconds.
n = 32 cells. A) time traces of CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower
pannel) of the individual cells. B) Mean traces of the time course data for CFP (cyan), YFP (yellow)
and YFP/CFP ratio (red). Error bars indicate SEM. C) Dose-response curves generated from the
steady-state responses of CFP (upper), YFP (middle) and YFP/CFP ratio (lower pannel) to the
increasing stimulus concentrations. Empty circles: individual cells. Filled circles: mean values. Error
bars indicate SEM. D) Negative control: HEK293 wild-type cells transfected with the Gq FRET sensor
were exposed to the same experimental setup as described above. n = 12.
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Figure 3.10: Spermine titration experiment. CaSR-HEK cells transiently transfected with the Gq
FRET sensor were kept in low calcium medium (0.5 mM) for 20 minutes before the experiment.
During the experiment, the cells were exposed to cumulative increasing spermine concentrations and
CFP and YFP emission wavelengths were recorded. Spermine concentrations used: 0, 0.1, 0.25, 0.5, 1,
3, and 5 mM. The period between stimulus addition was 90 seconds. n = 34 cells. A) time traces of
CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM.
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Figure 3.11: Spermidine titration experiment. CaSR-HEK cells transiently transfected with the Gq
FRET sensor were kept in low calcium medium (0.5 mM) for 20 minutes before the experiment.
During the experiment, the cells were exposed to cumulative increasing spermidine concentrations
and CFP and YFP emission wavelengths were recorded. Spermidine concentrations used: 0, 1, 3, 5, 7,
9, 11 and 13 mM. The period between stimulus addition was 90 seconds. n = 16 cells. A) time traces of
CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM. D) Negative control:
HEK293 wild-type cells transfected with the Gq FRET sensor were exposed to the same experimental
setup as described above. n = 13.
70
Biased activation of Gαq by the CaSR
A
B D
CF
P
YF
P
YF
P 
/ C
FP
Ca2+ titration + 1 µM NPS-2143
Figure 3.12: Calcium titration experiment in the presence of the calcilytic NPS-2143. CaSR-HEK
cells transiently transfected with the Gq FRET sensor were kept in low calcium medium (0.5 mM)
for 20 minutes before the experiment. At the start of the experiment, the cells were exposed to 1 µM
NPS-2143 and after 90 seconds incubation time calcium was increased in a step wise manner. The
CFP and YFP emission wavelengths were recorded. Calcium concentrations used: 0.5, 1, 2, 3, 4, 5,
and 7 mM. The period between stimulus addition was 90 seconds. n = 16 cells. A) time traces of CFP
(upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM. D) Negative control:
HEK293 wild-type cells transfected with the Gq FRET sensor were exposed to the same experimental
setup as described above. n = 3.
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Figure 3.13: Calcium titration experiment in the presence of the calcimimetic NPS-R568. CaSR-
HEK cells transiently transfected with the Gq FRET sensor were kept in low calcium medium (0.5
mM) for 20 minutes before the experiment. At the start of the experiment, the cells were exposed to 1
µM NPS-R568 and after 90 seconds incubation time calcium was increased in a step wise manner.
The CFP and YFP emission wavelengths were recorded. Calcium concentrations used: 0.5, 1, 2, 3, 4,
5, and 7 mM. The period between stimulus addition was 90 seconds. n = 25 cells. A) time traces of
CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM. D) Negative control:
HEK293 wild-type cells transfected with the Gq FRET sensor were exposed to the same experimental
setup as described above. n = 5.
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Figure 3.14: Calcium titration experiment in the presence of phenylalanine. CaSR-HEK cells
transiently transfected with the Gq FRET sensor were kept in low calcium medium (0.5 mM) for
20 minutes before the experiment. At the start of the experiment, the cells were exposed to 10 mM
phenylalanine and after 90 seconds incubation time calcium was increased in a step wise manner.
The CFP and YFP emission wavelengths were recorded. Calcium concentrations used: 0.5, 1, 2, 3, 4,
5, and 7 mM. The period between stimulus addition was 90 seconds. n = 43 cells. A) time traces of
CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM. D) Negative control:
HEK293 wild-type cells transfected with the Gq FRET sensor were exposed to the same experimental
setup as described above. n = 7.
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Figure 3.15: Calcium titration experiment in the presence of 0.5 mM spermine. CaSR-HEK cells
transiently transfected with the Gq FRET sensor were kept in low calcium medium (0.5 mM) for 20
minutes before the experiment. At the start of the experiment, the cells were exposed to 0.5 mM
spermine and after 90 seconds incubation time calcium was increased in a step wise manner. The
CFP and YFP emission wavelengths were recorded. Calcium concentrations used: 0.5, 1, 2, 3, 4, 5,
and 7 mM. The period between stimulus addition was 90 seconds. n = 35 cells. A) time traces of CFP
(upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM D) Negative control:
HEK293 wild-type cells transfected with the Gq FRET sensor were calcium depleted to a basal level
of 0.5 mM and after 20 min the emission wavelengths of CFP and YFP were recorded over time. The
cells were exposed to 5 mM spermine and after 90 seconds the cumulative addition of calcium was
started. The traces show mean data of CFP (cyan), YFP (yellow) and the YFP/CFP ratio (red) of n =
12 cells.
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Figure 3.16: Calcium titration experiment in the presence of 13 mM spermidine. CaSR-HEK cells
transiently transfected with the Gq FRET sensor were kept in low calcium medium (0.5 mM) for
20 minutes before the experiment. At the start of the experiment, the cells were exposed to 13 mM
spermine and after 90 seconds incubation time calcium was increased in a step wise manner. The
CFP and YFP emission wavelengths were recorded. Calcium concentrations used: 0.5, 1, 2, 3, 4, 5,
and 7 mM. The period between stimulus addition was 90 seconds. n = 35 cells. A) time traces of CFP
(upper) and YFP (middle) emission and YFP/CFP ratio (lower pannel) of the individual cells. B)
Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). Error bars
indicate SEM. C) Dose-response curves generated from the steady-state responses of CFP (upper),
YFP (middle) and YFP/CFP ratio (lower pannel) to the increasing stimulus concentrations. Empty
circles: individual cells. Filled circles: mean values. Error bars indicate SEM.
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Figure 3.17: Background intensity of spermine titration experiment and calcium titration in the
presence of the calcimimetic. A) CaSR-HEK cells transiently transfected with the Gq FRET sensor
were kept in low calcium medium (0.5 mM) for 20 minutes before the experiment. At the start of
the experiment, the cells were exposed to 1 µM NPS-R568 and after 90 seconds incubation time
calcium was increased in a step wise manner. The CFP and YFP emission wavelengths were recorded.
Calcium concentrations used: 0.5, 1, 2, 3, 4, 5, and 7 mM. The period between stimulus addition
was 90 seconds. The time traces of the background fluorescence of the YFP/CFP ratios do not
show a change in background fluorescence after the addition of the calcimimetic. Black line: mean.
Dotted lines: individual measurements. N= 18 measurements. Error bars indicate SEM. B) The
CaSR-HEK cells were treated following the scheme described above, besides stimulation resulted
by increasing concentrations of spermine in the absence of any CaSR modifier or drug. Spermine
concentrations used: 0, 0.1, 0.25, 0.5, 1, 2, 3, 5 mM. The time traces of the background fluorescence of
the YFP/CFP ratios do not show a change in background fluorescence while increasing the polyamine
concentration. Black line: mean. Dotted lines: individual cells. Error bars indicate SEM.
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Assessing the covariation of Gαq activity and intracellular
calcium mobilization upon GPCR stimulation
In collaboration with:
Jakobus van Unen, Joachim Goedhart, Theodorus W.J. Gadella, and Frank J.
Bruggeman
Manuscript submitted for publication
77
Abstract
Background G protein-coupled receptor (GPCR) signaling is initiated by binding of
the receptor to extracellular ligands. Different ligand combinations stabilize distinct
receptor conformations that each activate intracellular signaling pathways to differ-
ent degrees. This phenomenon is called biased signaling. Experimental read-outs of
GPCR signaling are usually chosen downstream in the signaling network. Biased sig-
naling that is observed at this level may therefore not solely originate from
receptor-level bias but in addition from network bias that occurs downstream of the
receptor.
Aim In this study, we measure the dynamic co-activation of two different signaling
molecules by the external calcium sensing receptor (CaSR). We measure the direct
activation of the G protein Gq by CaSR and the downstream mobilization of intracel-
lular calcium, (Ca2+)i, upon exposure to various (allosteric) CaSR ligands. By
measuring their co-activation in real time, we aim to distinguish the contributions of
the receptor and the downstream network to biased signaling.
Results Using Förster Resonance Energy Transfer (FRET) and multicolor fluores-
cence microscopy, we measured simultaneously the dynamics of Gq (de-)activation
and (Ca2+)i mobilization in single cells, in response to distinct CaSR ligands. The co-
variation of these signaling outputs allowed us to discriminate between of receptor
and network contribution to biased signaling.
Conclusions We successfully co-imaged the GPCR-induced dynamics of Gαq and
(Ca2+)i in single cells. The treatment with different ligands resulted in similar trends
of the Gq-(Ca2+)i covariation, confirming the major role of Gq in (Ca2+)i mobiliza-
tion. We found that the precise covariation depended on the ligand combinations
used. This indicates that biased signaling results at level of the CaSR and in the
downstream signaling network.
4.1 Introduction
Intracellular calcium is a versatile messenger molecule that is involved in many
cellular processes. Its concentration in the cytosol is regulated by the interplay
of many molecular processes, involving second messengers, calcium pumps and
channels [182]. Many of these processes are indirectly regulated by GPCRs.
GPCRs bind and activate distinct intracellular signaling proteins, such as het-
erotrimeric G proteins and β-arrestins. Different receptor conformations vary in their
binding preferences for intracellular proteins ([36], reviewed in [43]). Heterotrimeric
G protein binding to an active receptor induces conformational changes that lead to a
GDP/GTP exchange on the Gα subunit. The GαGTP and Gβγ subunits then dissoci-
ate and activate downstream signaling proteins, leading to, amongst other processes,
activation of intracellular calcium.
78
Simultaneous detection of Gαq and (Ca2+)i covariation
Increases in intracellular calcium are induced by GPCR signaling mainly via activation
of the heterotrimeric G protein Gαq. The GTP-bound, active form of Gαq activates
phospholipase Cβ (PLCβ). PLCβ cleaves phosphatidylinositol 4,5-bisphosphate (PIP2)
into inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 induces the
opening of channels of the endoplasmatic reticulum (ER), the intracellular calcium
store, resulting in a calcium flux into the cytosol. In addition, Gβγ subunits of active
Gi proteins can also activate PLC [183, 184]. Calcium channels and pumps in the
plasma membrane allow for the influx of external calcium. Crosstalk between GPCRs
and plasma membrane channels has been reported in various cases, either through
direct interactions or second messenger molecules [183, 185, 186] (figure 4.1).
Intracellular calcium mobilization is often used as a GPCR signaling read-out (e.g.[91,
187–189]). Different optical methods allow for the measurement of calcium in single,
living cells; examples are fluorescent dyes such as Fura-2 or Fluo 4 [190],
genetically-encoded fluorescent sensors from the cameleon or CaMP family [191] and
bioluminescence-based assays [190]. These tools provide a rich palette of techniques
that differ in measurement characteristics such as, for example, dynamic range, bind-
ing kinetics, photostability, excitation and emission wavelengths or calcium buffering
capacity [190].
Since changes in free cytosolic calcium are brought about by many intracellular
processes (reviewed in [182]), intracellular calcium mobilization is characterized by
several complex, spatio-temporal dynamics, ranging from single channel events to
(inter-)cellular calcium waves. It appears that stimulus information is encoded in the
amplitude and frequency of calcium oscillations [182, 192].
GPCRs couple to many signaling pathways. Ligands activate different signaling
pathways to varying degrees, a phenomenon described as ligand bias or biased
agonism [70, 74–77]. The biasing ligands stabilize distinct receptor conformations
that activate downstream signaling molecules to varying degrees [44, 69, 75, 193,
194]. Clinically relevant compounds have been shown to have biased activities [84,
85] and particular compounds with biasing effects have been developed [86, 87].
Most experimental studies deduce ligand bias from shifts in dose-response curves of
downstream signaling read-outs [80, 94]. Since only few studies focus on the onset of
ligand bias at the receptor level, it is often unknown whether ligand bias is induced
by the receptor or whether it is a signaling network effect. Here we investigate the
role of the network in establishing network bias.
In this study, we use the human extracellular calcium sensing receptor (CaSR). It is
known for its biased signaling upon stimulation with various ligands. It is activated
and allosterically modified by many external signals besides calcium, such as di- and
trivalent ions, amino acids or polyamides, as well as CaSR-specific pharmaceutical
compounds with activating or inhibiting effects [50, 54]. Further, it has recently been
identified as an amino-acid sensor [164, 165]. Mutations in this receptor are associated
with hereditary diseases related to the body calcium regulation [67, 166], as well as
biased agonism resulting from gain- or loss-of-function mutations [167].
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Figure 4.1: Schematic overview of the intertwined GPCR signaling pathways leading to intra-
cellular calcium mobilization and the CaSR ligands used in this study. A) G protein-coupled
receptors initiate signaling routes that lead to an increase in intracellular calcium. Activated Gαq and
βγ subunits of Gi proteins activate PLC, which cleaves PIP2 into IP3 and DAG. IP3 binding to recep-
tors in the membrane of the ER initiates calcium release from the internal stores. Further, GPCRs
interact with calcium channels at the plasma membrane, allowing calcium influx to the cytosol from
the extracellular space. B) HEK293 cells stably expressing the CaSR were transfected with the Gq
FRET sensor and the red fluorescent calcium sensor R-GECO-1 and exposed to different stimuli. The
stimuli we chose fall into three groups: i. direct activators, ii. allosteric, CaSR specific drugs and
iii. modulators that act in combination with external Ca2+ as main stimulus. Dynamics of Gq and
(Ca2+)i were recorded.
The three families of heterotrimeric G proteins Gαq, Gαi and Gα12/13 are activated by
the CaSR, as well as β-arrestins, and initiate signaling of several downstream targets
[55]. These have been observed, for instance IP3 accumulation, cAMP levels, ERK
phosphorylation and changes in intracellular calcium, in order to address the biasing
influence of several CaSR ligands [66, 78, 167, 168]. There has been great interest in the
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biased signaling capacity of GPCRs, implying a great potential for the development
of ‘biasing drugs’ [81–83]. However, remarkably few studies are focusing on the
receptor as origin of biased signaling as mainly downstream read-outs are observed.
As a consequence, it is largely unknown to what extend the receptor contributes to
ligand bias and how important the underlying signaling network is in establishing
and modulating signaling bias.
In this work, we addressed the propagation of biased signaling induced by the
CaSR. We measured the responses of CaSR-induced Gαq and intracellular calcium
mobilization simultaneously in real-time and in single cells, upon receptor stimulation
with various CaSR ligands. We used a Gq FRET sensor, described in [169, 170], and
a red fluorescent, genetically encoded calcium sensor, R-GECO-1, to elucidate the
covariation of these signaling components in life cells and to assess the importance of
network bias.
4.2 Results
Characterization of R-GECO-1, an intracellular calcium sensor
R-GECO-1 is a genetically encoded, red fluorescent calcium sensor belonging to the
CaMP family [195]. It is dim in the absence of calcium and bright in the calcium
bound state. It has a dissociation constant for calcium of 480 nM [195]. It consists of
the circular permutated fluorescent protein mApple that is fused to the calmodulin
binding site of chicken myosin light chain kinase (M13) and a vertebrate CaM [195],
illustrated in figure 4.2A. Following calcium binding, the two CaM domains interact
and induce a reorganization of the fluorescent protein, which results in an increase
in fluorescence [196]. Absorption and emission wavelengths of 560 nm and 600 nm
are reported, respectively, which makes them applicable for the combined use with
cyan/yellow fluorescence FRET sensors, as there is hardly any overlap with their
respective emission spectra (figure 4.2B).
In order to determine fluorescent crosstalk between the emission channels, CaSR-HEK
cells were transfected with R-GECO-1 and exposed to wavelengths for CFP (420 nm)
and RFP (570 nm) excitation. Fluorescence emission was recorded in the CFP, YFP
and RFP channel (470/30, 535/30 and 620/60 bandpass filters, respectively). The
crosstalk of R-GECO-1 was assessed as 2.6 % and 2.4 % for the CFP and YFP emission,
respectively (see Fig. 4.3A). However, the same set-up shows a decrease of RFP
fluorescence (photobleaching) over the time course of a typical experiment (about 800
seconds, see Fig 4.3B, upper pannel). In order to correct for this effect, the data was
fitted to an exponential decay function (see equation 4.3) and the decay parameters
determined were used to correct further R-GECO-1 data for bleaching. Interestingly,
R-GECO-1 transfection also affects CFP and YFP emissions over time. The average
CFP emission increases slightly over time, whereas YFP emission decreases in the
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first 100 seconds and stays constant thereafter (Fig. 4.3B, middle and lower panel,
respectively).
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Figure 4.2: Overview of the fluorescent sensors R-GECO-1 and Gq FRET. A) Schematic of the
amino-acid sequence of R-GECO-1 (left), according to [195], and the Gq FRET sensor (right) as
described in [169, 170]. B) Emission spectra of R-GECO-1 (left) in high-calcium conditions (stimulated
cells, solid line) and low-calcium conditions (non-stimulated cells, dashed line). Right: relevant
excitation and emission spectra of the fluorophores in the Gq FRET sensor. Cyan: absorption and
emission spectra (lighter and darker line, respectively) of mTurquoise; Orange: emission spectrum of
YFP (FRET).
R-GECO-1 compared to the established calcium indicator Ycam
In order to test if R-GECO-1 captures the calcium dynamics as good as other estab-
lished, genetically encoded calcium sensors of the cameleon family, we transfected
CaSR-HEK cells either with R-GECO-1 or the cyan/yellow fluorescence based FRET
sensor Ycam. The CaSR was stimulated by sequentially increasing external calcium
concentrations and the emission of both sensors was recorded. For both sensors, we
found similar calcium dynamics that can roughly be clustered into for types of cellu-
lar responses: i) no response, ii) steady increase, iii) spiking, and iv) oscillations. In
figure 4.4 representative responses of intracellular calcium dynamics in single cells
are displayed for R-GECO-1 transfection (Fig. 4.4A) and transfection with Ycam (Fig.
4.4B). The cells either hardly showed any reaction to stimulation (left panel), rapid
increases upon higher stimulus concentration and more or less stable fluorescence be-
tween two stimuli (second panel from left), single calcium spikes at low stimuli and
damped oscillations at higher concentrations (second panel from right), and sus-
tained oscillations for external calcium concentrations between 3 and 5 mM (right
panel). In the R-GECO-1 transfected cells, basal fluorescence displayed a tendency to
increase, whereas such a behavior was not observed in Ycam transfected cells.
Further, the distinct responses were observed to different percentages for the two con-
structs (Fig. 4.4C). A higher percentage of cells transfected with Ycam displayed
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Figure 4.3: Photophysical effects of R-GECO-1. A) Fluorescent crosstalk (bleed-through) analysis
of R-GECO-1. CaSR-HEK293 cells were transiently transfected with the R-GECO-1 construct. The
cells were exposed to wavelengths for CFP (420 nm) and RFP (570 nm) excitation and fluorescence
emission was recorded in the CFP, YFP and RFP channels (470/30, 535/30 and 620/60 bandpass
filters, respectively). R-GECO-1 shows 2.6% and 2.4% crosstalk with the CFP and YFP channel,
respectively. Representative images of two cells are shown, crosstalk was calculated as the mean
from 8 cells. B) Bleach curve of R-GECO-1. CaSR-HEK293 cells transfected with R-GECO-1 were
exposed to CFP and RFP excitation wavelengths and emission in the RFP, CFP and YFP channel was
recorded over 800 sec. Colored dots: individual cells. Black dots: Mean. Red, solid line in the RFP
ex/em plot: fit to exponential decay, see equation 4.3.
sustained or damped oscillations and fewer non-responding cells compared with
R-GECO-1 transfections. Despite these discrepancies, both sensors recorded qualita-
tively comparable dynamics and also seem to exhibit similar sensitivities for
intracellular calcium as characteristic (Ca2+)i events, as initial rises, peaks or sus-
tained oscillations are recorded at same stimulus levels. From this we concluded that
R-GECO-1 is reliably recording intracellular calcium dynamics.
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Figure 4.4: Comparison of R-GECO-1 and Ycam as intracellular calcium sensors. CaSR-HEK293
cells were transiently transfected with the R-GECO-1 or the Ycam construct. The cells were calcium
depleted for at least 15 min prior to the experiment and subsequently stimulated with step-wise
increasing external calcium concentrations up to 7 mM and 10 µM ionomycin as positive control
at the end of the experiments. Fluorescence emission was recorded throughout the experiment. A)
normalised R-GECO-1 fluorescence, B) the normalised YFP/CFP fluorescence ratio of the Ycam
sensor. Cellular responses upon the stimulation were comparable for both sensors and could be
clustered in four typical responses, from left to right: no response, increase, spiking and oscillations.
C) The distribution of responses in percentage for a total of 161 R-GECO-1 (left) and 75 Ycam (right)
transfected cells, respectively.
Simultaneous measurements of Gq and intracellular calcium
We co-transfected the CaSR-HEK cells with R-GECO-1 and the Gq-FRET sensor to
test whether we could trace changes in Gq activity and intracellular calcium simul-
taneously. The cells were calcium depleted to a basal concentration of 0.5 mM and
stimulated with a pulse of high external calcium. After a period of lower calcium con-
centration in the medium, a second stimulus with varying CaSR ligands was added.
ionomycin-induced internal-calcium release was used as a positive control (Fig. 4.5).
As can be seen in the time-course plots and displayed images of the cells, CaSR acti-
vation by an external calcium pulse leads to an immediate, sustained activation of
Gq, followed by a fast deactivation back to base line levels, as soon as the external cal-
cium signal was reduced (upper images in figure 4.5A, left plots in figure 4.5B-E). The
second stimulation again results in a very fast, sustained activation, its magnitude
dependent on the stimulus strength (e.g. compare figures 4.5B and C). Similarly, in-
tracellular calcium increases about 4-6 fold from its basal level upon the first stimulus
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pulse, and returns quickly to basal levels as soon as the stimulus level drops (lower
images in figure 4.5A and right plots in figure 4.5B-E). However, in contrast to Gq ac-
tivity, the cells respond to the polyamine stimulation with a transient peak in (Ca2+)i,
that is shorter in duration and amplitude than the peak upon the first external cal-
cium stimulation. Possibly, the (Ca2+)i response to calcium stimulation is a combina-
tion of calcium influx and CaSR-induced signaling, whereas the (Ca2+)i increase to
polyamine stimulation is a signaling specific response.
Interestingly, even when the external calcium concentration is increased during
a second stimulation, (Ca2+)i does not reach the same amplitude hight observed
initially. It shows a more transient behavior (see figures 4.5D and E). We did not
observe substantial differences in the intracellular calcium response in the presence
of calcium and phenylalanine (figure 4.5E), compared to calcium alone (figure 4.5D).
These results demonstrate that we are able to trace the comprehensive dynamics of
both Gαq and intracellular calcium simultaneously in single cells.
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Figure 4.5 (previous page): Simultaneous acquisition of Gq activities and intracellular calcium
mobilization upon CaSR activation. CaSR-HEK cells were transfected with the Gq FRET sensor
and R-GECO-1 and calcium depleted to 0.5 mM basal calcium concentration in the medium before
the experiments. The cells were stimulated with a pulse of 5 mM external calcium, followed by a
second treatment with different CaSR-specific ligand or calcium and ionomycin at the end of the
experiments. Fluorescence emission of both sensors in the single cells was recorded over time. A) Gq
ratio fluorescence (left image: widefield image, others: YFP/CFP ratio, green: low activity, red: high
activity) and R-GECO-1 fluorescence (widefield) of representative cells at time points of characteristic
dynamics. Experimental set-up as depicted in B. B) time courses of Gq activity (left) and intracellular
calcium (R-GECO-1, right) with 13 mM spermidine as second stimulus. Cells from this experiment
are depicted in A. C, D, E) same set-up as in B, with 0.5 mM spermine, 5 mM Ca2+, and 5 mM Ca2+
with 10 mM PHE as second stimulus, respectively. Cyan, yellow and red solid lines are depicting
mean fluorescence of CFP, YFP and YFP/CFP ratio of the Gq FRET sensor; colored lines in the right
plots display individual cells and the black, solid line depicts the mean value. Error bars represent
SEM. 6 to 18 individual cells were observed for the different conditions.
Titration experiments
Next, we assessed biased signaling by monitoring the covariation of Gq and intracel-
lular Ca2+, two signaling read-outs at different layers within the signal-transduction
cascade that responds to CaSR ligands. To achieve this we exposed the doubly trans-
fected CaSR-HEK cells to increasing dosages of agonist, in the presence or absence of
allosteric CaSR modifiers.
In this study, we made use of calcium and strontium as direct agonists. The amino
acid L-phenylalanine (PHE), as well as the CaSR-specific, synthetic allosteric ligands
NPS-2143 (calcilytic) and NPS-R-568 (calcimimetic) were used in combination with
external calcium as main stimulus.
During the titration experiments, we monitored the responses of the single cells to the
rising ligand concentrations in real time. These were used to calculate mean traces
and standard errors (SEM). We observed steady-state Gq activation after the single
agonist additions as periods of constant fluorescence. These steady-state levels were
related to the varied agonist concentrations in order to determine the dose-response
relationships of the different treatments.
In most cases, we did not observe steady-states of the intracellular calcium. Therefore,
we used the mean fluorescence of a defined period in between agonist additions
to establish the dose-response curves. A graphical summary of the procedure is
displayed in figure 3.2 in the previous chapter.
In figure 4.6 the time-courses and dose-response curves of Gq activity and intracel-
lular calcium upon external calcium stimulation are depicted as an example; simi-
lar curves were obtained for the experiments with the different ligands and modifier
combinations (see supplementary information).
Due to the influence of R-GECO-1 transfection on the CFP and YFP emission channels
reported earlier, we note that the results of the simultaneous measurements (Gq and
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Figure 4.6: Time course and dose-response curves of Gq and intracellular calcium upon calcium-
titration. CaSR-HEK cells were transfected with the Gq FRET sensor and R-GECO-1 and calcium
depleted to 0.5 mM basal calcium concentration at least 15 min prior to the experiments. The cells
were stimulated with increasing agonist concentrations, in this case external calcium up to 7 mM.
Ionomycin served as positive control at the end of the experiments. Fluorescence emission of both
sensors in the single cells was recorded over time. Time courses (left panels) and dose-response
curve (right panels) of Gq (upper panels) are depicted as means of the individual cells, the colored,
open circles display the responses of the individual cells. Responses of individual cells (colored lines
and open circles, respectively) as well as mean traces (black, solid line and black, filled circles) are
shown for the intracellular calcium (lower panels). Error bars indicate SEM. Red, solid line in the Gq
dose-response curve: fit to equation 4.1.
(Ca2+)i) are not directly comparable with the results obtained when only the Gq-FRET
sensor was used (chapter 3). The two systems, however, give qualitatively similar
results, see figure 4.7.
Covariance of intracellular calcium mobilisation and Gq activation
Next, we compared results obtained from the double transfection experiments, by
comparing cells with the same transfection properties, to investigate network bias
that occurs downstream of Gq and upstream of intracellular calcium mobilisation. In
figure 4.8, we compare the mean values of both read-outs for different CaSR ligands
and stimulus combinations. We plotted the normalized R-GECO-1 intensity, the
indicator for (Ca2+)i, as function of the Gq activity. Since Gq is upstream of (Ca2+)i,
Gq can be viewed as an input and (Ca2+)i as an output. Inputs of Gq are then all
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Figure 4.7: Comparison of the effects of single versus double transfection on time courses and
dose-response curves. CaSR-HEK cells were either transfected with the Gq FRET sensor alone
(lighter colors), or with the Gq FRET sensor and R-GECO-1 simultaneously (darker colors). After
calcium depletion to 0.5 mM basal calcium concentration, the cells were stimulated with increasing
agonist concentrations, in the absence of CaSR-modifiers (upper panels) or in the presence of 1 µM of
the calcimimetic NPS-R-568 (lower panels). Fluorescence emission of the single cells was recorded
over time. Time courses (left panels) and dose-response curves (right panels) of Gq are depicted as
means of the individual cells. Lighter blue: calcium titration in solely Gq transfected cells; darker
blue: calcium titration in doubly transfected cells. Lighter orange: calcium titration in the presence of
1 µM calcimimetic of solely Gq transfected cells; darker orange: calcium titration in the presence of 1
µM calcimimetic of doubly transfected cells. Error bars indicate SEM.
ligands used to activate CaSR.
A calcium titration (blue, all plots in figure 4.8) induces an intracellular calcium
increase, even when no G protein activity was recorded, followed by a slight increase
of G protein activity. At slightly higher concentrations of external calcium, the (Ca2+)i
response increases with Gq activity, after which it settles to a slightly lower level.
In the presence of the calcilytic (NPS-2143) and the calcimimetic (NPS-R-568) (fig.
4.8A, red and yellow, respectively), the intracellular calcium release is reduced in
comparison to the Ca2+ titration alone. The calcilytic also blocks Gq activity while
the calcimimetic enhances it. Further, intracellular calcium mobilization is induced
by the calcimimetic even at basal calcium concentrations in the medium (see also
supplementary information, figure 4.13).
Strontium is also less potent in activating Gq and releasing intracellular calcium. It
reaches however similar Gq activation levels as external calcium at high concentrations
(figure 4.8B, black).
In the presence of 10 mM phenylalanine (fig 4.8C, green), the (Ca2+)i-vs-Gq relation is
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Figure 4.8: Direct comparison of Gq activity and intracellular calcium release as response to
different stimuli. CaSR-HEK cells transiently transfected with both Gq-FRET sensor and R-GECO-1
were stimulated with increasing concentrations of CaSR-specific ligands, as described in section
earlier. Gq activity and internal Ca2+ release were measured simultaneously and the data was
processed as described. Dose-response data of Gq activity and intracellular calcium for the increasing
stimulus doses is plotted against each other. A) comparison of the CaSR-drugs. Blue: Ca2+ titration,
red: Ca2+ titration + 1 µM CaSR inhibitor NPS-2143, yellow: Ca2+ + 1 µM CaSR activator NPS-R568.
B) CaSR activators Ca2+ (blue) and Sr2+ titration (black). C) Comparison of Ca2+ titration (blue) with
Ca2+ titration in the presence of 10 mM L-PHE (green). Error bars indicate SEM. Mean results from
at least 25 cells are shown.
right-shifted. (Ca2+)i is less sensitive to Gq at low concentrations of calcium.
All (Ca2+)i-vs-Gq curves follow a comparable trend: a steep increase in (Ca2+)i
mobilization at low Gq activity levels, when extracellular calcium or strontium are
at low concentrations, followed by an increasing G protein activity, at intermediate
extracellular calcium concentrations, and a slight reduction in (Ca2+)i at high Gq
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activity when extracellular calcium is high.
We conclude that Gq is an upstream regulator of calcium mobilization, in response to
CaSR activation. Since the precise (Ca2+)i-vs-Gq relation depends on the combination
of CaSR-ligands, we conclude that CaSR-level as well as downstream signaling
network bias occurs.
4.3 Discussion
GPCRs display ligand-biased signaling when exposed to various ortho- and allosteric
ligands and combinations thereof. It is however largely unknown how the interplay
between receptor and downstream players of signal transduction is affecting biased
signaling and how the bias introduced at the level of the receptor is propagated
through the downstream signal transduction network. To address this question, we
aimed to visualize the activity of two different read-outs of signal transduction upon
CaSR activation and explore their covariation upon receptor activation by different
ligands. We used two fluorescent sensors that enabled the time-resolved monitoring
of Gq activity and intracellular calcium mobilization, which are two signaling read-
outs that are localized at different levels of CaSR signaling. Gq activity is a more direct
receptor read-out, whereas intracellular calcium is a downstream read-out, a node in
several interacting and intertwining signaling pathways.
In this work, we showed for the first time the dynamics of two GPCR signaling read-
outs, simultaneously in single cells. We were able to capture the covariation of two
read-outs in response to different ligands. In these studies (Fig. 4.8), intracellular cal-
cium responded in several treatments even though we did not detect a change in Gq
activity. This could have to do with a higher sensitivity of R-GECO-1 relative to the
Gq FRET sensor, or with the amplification of the signal occurring before the internal
calcium release. In agreement with the experiments where we transfected the cells
only with the Gq sensor (chapter 3), and with previous studies [177], strontium is less
potent in triggering Gq activation and also of (Ca2+)i release. This reduced potency in
mobilizing intracellular calcium might be due a reduced influx of calcium, from the
medium into the cell, upon stimulation with strontium, as during those experiments
extracellular calcium is kept low at 0.5 mM. We found that the calcilytic (NPS-2143)
inhibits both CaSR-induced Gq activation as well as (Ca2+)i mobilization, which is
consistent with previous findings [59]. The calcimimetic (NPS-R-568) already trig-
gered intracellular calcium release and Gq activation at basal calcium concentrations
in the medium, and did not show further enhancing effects at high stimulus concen-
trations (Fig. 4.8A), which is in good agreement with [58]. We clearly see an effect of
PHE on the mobilization of intracellular calcium (Fig. 4.8C). The intracellular calcium
release response is right shifted to higher Gq activity levels and higher calcium stimu-
lus concentrations, respectively. The time courses of intracellular calcium in absence
and presence of phenylalanine (cf. figures S4.9 and S4.11) resemble earlier measure-
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ments [178]. These results are pointing towards the hypothesis that the amino acid
triggers different signaling routes, independent from Gq, as described in [65, 179].
This is a clear indication that downstream processes are involved in the release of
intracellular calcium, on top of CaSR activity, which implies network-level bias.
A similar trend can be seen in all covariation plots: a steep intracellular calcium
mobilization at low levels of Gq activity, followed by constant or slightly diminished
(Ca2+)i concentrations at higher Gq activity. This confirms Gq as a major regulator of
intracellular calcium mobilization. Nevertheless, Gq is ectopically expressed in these
studies and it therefore potentially triggers signaling towards calcium mobilization.
However, the (Ca2+)i-Gq relation does depend on CaSR-ligand combinations, which
indicates that the signaling network downstream of CaSR determines ligand bias, in
addition to CaSR itself.
We observed photobleaching of R-GECO-1 emission, in addition to influences on CFP
and YFP emission over time (Fig. 4.3). Issues with the photophysical properties of R-
GECO-1 have been reported earlier. In a study of Akerboom and colleagues, the sensor
showed fast multi-state photobleaching and rapid photoswitching as known for its
core FP mApple [197, 198]. Further, R-GECO-1 was activated also by wavelengths of
405 nm and 488 nm in addition to 561 nm, a feature that affected its emission when
excitation pulses of 561 nm wavelength were applied shortly (ms-s) after pulses of
488 nm [197]. The influence of blue light on R-GECO-1 emission reported in [197]
was only relevant when the second, red light excitation was applied a few milli-
seconds after the blue light pulse and lost significance for time intervals greater than
2.5 seconds. Such fast changes in excitation were not possible in our set-up due to
the automatic changes of the filters. The fastest switch that we could maintain had
a gap of five seconds between the 420 nm and 570 nm excitation. Therefore, CFP
excitation should not affect R-GECO-1 fluorescence emission in our set-up. Despite
the known characteristics of R-GECO-1, we observed negligible crosstalk between the
channels (2.4 and 2.6 % in CFP and YFP emission channel, respectively, Fig. 4.3) in our
set-up. Further, high RFP emissions in response to ionomycin treatment influenced
the CFP and YFP emissions hardly (cf. figures B and D in figures S4.9 - S4.13). We
conclude therefore that the R-GECO-1 signal in the CFP/YFP channel does not affect
the Gαq sensor measurements. The quantitative differences of the dose-response
curves observed under single versus double transfection conditions (figure S4.14) are
most probably resulting from different transfection efficiencies in the two conditions.
Possibly, the observed fluorescence emission of R-GECO-1 into the CFP channel over
time (Fig/ 4.3B) is caused by green components of the fluorophore that emerge due
to photoconversion or represent a fraction of proteins that remain in their immature,
green state. R-GECO-1 is a non-ratiometric fluorophore, implying that the absolute
fluorescence of one emission wavelength is recorded. In contrast, emissions of two
distinct wavelengths are recorded and a ratio of these two is obtained as read-out
for ratiometric sensors. The latter sensors are advantageous, as the ratio corrects
for changes in cell volume, movement and sensor concentration [199]. For further
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studies, it will therefore be beneficial to use ratiometric red fluorescent sensors such
as Fura-2, an indicator we could not use with our equipment.
Intracellular calcium is a well-studied and often-used read-out of GPCR signaling;
several approaches with different characteristics are available which make it easy to
monitor. However, the signaling pathways leading to (Ca2+)i mobilization are diverse
and intertwined [182] and can be influenced by various factors. Thus, intracellular
calcium is rather a signaling network read-out than a specific receptor read-out and
its dynamics have to be related to the cellular and experimental context in which they
have been acquired. Further, there are different approaches to convert the oscillations
usually observed in (Ca2+)i mobilization into dose-response curves. For example, the
peak hight, mean value or area under the curve are used to quantify its dynamics and
impede the comparison of different studies.
Consequently, studies focusing on the biased signaling of a receptor can be improved
by not solely relying on intracellular calcium as single read-out, but by combining
two read-outs located at different layers within the network. By doing so, informa-
tion about the contribution of the receptor to the bias as well as the amplifying or
modulating influence of the signaling network for the propagation of the bias can be
obtained. With this work, we showed that such an approach is feasible.
We find that ligand bias can be established at the onset of receptor signaling by
receptor-G protein interactions and further be modulated by the downstream signal-
ing network. We were able to trace the cellular responses to different ligands and
monitor the signaling dynamics in single cells. Large cell-to-cell variations have been
found in cell populations with the same origin [180, 181], and also in our experiments
we found differences between the single cells upon the treatments. Our results there-
fore show that single-cell based pharmacology adds information to the existing
high-throughput analyses. It shows that in cases where the cells show qualitative
different dynamics, even subpopulations of cells should be distinguished.
Studies tackling the onset and the propagation of ligand bias in single living cells,
for instance by using multicolor fluorsescent microscopy in real-time, therefore have
great potential to improve our understanding of ligand bias and might turn useful in
the directed design of biasing drugs.
4.4 Materials and Methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM) + GlutaMax, calcium free DMEM,
Hank’s Balanced Salt Solution (HBSS), penicillin-streptomycin (pen/strep), Lipofec-
tamine 2000 transfection reagent and Hygromycin B were purchased from Life
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Technologies; the allosteric CaSR modulators R-568 and NPS-2143 from Tocris Bio-
sciences. All other chemicals were from Sigma-Aldrich if not stated otherwise.
HEK-293 wild-type cells were obtained from the American Tissue Culture Collection
(ATTCr CRL-1573TM). HEK-293 cells stably expressing the human calcium-sensing
receptor (CaSR-HEK) were a friendly gift from Dr. Donald Ward, The University of
Manchester. The plasmid containing the cDNA encoding human Gαq, Gβ1 and Gγ2
tagged to the fluorescent proteins are described in [169, 170]. Plasmids encoding for
R-GECO-1 were obtained from addgene (www.addgene.org, CMV-NLS-R-GECO,
plasmid #32462).
Cell Culture & Transfection
HEK-293 cells and CaSR-HEK cells were grown in DMEM + GlutaMax supplied
with 10% FCS and 1 % penicilin/streptomycin. In addition, CaSR-HEK cells were
under Hygromycin B selection (200 ¯M/ml). Two days prior to the experiment, the
cells were seeded on fibronectin-coated glass coverlips. Lipofectamine 2000 was
used according to the manufacturer’s instructions to doubly transfect the cells with
plasmids encoding the FRET sensor Gqα-CFP / Gβγ-YFP and R-GECO-1 the day
before the experiment.
Wide-Field Fluorescent Microscopy
HEK-293 cells and CaSR-HEK cells grown on coverslips were mounted into an
Attofluor cell chamber and maintained in microscopy medium (20 mM HEPES (pH =
7.4), 137 mM NaCl, 5.4 mM KCl, 0.5 mM CaCl2, 0.8 mM MgCl2 and 20 mM glucose).
They were placed on a Zeiss inverted microscope (Axiovert 200M) equipped with an
oil immersion 40x objective and kept at 37 ◦C . For simultaneous measurements of CFP,
YFP and R-GECO-1 emission, the cells were excited at 420 nm (CFP excitation) and
additionally excited at 570 nm (RFP excitation). The CFP/YFP emission wavelengths
were detected with a 470/30 and 535/30 bandpass filter by automatically turning
the filter wheel. A 620/60 bandpass filter was used to detect R-GECO-1 emission.
This was accomplished by automatically changing the filter blocks. The images were
binned (4x4) and recorded with a cooled charged coupled device camera (Coolsnap
HQ, Roper Scientific, Tucson, AZ, USA). The illumination time was set to 210 ms for
both CFP and YFP. The illumination time for R-GECO-1 was set to 100 ms.
Experimental Design
Prior to the experiments, the cells were Ca2+-depleted to reduce G protein activity
induced by the CaSR to a minimum. The medium of the cells was changed twice
with serum free DMEM containing 0.5 mM Ca2+ and subsequently incubated in the
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low-calcium medium for at least 20 min prior to experiments at 37 ◦C and 5% CO2.
The cells were stimulated with stepwise increasing agonist concentrations every 90
seconds to allow the formation of a new steady state of Gq activity and new levels
of intracellular calcium concentrations. Direct agonists used were Ca2+andSr2+.
Dependent on the experimental set up, CaSR specific drugs and modulators were
added to the cells 90 seconds before the Ca2+ stimulation as follows: 1 ¯M allosteric
inhibitor NPS-2143 or 1 ¯M calcimimetic R-568, or 10 mM Phenylalanine NPS-2143
and R-568 were dissolved in DMSO. It was made sure that only a total amount of 0.01
% DMSO was added to the cells.
Image and data analysis
ImageJ (http://rsbweb.nih.gov/ij/) has been used to analyze the imaging data: The
average fluorescence intensity of individual cells in the CFP, YFP and RFP channel in-
tensity were obtained by drawing regions of interest (ROI) of the individual cells.
Background intensity was obtained by selecting an ROI outside of cells. The back-
ground data was subtracted from average intensities of the cells and the data was
normalized to the average of the first 20 frames without stimulus. Further, YFP data
was corrected for crosstalk from CFP emission into the YFP channel. These normal-
ized intensity data were used to calculate the YFP/CFP ratio, which accounted as a
measure of Gq activity. RFP data was normalized as described above.
Mean intensities of CFP, YFP and YFP/CFP ratio data as well as RFP (R-GECO-1)
fluorescence and standard error of the mean (SEM) were calculated from at least 25
cells, obtained in at least 12 independent experiments. For the dose response data,
short periods of the steady states intermediating the stimulus additions have been
chosen for which the YFP/CFP ratio is plotted against the corresponding agonist dose.
Same holds true for the RFP fluorescence emission, whereas steady states were hardly
obtained in these measurements and mean intensities were used for the dose-response
curves. YFP/CFP ratios have been fitted to a distorted Hill equation (equation 4.1)
ymodel = α+
βxh
Kh + xh
(4.1)
for which x being the agonist concentration and y the normalized fluorescent intensity.
K and h are the dissociation constant and Hill coefficient, respectively with α as the
basal value and β the distortion factor. Fitting of the complete data sets was conducted
by minimizing the objective function, the weighted sum of squares residuals (equation
4.2):
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objcomplete =
n
∑
i=1
(ymodel,i − ydata,i)2
σ2data,i
, (4.2)
Here, ymodel denotes the fluorescent intensity calculated by the model, described in
equation 4.1; ydata are the data points for agonist concentration i. σdata,i is represent-
ing the standard deviation of the data per concentration i.
In order to correct for the decrease in fluorescence of R-GECO-1 over time (bleaching),
the time course of R-GECO-1 emission (Fig. 4.3B) was fitted to an exponential decay
curve:
y = aE−(k·t)
γ
. (4.3)
Values for the parameters were found as follows: a = 1.3, k = 0.14, γ = 0.23 and
R-GECO-1 data was corrected for the bleaching in all experiments.
All corrections and analyses, as well as plotting and curve fitting have been carried
out using Wolfram Mathematica version 10.0.
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Figure 4.9: Calcium titration experiment in double transfected cells. CaSR-HEK cells transiently
transfected with the Gq FRET sensor and R-GECO-1 were kept in low calcium medium (0.5 mM)
for 20 minutes before the experiment. During the experiment, the cells were exposed to cumulative
increasing calcium concentrations of 0.5, 1, 2, 3, 4, 5 and 7 mM and CFP, YFP and RFP emission
wavelengths were recorded. The time-laps between stimulus addition was 90 seconds. 10 µM
ionomycin were added 90 seconds before the end of the experiment. n = 42 cells. A) time traces of
CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower panel) of the individual cells.
B) Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). C)
Dose-response curves generated from the steady-state responses of CFP (upper), YFP (middle) and
YFP/CFP ratio (lower panel) to the increasing stimulus concentrations. D) Time traces of R-GECO-1
(RFP) emission of the individual cells (colored lines) and mean traces (black). E) Dose-response curves
generated from responses of R-GECO-1. In all plots, error bars indicate SEM; in the dose-response
curves the empty circles represent individual cells, the filled circles represent mean values. Solid
lines in the dose-response curves were fitted to equation 4.1.98
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Figure 4.10: Strontium titration experiment in double transfected cells. CaSR-HEK cells transiently
transfected with the Gq FRET sensor and R-GECO-1 were kept in low calcium medium (0.5 mM)
for 20 minutes before the experiment. During the experiment, the cells were exposed to cumulative
increasing strontium concentrations of 0, 1, 3, 5, 7, 9 and 11 mM and CFP, YFP and RFP emission
wavelengths were recorded. The time-laps between stimulus addition was 90 seconds. 10 µM
ionomycin were added 90 seconds before the end of the experiment. n = 25 cells. A) time traces of
CFP (upper) and YFP (middle) emission and YFP/CFP ratio (lower panel) of the individual cells.
B) Mean traces of the time course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). C)
Dose-response curves generated from the steady-state responses of CFP (upper), YFP (middle) and
YFP/CFP ratio (lower panel) to the increasing stimulus concentrations. D) Time traces of R-GECO-1
(RFP) emission of the individual cells (colored lines) and mean traces (black). E) Dose-response curves
generated from responses of R-GECO-1. In all plots, error bars indicate SEM; in the dose-response
curves the empty circles represent individual cells, the filled circles represent mean values. Solid
lines in the dose-response curves were fitted to equation 4.1.
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Figure 4.11: Calcium titration experiment in the presence of 10 mM phenylalanine in double
transfected cells. CaSR-HEK cells transiently transfected with the Gq FRET sensor and the intracellu-
lar calcium indicator R-GECO-1 were kept in low calcium medium (0.5 mM) for 20 minutes before
the experiment. 90 seconds prior to the calcium additions, 10 mM PHE were added to the medium
and kept constant. During the experiment, the cells were exposed to cumulative increasing calcium
concentrations of 0.5, 1, 2, 3, 4, 5, and 7 mM and CFP, YFP and RFP emission wavelengths were
recorded. The time-laps between stimulus addition was 90 seconds. 10 µM ionomycin were added 90
seconds before the end of the experiment. n = 28 cells. A) time traces of CFP (upper) and YFP (mid-
dle) emission and YFP/CFP ratio (lower panel) of the individual cells. B) Mean traces of the time
course data for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). C) Dose-response curves gener-
ated from the steady-state responses of CFP (upper), YFP (middle) and YFP/CFP ratio (lower panel)
to the increasing stimulus concentrations. D) Time traces of R-GECO-1 (RFP) emission of the individ-
ual cells (colored lines) and mean traces (black). E) Dose-response curves generated from responses
of R-GECO-1. In all plots, error bars indicate SEM; in the dose-response curves the empty circles
represent individual cells, the filled circles represent mean values. Solid lines in the dose-response
curves were fitted to equation 4.1.
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Figure 4.12: Calcium titration experiment in the presence of calcilytic in double transfected cells.
CaSR-HEK cells transiently transfected with the Gq FRET sensor and the intracellular calcium
indicator R-GECO-1 were kept in low calcium medium (0.5 mM) for 20 minutes before the experiment.
90 seconds prior to the calcium additions, 1 µM NPS-2143 was added to the medium and kept constant.
During the experiment, the cells were exposed to cumulative increasing calcium concentrations of
0.5, 1, 2, 3, 4, 5, and 7 mM and CFP, YFP and RFP emission wavelengths were recorded. The time-laps
between stimulus addition was 90 seconds. 10 µM ionomycin were added 90 seconds before the
end of the experiments. n = 44 cells. A) time traces of CFP (upper) and YFP (middle) emission
and YFP/CFP ratio (lower panel) of the individual cells. B) Mean traces of the time course data
for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). C) Dose-response curves generated from
the steady-state responses of CFP (upper), YFP (middle) and YFP/CFP ratio (lower panel) to the
increasing stimulus concentrations. D) Time traces of R-GECO-1 (RFP) emission of the individual
cells (colored lines) and mean traces (black). E) Dose-response curves generated from responses
of R-GECO-1. In all plots, error bars indicate SEM; in the dose-response curves the empty circles
represent individual cells, the filled circles represent mean values. Solid lines in the dose-response
curves were fitted to equation 4.1.
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Figure 4.13: Calcium titration experiment in the presence of calcimimetic in double transfected
cells. CaSR-HEK cells transiently transfected with the Gq FRET sensor and the intracellular calcium
indicator R-GECO-1 were kept in low calcium medium (0.5 mM) for 20 minutes before the experi-
ment. 90 seconds prior to the calcium additions, 1 µM NPS-R-568 was added to the medium and
kept constant. During the experiment, the cells were exposed to cumulative increasing calcium con-
centrations of 0.5, 1, 2, 3, 4, 5, and 7 mM and CFP, YFP and RFP emission wavelengths were recorded.
The period between stimulus addition was 90 seconds. 10 µM ionomycin were added 90 seconds
before the end of the experiment. n = 49 cells. A) time traces of CFP (upper) and YFP (middle) emis-
sion and YFP/CFP ratio (lower panel) of the individual cells. B) Mean traces of the time course data
for CFP (cyan), YFP (yellow) and YFP/CFP ratio (red). C) Dose-response curves generated from
the steady-state responses of CFP (upper), YFP (middle) and YFP/CFP ratio (lower panel) to the
increasing stimulus concentrations. D) Time traces of R-GECO-1 (RFP) emission of the individual
cells (colored lines) and mean traces (black). E) Dose-response curves generated from responses of
R-GECO-1. In all plots, error bars indicate SEM; in the dose-response curves the empty circles repre-
sent individual cells, the filled circles represent mean values. Solid lines in the dose-response curves
were fitted to equation 4.1.
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10 mM PHE
A B
10 mM PHE
Figure 4.14: Comparison of transfection with the Gq FRET-sensor and double transfection with
Gq FRET-sensor and R-GECO-1. CaSR-HEK cells were either transfected solely with the Gq FRET-
sensor (A), or doubly transfected with R-GECO-1 and the Gq FRET-sensor (B). In the presence or
absence of allosteric modulators, CaSR ligands were increased in a step-wise manner as described
above, and fluorescence emission of CFP and YFP was recorded. Despite different absolute numbers
and slightly different kinetics, the results from the two different transfections show a qualitatively
comparable behaviour. Here, the mean data of at least 16 cells are depicted, error bars indicate SEM.
The solid line depicts the fit to equation 4.1.
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Abstract
The signal-transduction network of a mammalian cell integrates internal and external
cues in order to initiate adaptive responses. Amongst the cell-surface receptors are
the G protein-coupled receptors (GPCRs) that have remarkable signal-integrating
capabilities. Binding of extracellular signals stabilizes intracellular-domain conforma-
tions that selectively activate intracellular proteins. Hereby, multiple signaling routes
are activated simultaneously to degrees that are signal-combination dependent.
Systems-biology studies indicate that signaling networks have emergent processing
capabilities that go far beyond those of single proteins. Such networks are spatiotem-
porally organized and capable of gradual, oscillatory, all-or-none and
subpopulation-generating responses. Protein-protein interactions, generating feed-
back and feedforward circuitry, are generally required for these spatiotemporal
phenomena. Understanding of information processing by signaling networks there-
fore requires network theories in addition to biochemical and biophysical concepts.
Here we review some of the key signaling-systems behaviors that have been discov-
ered recurrently across signaling networks. We emphasize the role of GPCRs, so far
under appreciated receptors in systems-biology research.
5.1 Systems biology of signaling networks
We are far from a complete molecular understanding of how a single mammalian-
cell makes its decisions, given extracellular and intracellular signals. We do not yet
have the capabilities to determine the complete connection topology of its signaling
networks (although we are moving towards this goal [200, 201]), how it adapts in
time, and how the kinetic properties and interaction partners of the signaling proteins
shape network responses. Such information is required for truly predictive medicine
that is expected to rely heavily on mathematical models [202–204].
Great strides have however been made in identifying key principles of cellular sig-
naling, at the level of single proteins and protein networks, including spatiotempo-
ral aspects [205, 206]. These efforts promise to lead to a set of standardized, quanti-
tative approaches for mapping and exploring the dynamic-signaling capabilities of
protein networks. That such an approach can be a great success is indicated by cur-
rent molecular and cellular biology. Generic protein concepts, such as, for instance,
cooperativity, allostery and catalysis, have led to a standardized nomenclature and
design of experiments that greatly accelerates molecular-biology approaches. The
subsequent combination of molecular concepts with network concepts by systems bi-
ology is similarly powerful. For metabolism this already had great consequences. All
metabolic capabilities of a cell can nowadays be computed with metabolic-network
models [207]. Cell biology and systems biology are together aiming at reaching a sim-
ilar status for the signaling network of a cell, requiring the merger of network con-
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cepts with the biochemistry of signaling proteins [200, 201]. This is for many reasons,
however, a much harder problem.∗
5.2 Why GPCRs are so attractive for systems biology
From a biophysics and systems biology perspective, G protein-coupled receptors
(GPCRs) are particularly attractive. They can attain different conformations that
co-exist in a thermodynamic equilibrium, which shifts under the influence of signal
binding [208]. Agonist binding will induce a conformational change of the receptor
that activates intracellular signaling, while inverse agonists inhibit basal signaling
and force the receptor in an inactive state. Allosteric modulators, which bind to al-
losteric sites of the GPCR, promote conformational changes that can alter orthosteric
ligand affinity and/or efficacy, or may selectively activate a specific signaling path-
way. For long it was thought that GPCRs exclusively signal via G proteins. However,
GPCRs can also signal via G protein-independent signaling pathways that involve,
for example, G protein receptor kinases (GRKs) and β-arrestins or GPCR interacting
proteins (GIPs) that activate (unexplored) G protein-independent signaling pathways.
Intriguingly, different ligands that bind to the same GPCR protein are able to induce
distinct downstream signaling pathways. These biased ligands selectively stabilize
only a subset of receptor conformations, thus preferentially modulating certain
signaling pathways. Classical approaches for equilibrium-binding models of coopera-
tive proteins immediately apply to GPCRs [209, 210] and can account for signal
integration by receptors – so called ‘combinatorial ligand-bias’ [69]. This is in contrast
to, for instance, receptor tyrosine kinases (RTKs) that require phosphorylations, a
kinetic non-equilibrium process, for activation and conformation transitions.
The activation of G-proteins by GPCRs and their inactivation by GTPases, leading to
steady-state activation of G-proteins, can be understood to a great extent in terms of
existing principles of covalent-modification cycles [211–213]. Likewise, biochemical
equilibrium-models of competitive binding describe the competition of immediate
downstream proteins, such as G-proteins, GPCR receptor kinases (GRKs), and β-
arrestins, for receptor conformations.
The conceptual and quantitative framework for understanding GPCRs and G-protein
activation is therefore largely in existence, shifting the challenges more to the experi-
mental and data-analysis side. Yet, systems biology has focussed much more on
RTK-induced cellular signaling (the RAF-MEK-ERK axis) than on GPCR-activated
networks.
∗The calculation of the metabolic capabilities of a cell requires only the knowledge of the stoichiometry
of the metabolic reactions encoded on the cell’s genome, not their kinetics. This is not so for the signaling
capabilities of a cell, which do require the kinetics of the proteins, especially since signaling is such a
dynamic phenomenon. Kinetic assays with signaling proteins are however notoriously hard. Whereas
kinetic constants for metabolic enzymes can be determined in cell-free extract, this is not feasible for many
signaling proteins, in particular for those that are active in protein complexes and the cellular membrane.
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In this review, we aim to introduce the GPCR researchers to several systems-biology
findings about signaling networks. This review is organized in a pragmatic manner
(figure 5.1), we start by reviewing some of the basic biophysics aspects of GPCRs, fol-
lowed by the kinetics of G-protein activation cycles, and finally we discuss several of
the dynamic phenomena emerging in signaling networks that have been found with
systems-biology approaches. Throughout this review we placed informative boxes,
in which we explain a finding in quantitative systems-biological or biophysical terms,
using mathematical models. We hope that this review sparks further interest in
systems-biology studies of the principles of GPCR signaling networks.
Box 1: Membrane-diffusion and the time scales of dimerization equilibria of re-
ceptors. GPCRs are very dynamic, they continuously diffuse through the plasma membrane
and dimers (or oligomers) are continuously forming and falling apart. Dynamic dimeriza-
tion equilibria exist that are characterized by a constant, rapidly-fluctuating monomer and
dimer fraction. Kasai et al [21] have recently quantified the monomer-dimer equilibrium of the
N-formyl peptide receptor (FPR), a GPCR. They found that:
2 m
k+−⇀↽−
k−
m2, k+ = 1.085× 10−3
(
copies
cell
s
)−1
, k− = 11 s−1, KD =
k−
k+
= 10138
copies
cell
,
indicating that the dimer, denoted by m2, life-time is about 0.1 seconds (1/k−): 10 dimers
fall apart every second. The total number of receptor monomers per cell, mT , was 6000. At
thermodynamic equilibrium, when KD = m
2
m2 , and given mT = m + 2m2, the equilibrium
concentrations of the monomer and the dimer become: m = 3534 copiescell and m2 = 1233
copies
cell :
less than 50% of the monomers exist as dimers. The life time of a monomer equals 0.4
seconds (=
(
k f m2
mT
)−1
). The diffusion coefficient of a monomer in the membrane sets the
upper limit of the association rate constant [214] to 3× 10−3 cellcopies s [215]. The k+ of FPR is very
close to this limit. Given a realistic diffusion coefficient (D) of 0.1 µm
2
s for a GPCR [216], the
average distance that a GPCR travels in a membrane in one second equals
√
4Dt = 0.6 µm.
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Figure 5.1: Overview of receptor and network modules that are involved in cellular decision-
making and that are discussed in this review. Dimerization kinetics and ligand bias are biophysical
aspects of GPCRs. The kinetics of G-protein activation cycles and of covalent-modification cascades
together determine the sensitivity properties of signaling networks while feedbacks induce dynamic
phenomena such as robustness, oscillations and bistability.
5.3 Quantification of the membrane processes
In systems biology, emphasis is put on quantitative studies [217]. In case of GPCRs,
this concerns quantification of their kinetics and abundance. Quantification is, for in-
stance, required for understanding the signaling outcome of competition of multiple
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GPCRs for the same pool of G proteins [218]. This requires knowledge of ratios of re-
ceptor abundances and conformation-dependent G protein affinities. The expectation
is that the kinetic constants of a GPCR will be constant across cell types, as long as
isoenzymes or covalently-modified variants do not occur, while their abundances (ex-
pression level) can greatly vary. In addition, monomer-mobility and oligomerization
affinities of GPCRs are key factors, as they determine the active fraction of receptors.
Box 2: Conformation equilibria of a GPCR and their shifts upon ligand binding.
We consider a receptor homodimer. Each monomer has an extracellular domain, with two
ligand binding-sites. A homodimer has a single intracellular G-protein binding-domain. The
homodimer is in an ‘off’ state when its subunits are both in their ‘T’ (tensed) conformation.
When the subunits are in the ‘R’ (relaxed) conformation the receptor can activate G-proteins
in an intracellular-domain-state specific manner. We consider two G-proteins, ‘1’ and ‘2’,
that are activated by the receptor in the R state if its intracellular binding domain is in the
matching ‘1’ or ‘2’ conformation. This is a minimal mechanism of conformation selection
by ligand combinations and conformation-dependent G-protein activation. The fraction of
active, ligand-saturated receptor with its intracellular domain in state ‘1’ is (rT denotes the total
receptor concentration) [69],
r1s4
rT
=
(
s2
αK2R,1
)2
(zR,1 + `RzR,2)
2 + L (zT,1 + `TzT,2)
2 , zi,j = 1+ 2
s
Ki,j
+
s2
αK2i,j
, (5.1)
it depends on the ligand concentration s, the conformation-dependent affinity of the subunits
for the ligand KR,1, the allosteric factor α, the intracellular-domain conformation equilibrium
constants `R and `T and, finally, on the receptor equilibrium constant L. The power ‘2’ indicated
in red signifies the additional sensitivity of the receptor due to the fact that is a dimer, the
dimer makes the active fraction dependent on s raised to the power 4 (rather than 2). When
positive allostery is really potent and the receptor its affinity for the ligand is independent of
its intracellular domain conformation then,
r1s4
rT
=
(
s2
αK2R
)2
((
1+ s
2
αK2R
)
(1+ `R)
)2
+ L
((
1+ s
2
αK2T
)
(1+ `T)
)2 . (5.2)
This equation gives a sigmoidal dependency of the active receptor fraction on the ligand
concentration. The Hill coefficient of this equation equals 2 ∂ ln r1s4∂ ln s at s = s0.5 when r1s4 =
rT
2 . This model displays all the features associated with ligand bias [69]. Ligand affinity,
maximal response, and signal sensitivity are all dependent on the precise combination of
ligands bound to the extracellular binding domain, in agreement with experiments.
Advanced techniques have been developed for the determination of receptor mobility
and dimerization properties. In particular, tracking of single receptor-molecules at
the surface of intact cells has proven very informative [99]. Receptors are expressed
at several hundreds to several thousands of copies per cell. They are surprisingly
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mobile with often localization-independent diffusivities [97, 216]. The dimerization
kinetics for several members of distinct GPCR-families has been determined as well
[21, 216, 219]. In box 1, we discuss the quantitative aspects of dimerization kinetics
on the basis of recent findings.
5.4 Receptor activation and conformation selection
The advantage of receptor dimerization, and, in general, of oligomerization, is that
the signal affinity can be better modulated, via allosteric interactions, and the signal
sensitivity can be greatly increased, via cooperativity [210]. An influential view is
that the functional, signaling states of the receptor correspond to specific receptor
conformations, in particular of their intracellular domain to which downstream
signaling proteins bind. The presence of extracellular ligands is transduced to the in-
tracellular domain by ‘conformation selection’: the precise combination of ligands
bound to the extracellular domain stabilises particular conformations of the intracel-
lular domain. Whether this involves stabilization of multiple conformations of a
single GPCR in particular fractions, leading to a ‘G-protein code’ that is ligand spe-
cific, or of a single conformation is unclear, and presumably even GPCR
dependent.
These ideas are in flux at the moment, with the introduction of powerful structural
methods. Structural studies provide evidence for conformation selection and
conformation-dependent activation of downstream signaling proteins [220]. Kinetic
information is given additional support for this mechanism [33, 99, 100, 221].
It is not a new concept in biochemistry that cooperative proteins can accommodate
alternative conformations with different activities. Theories on cooperative proteins,
reviewed by Changeux [210], have been describing such behavior already for a long
time, early on mostly for metabolic enzymes and transcription factors. Allostery and
cooperativity are key signaling features of GPCRs that make them versatile signal
integrators.
An emerging view is that conformation selection by combinations of bound ligands
and conformation-specific G-protein activation underlies ligand bias of GPCRs. This
behavior can be accounted for by extended models of cooperative proteins [69]. In
box 2 we present an example of such a model. Cooperative proteins are generally
composed out of multiple subunits with allosteric interactions between ligand binding
sites. Those properties play an important role in pharmacological applications, where
conformation selection is used as a drug-design objective for altering ligand bias [222,
223].
Ligands can induce shifts in the conformation equilibrium of a GPCR, influencing its
activation of intracellular G proteins and β arrestins [72] (see figures 5.1, 5.2). Using
spectroscopy methods, Rahmeh and colleagues were able to show that distinct con-
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formations of the V2 arginine-vasopressin (AVP) receptor were induced in response
to different (biased) ligands [162]. The resulting ligand-biased signaling, or functional
selectivity, is now viewed more often as an intrinsic property of the receptor-ligand
complex, which can be understood from the thermodynamics associated with stabi-
lization of particular receptor conformations [77]. Approaches for quantification of
biasing effects has recently been reviewed [224]. During quantification of ligand bias,
it is important to discern receptor biases from other sources, such as the signaling
network [80].
In addition to classical, extracellular signals, peptides, pepducins and nanobodies
that bind the receptor intracellularly can also affect the coupling GPCR to signaling
molecules [225, 226] (reviewed in [86]). This indicates that the intracellular state can
also modulate biased signaling. Scaffolding proteins, or other molecules that influ-
ence the receptor, may therefore prime the receptor from the inside for specific
extracellular signals or alter intracellular signaling. A dynamic model of G-protein ac-
tivation [227], which incorporates measured biochemical parameters, indicates the
importance of cell-specific parameters, such as receptor and downstream protein ex-
pression ratios, and kinetic constants, for instance for GTP hydrolysis and
ligand-binding affinities, for G-protein activation dynamics [227]. Similarly, a model
of the M1 muscarinic receptor signaling, involving ligand-binding constants,
receptor-G protein interactions and Gα-PLC interactions, gave rise to ligand-response
relationships in close agreement with experiments [113]. The GPCR-field has ad-
vanced to a stage where enough kinetic information is available to quantitatively
explain the dynamic responses of G-protein activation to extra- and intracellular stim-
uli. Such an approach is particularly relevant when mutant and wild type receptors
are compared with respect to their signaling properties.
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Figure 5.2: Illustration of ligand bias and ultra sensitivity. Left: Two different signaling outputs
are plotted against each other in a ‘bias plot’. In such a plot, identical signaling responses lead to a
straight line with slope 1 (solid line). Biased signaling responses causes a deviation from this linear
relation and are represented by the curved, dashed lines. Right: Ultra sensitivity is represented
as a sigmoidal dose-response curve (solid line), whereas a hyperbolic curve, characteristic for a
hyperbolic, ‘Michaelis-Menten’ response, is not ultra sensitive (dashed line).
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Box 3: G-protein activation and sensitivity of its GTP-bound state (
[
GGTP
]
) to
GPCR ligands A GPCR acts as a guanine exchange factor (GEF) for G proteins. The resulting
exchange of GDP by GTP leads to the activation of the G-protein; whereas a GAP hydrolyses
this GTP,
RA + GGDP −⇀↽− RAGGDP −→ RAGGTP −⇀↽− RA + GGTP (5.3)
GAP + GGTP −⇀↽− GAPGGTP −→ GAPGGDP −⇀↽− GAP + GGDP (5.4)
Here RA denotes the active conformation of the receptor. Using an equilibrium-binding model,
these reactions lead to the following enzyme kinetic equation for the GEF and GAP activities,
vGEF(GGDP, GGTP) = kGEFRA
GGDP
KGEFGDP
1+ G
GDP
KGEFGDP
+ G
GTP
KGEFGTP
(5.5)
vGAP(GGDP, GGTP) = kGEFGAPT
GGTP
KGAPGTP
1+ G
GDP
KGAPGDP
+ G
GTP
KGAPGTP
. (5.6)
The sensitivities of the steady-state signaling output, the steady-state concentration of activated
G-protein, GGTP, with respect to a change in the concentration of the GEF reaction catalyst, the
active conformation of the receptor (RA) equals [228],
∂ ln GGTP
∂ ln RA
≡ rGGTPRA =
1
[GGTP ]
[GGDP ] e
vGEF
GGDP − e
vGEF
GGTP + e
vGAP
GGTP −
[GGTP ]
[GGDP ] e
vGAP
GGDP
(5.7)
The e coefficients are generalized kinetic orders (or elasticity coefficients [228]) of the reactions:
evGAPGGDP =
∂ ln vGAP
∂ ln GGDP . When they are close to zero, the enzyme operates in its zero-order regime
(v ∝ [substrate]0) and zero-order ultra-sensitivity occurs [213]. This is most noticeable, when
we assume both enzyme rates insensitive to their product concentrations; then ∂ ln G
GTP
∂ ln RT
≡
rG
GTP
RT =
1
[GGTP ]
[GGDP ]
e
vGEF
GGDP
+e
vGAP
GGTP
, which is much greater than 1 when the e coefficients are close to 0.
The sensitivity of [GGTP] to a ligand of the GPCR, RG
GTP
S =
d ln GGTP
d ln S , can be decomposed into
[228],
s
rRAS−−→ RA r
GGTP
RA−−−→ GGTP, RGGTPRA = rG
GTP
RA r
RA
S . (5.8)
In a dose-response curve of log[GGTP] as function of log S, the slope, which is the sensitiv-
ity, equals the product of the receptor sensitivity, rR
A
S , and the G protein sensitivity, r
GGTP
RA .
Therefore, ‘sensitivity amplification’ [212, 228, 229] occurs when both r’s exceed 1.
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5.5 G protein activation and inactivation cycles
Upon binding of a GDP-bound G-protein to an active conformation of a GPCR, the
G protein can become activated in this complex via a guanine exchange event, this
kinetic activity presumably resides on the GPCR [230]. The activating conformation
change of the GPCR causes it to have GEF activity. Upon activation, the G-protein can
dissociate from the complex and activate downstream signaling until it is inactivated
by its GTPase activity usually enhanced by GTPase-activating proteins (GAPs). The
G-protein therefore cycles between active and inactive states. The fraction of active
G-protein is determined by the balanced between GEF and GAP activities [230]. In
box 3 we show some of the basic aspects of such processes.
Covalent-modification cycles, e.g. formed by a kinase and phosphatase pair, can
display zero-order ultra sensitivity with respect to signals (figure 5.2)[175, 213, 229].
A GPCR activation/inactivation cycle can in principle show the same behavior – even
though it is not strictly a covalent-modification cycle – with respect to signals acting
on the GPCR.
In case of ultra sensitivity, a large fractional change in the GGTP concentration occurs
upon a small fractional change in the concentration of the ligand that binds to the
receptor. Accordingly, the dose-response curve of [GGTP] as function of the signal
concentration is switch-like (e.g. with a Hill coefficients exceeding 4). Switch-like,
zero-order ultra-sensitive behavior occurs when both the GEF and the GAP enzymes
are saturates with their substrates – [GGDP] >> KGEFM and [G
GTP] >> KGAPM –,
such that they operate in their zero order regime (KM denotes the Michaelis-Menten
constant of the enzyme.) (box 3). Trunnel et al. [231] present an experimental
illustration of ultra sensitivity.
Turcotte and coworkers [232] developed a kinetic model of a G-protein covalent-
modification cycle and found ultrasensitivity in the calculated dose-response curves.
Ultrasensitive responses have found experimentally with PIP3 activation [233]. In a
combined experimental and modeling study, Karunarathne et al [233] demonstrated
that PIP3 concentrations are ultrasensitive with respect to GPCR activation [233].
The phosphorylation of GPCRs by GRKs and the associated dephosphorylation events
can also lead to G protein ultra sensitivity. GRKs have also been shown to have a
broad influence on GPCR signaling [234]. Systems biology studies on GRK-regulated
GPCR activity [114, 235] indicate the versatility GRK regulation and are examples of
the insightful combinations of experiments and modeling.
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Box 4: Sensitivity of networks to signals: cascades, feedback and feedforward
networks In a signaling cascade, the net sensitivity of the output D with respect to the input A
at steady state equals the product of the sensitivities along the cascade [228, 236], with A-to-D
as concentrations of signaling proteins,
A
rBA−→ B r
C
B−→ C r
D
C−→ D, RDA = rDC rCBrBA (5.9)
All these local sensitivities, the r’s, can be obtained from steady-state dose-response curves.
When D feedbacks onto A, regardless of whether this is a positive or negative interaction, we
obtain,
FRDA =
RDA
1− rADRDA
, (5.10)
with rAD as the feedback strength, it is < 0 in case of negative feedback and > 0 in case of
positive feedback. The effect of negative feedback is that the sensitivity of the output D with
respect to the input signal A is reduced. These equations loose their meaning when the feedback
destabilises the system. In the case of positive feedback, stability is guaranteed as long as
the denominator remains positive. The positive feedback sensitises the cascade for the signal
when FRDA > R
D
A . When r
A
DR
D
A = 1, the sensitivity becomes infinite and all-or-none response
occurs – associated with ‘bistability’ –, which is a known response of signaling cascades. When
feedbacks destabilise the system oscillations or bistability can occur as discussed in the main
text.
5.6 Signal transduction cascades of biochemical
reaction cycles: sensitivity amplification
Downstream of GPCRs and their direct activation targets, such as G-proteins and
arrestins, signals that initiated at the cell surface are transduced via cascades of
covalent-modification cycli, amongst other processes. The best understood cascade of
covalent-modification cycles is the mitogen-activated protein kinase (MAPK) cascade,
involving three covalent-modification processes in sequence [237]. GPCRs activate the
ERK, JNK and p38 MAPK cascades using spatially and temporally distinct pathways
that are dependent on either G-proteins or β-arrestins [238]. Direct MAPK activation
via Gα is transient, β-arrestin independent, and can involve PKC activity [239]. The
other pathway leading to MAPK activation is triggered by the recruitment of β-
arrestins as scaffolding molecules [239, 240]. For β-arrestin-mediated ERK signaling,
β-arrestins scaffold all three MAPK cascade kinases, Raf, MEK and ERK [241]. Since
β-arrestins interact with components of the clathrin-mediated endocytic pathway,
GPCRs bound to β-arrestins are targeted to clathrin-coated pits. For different GPCRs,
β-arrestins either rapidly dissociate and receptors recycle to the plasma membrane, or
GPCR-β-arrestin complexes stay together on the surface of endocytic vesicles. In either
case, β-arrestins scaffolds mediate activation of multiple signaling proteins, (such
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as the tyrosine kinase Src and MAPK cascades), thereby displaying a novel role of
signal transducers in addition to their classic function of GPCR signaling attenuation
[242]. Strikingly, only ERK molecules that are stimulated via G protein-dependent
pathways translocate into the nucleus, leading to transcriptional activation and DNA
synthesis, whereas active ERK molecules generated via β-arrestins accumulated on
endosomal vesicles, are entirely retained in the cytoplasm [243]. Not only are the
MAPK cascades that are activated via G proteins or β-arrestins spatially separated, but
also their temporal activation profiles are remarkably different. In human embryonic
kidney (HEK)-293 cells, G protein-dependent ERK1/2 activation is transient, rapidly
reaching a peak at about 2 min and descending to low levels after about 10 min
following stimulation, whereas activation via β-arrestins is sustained until at least
90 min [243]. Different spatiotemporal patterns of ERK stimulation via G proteins
or β-arrestins entail distinct functional outcomes at the level of downstream ERK
substrates. A decrease in G protein-dependent ERK stimulation due to increased
expression of β-arrestins inhibits ERK-mediated phosphorylation of transcription
factors, such as ELK-1, whereas β-arrestin mediated ERK signaling induces cell
motility phenotype, which is associated with the rearrangement of cytoskeleton,
membrane ruffling and chemotaxis, caused by prolonged activation and retention of
active ERK in the cytoplasm.
α
β γ
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GTP
y y
x x
Figure 5.3: Sensitivity amplification by a signal-transduction cascade. A covalent-modification
cascade (left) can amplify the signal sensitivity (right). The signaling response becomes steeper along
the signaling cascade.
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The same principle of β-arrestin scaffolding leads to GPCR induced NFκB signaling
[244], a signaling cascade that is also controlled by a series of post-translational
modifications. The MAPK system has been studied extensively and several interesting
signaling features have been found, such as oscillations, drug-robustness and ultra
sensitivity [245–248].
One finding is that the outputs of cascades of covalent-modification cycli can display a
sensitivity to cascade input-signals that exceeds the sensitivity of any of its elemental
cycli [228, 229, 246, 249]. For instance, the MAPK pathway of Xenopus oocytes was
found to have a Hill coefficient of 8, which is truly a switch-like response [246], and
believed to be due to ‘sensitivity amplification’. Sensitivity amplification can be
understood in terms of intuitive theory [228], an example of this is shown in box 4,
and with mathematical models based on enzyme kinetics [249]. How heightened
sensitivity arises in cascades follows from basic principles of the enzyme kinetics of
the associated kinases and phosphates [175, 213]. The cascade sensitivity equals the
product of the sensitivities of the individual covalent-modification cycli in the cascade
(box 4) (figure 5.3) [228, 236]. The sensitivity of a single covalent-modification cyclus
depends on the extent of the saturation of the kinases and phosphatases (box 3).
Activation of signaling proteins by double-phoshorylation, such as of MEK and ERK
leading to MEKP2 and ERKP2, can cause to heightened sensitivity at the level of a
single cascade element [250]. It has also been show to give rise to a more surprising
phenomenon, called ‘bistability’, which is an all-or-none response of the output,
e.g. of ERKP2, with respect to the input, e.g. MEKP2, with hysteresis properties.
Bistability is explained in figure 5.5 and has been found in mathematical models for a
number of signaling networks [250–253]. Bistability is also a mechanism that can lead
to the formation of subpopulations in monoclonal cell cultures and it is for this reason
associated with differentiation of stem cells [254, 255]. Ultra-sensitivity, sensitivity
amplification and bistability [175, 256] are examples of network properties that arise
from the interactions between protein activities and cannot be attributed to single
proteins. Because multiple proteins are required for these systems properties, in
addition to precise values of kinetic parameters and expression levels, mathematical
models are useful tools when studying them [217].
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Box 5: Drug-insensitivity of signaling cascades due to negative feedback. The
response equation of a signaling network with negative feedback [228, 236],
FRDA =
RDA
1− rADRDA
, (5.11)
was introduced in the previous box. When negative feedback occurs, the feedback term rAD
is negative. When −rADRDA >> 1, which can occur when −rAD  1 or RDA  1, the previous
equation can be approximated by,
FRDA ≈
1
−rAD
. (5.12)
This equation represents the slope of the dose-response curve of log D as function of log A.
This equation indicates that the response of the output D of a cascade with negative feedback to
a change in its input A only depends on the feedback strength, provided the above mentioned
conditions are met! This result has remarkable consequences. Firstly, it shows how cells can
make their responses to signals insensitive to undesired disturbances that happen in their
own signaling networks and affect RDA . Secondly, the medical consequence is that the effect of
drugs, acting on the signaling cascade and changing RDA , will not have a huge effect as long as
−rADRDA >> 1; in particular in the case of strong negative feedback, when rAD  1 [247, 248].
5.7 Negative feedback in signal transduction cascades:
oscillations and robustness to drugs
The output of signaling networks, such as cascades, often feedback to stimulate or
inhibit the processing of the input(-s) of the network [257]. Negative feedback is a
prerequisite for the emergence of oscillations. Feedback mechanisms arise from tran-
scriptional regulation of cascade compounds, their covalent modification, endocrine
actions or receptor initiation [258]. The study of negative feedbacks has revealed their
impact on signaling and appear to contribute to adaptation, robustness and oscilla-
tions [204]. Oscillatory dynamics has been found in a range of signaling networks,
e.g. during NFκB, ERK, and intracellular-Ca2+ signaling [259–262], many of which
are linked to GPCRs. GPCRs are also directly regulated by negative feedback; for in-
stance, via feedback activation of GRKs leading to inhibitory phosphorylation of a
GPCR [263] or via other mechanisms [264].
Calcium oscillations are linked to GPCR signaling. Feedback inhibition by calcium of
the agonist-receptor complex, presumably through the calcium-sensitive receptor ki-
nases, has shown that oscillations of intracellular calcium are influenced by
activation of Gα [265] and the internalization rate of βγ subunits [266]. Various math-
ematical models exist that focus on different aspects of calcium oscillations (reviewed
in [262]). Cross-talk between Gαi and Gαs regulated signaling, investigated with a
modeling approach by Siso-Nadal et al. [267], suggests that both species can oscillate,
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likely providing an additional layer of complexity that allows the cell to discriminate
between different combinations of signals. Future studies with, for instance,
G-protein FRET-sensors should give more insight into oscillations of G-protein activa-
tion. It was also found that GPF-tagged ERK displayed oscillations between cytosol
and nucleus over a broad range of ligand concentrations [260]. Through modeling
and experiments it was concluded that the negative feedback from ERK onto
upstream proteins underlies these oscillations, which are likely functional during de-
velopment [245, 260]. In NFκB signaling, a strong negative feedback of IκBα is
leading to oscillations in NFκB [259]. Thus, the function of NF-kB as a transcription
factor might therefore depend on the characteristics of its oscillations, leading to dy-
namic control of gene expression [261]. Direct involvement of negative feedback of
GPCRs in signaling oscillations has, as far as we know, not yet been established.
Besides oscillations, robustness is another feature associated with negative-feedback
activity. The negative feedback from ERK to upstream Raf in the MAPK pathway re-
sembles a negative feedback amplifier (NFA), used in engineering to design robust
systems [112]. The switch-like behavior of the RAF-MEK-ERK cascade, in the absence
of feedback, is changed to a more gradual, linear response (illustrated in figure 5.4)
by the feedback. The feedback causes robustness of phosphorylated ERK against vari-
ations in the total ERK level, via expression regulation, in agreement with theory and
experiments [247]. It also contributed to robustness to a MEK inhibitor, during medi-
cal treatment [112, 247]. For colorectal cancer-cells it was shown that the negative
feedback in EGFR signaling led to crosstalk between ERK and AKT signaling; inhibi-
tion of ERK resulted in activation of AKT, via EGFR, and combined inhibition of ERK
and EGFR inhibited Ras, ERK and AKT [112, 268]. These predictions were first made
with a mathematical model before being validated with a xenograft model. All these
studies indicate that targeting of signaling networks at a single protein, for example
during cancer treatments, can be insufficient and be overcome by the cell, due to com-
pensatory feedback mechanisms. Likewise, studies indicate that the absence of a
feedback, e.g. by a mutation in Raf, can sensitise cells to inhibitors [112, 247] (box 5).
Mathematical models and network concepts are therefore providing new ways for
studying signaling networks and predicting drug responses.
119
feedback intact
feedback removed
Raf
MEK
ERK
Rafactive
pMEK
pERK
signal
inhibitor
A
B
feedback intact
feedback removed
Figure 5.4: Robustness of the Raf-MEK-ERK cascade due to negative feedback. A) A network
diagram showing that phosphorylated ERK inhibits the activation of Raf by negative feedback.
(B). This feedback reduces signaling sensitivity (B, left panel, blue line). The inhibition of ERK
phosphorylation by a MEK inhibitor (A, indicated in red; B, right panel, blue) is reduced by the
negative feedback, it makes the cascade robust to perturbations [247].
5.8 Positive feedback in signal transduction cascades:
from gradual to all-or-none, bistable responses
While mild negative feedback makes cells robust and strong negative feedback causes
them to oscillate, positive feedback increases signal-sensitivities, amplifies these
sensitivities and can even lead to all-or-none, switch-like, binary responses [175, 204,
256]. Thus, negative and positive feedback have very different functions in a signaling
network.
Positive feedback can cause networks to display bistability. Bistability has three fea-
tures: a switch-like response, a history-dependent response (hysteresis) [175] and gen-
eration of cellular subpopulations (phenotypic diversification, cellular differentiation)
[175, 255] (see figure 5.5). Bistability has been documented for a large number of sys-
tems. Most examples are currently of microbial systems, because the type of single-
cell experiments required for identification of bistability are still laborious for mam-
malian cells. Bistability has however been shown in experiments of differentiating
Xenopus oocytes [246, 269], during immune responses [270], cellular differentiation
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[271, 272] and the MAPK pathway [246, 273]. A requirement for bistable behavior is
that the signaling cascade displays sensitivity amplification along the feedback loop
(box 4).
Theoretical analyses suggest that bistability can also arise in signaling networks via
other mechanisms. For instance, double-phosphorylation of signaling proteins, such
as of MEK and ERK in MAPK cascade, can bring about bistability even in the absence
of feedback loops or cascade interactions [250]. Legewie and coworkers reported
that complex formation in signaling cascades, for instance via scaffolds, can cause
bistability [274]. One of the uses of mathematical models is therefore to explore the
capabilities of signaling networks and then design targeted experiments that either
validate or falsify model predictions.
Applications of quantitative, single-cell-based assays of signaling dynamics, e.g. us-
ing fluorescence methods, will undoubtedly lead to more cases of bistability and os-
cillations of signaling networks. With cell-population based methods those behaviors
can generally not be observed.
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Figure 5.5: Illustration of bistability. Positive feedback in a system can cause it become bistable. A
bistable system can be in one out of two stable states, represented as two valleys in a hilly surface.
The state is represented in this analogy by the position of the ball. A separating tipping-point –
a metastable state – exists that separates the two stable states. When the system resides in the
metastable state, fluctuations can cause the system to end up in stable state 1 or 2. Parameter changes,
e.g. transcription rate, alter the shape of the surface, such that the number of stable states can vary
from 1 to 2 to 1 (left figure). Depending on the direction of parameter changes (from low to high or
the reverse), the system switches between stable states at different points. This phenomenon is called
hysteresis.
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5.9 Experimental observations of bistability and oscilla-
tions require single-cell approaches
The complication of studying dynamic features of signaling networks is that cell-
population studies are not always reflective of the dynamic behavior of single cells.
Since cells do generally not function in exact synchrony, oscillations may not be
visible at the level of a population of cells, only at the single-cell level. Likewise,
subpopulations that arise during bistability are not visible from cell population
studies. Single-cell studies, using for instance fluorescent protein based methods, are
therefore required to study dynamics of signaling circuits. For instance, studies of
NFκB, intracellular Ca2+ and ERK oscillations and of bistability, during signaling and
cellular differentiation, relied on fluorescent reporters [259–261, 275, 276].
Single-cell studies also indicate that isogenic cells, with the same cultivation history,
display fluctuations in the level of signaling proteins, likely arising from stochastic
events during transcription and cell division [181, 275–277], which can be understood
from basic biophysics [278]. This phenomenon has been termed ‘noise’ [277]. Feed-
backs in networks can both reduce and enhance noise. A consequence of noise is that
cells can vary in their individual responses to physiological triggers [180], including
drugs [181]. Kempe et al. [279] have quantified the variability of transcript level in
human cells and showed that transcript-number variabilities between cells derive
from differences in cell volume and stochasticity at the level of transcription. Noise
is not only an undesirable feature of molecular systems that scrambles information
transfer, it is functional as well. It is, for instance, intimately linked to bistability giv-
ing rise to subpopulations during cellular differentiation [280].
5.10 Fold-change detection by networks compensates
for stochastic fluctuations in protein levels
Due to inevitable fluctuations in molecular activities [281, 282], cells exploit regulatory
circuitry to reduce the harmful impacts of noise, occurring in signal transduction and
transcription [283, 284]. In this way, cells increase the reliability of information transfer
in signaling networks [285]. Negative feedback is an example of a noise-reduction
mechanism [286].
Another mechanism for noise reduction is fold-change detection (box 6). Networks
that detect fold changes have the same dynamics upon the same fold change in the
stimulus, regardless of its basal level [287]; this is visualized in figure 5.6. An (inco-
herent) feedforward loop in a signaling network gives rise to fold-change detection
[287], as well as other network motifs [288]. Fold-change detection has been reported
for mammalian signaling [275, 287]. For instance, Cohen-Saidon and co-workers
[275] studied the dynamics of nuclear ERK2 upon EGF stimulation using a
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genetically-encoded, YFP-tagged ERK2 in single cells. They found that ERK levels in
the nucleus differed greatly from cell to cell, but the fold changes of individual cells,
upon EGF addition, was a much more homogeneous. In addition, the fold-changes
returned to basal levels after a transient period, indicating exact adaptation. All these
phenomena can be understood from a simple mathematical model of an
incoherent-feedforward loop network [275, 287].
Hart et al. [289] studied the integration of two different stimuli by fold-change
detecting systems, using mathematical models. They used Monod-Wyman-Changeux-
based models of receptors associated with bacterial chemotaxis. These models are
also applicable to GPCRs (box 2) and it is therefore tempting to speculate that some
GPCRs may have fold-change detecting properties as well.
These studies indicate the operation of some signaling systems should not be appreci-
ated in terms of absolute concentrations of signaling proteins, but rather in terms of
fold changes in concentrations of active signaling proteins. Again a system concept,
originating from engineering in this case, proves a useful concept for the quantitative
study of signaling networks.
Box 6: Fold change detection by a molecular activation cascade. A simple model of a
feedforward motif illustrates the principle of fold change detection [287]. We consider a system
with the signal S and two signaling proteins X and Y, their concentrations change according to,
d
dt
x = k1s− k2x
d
dt
y = k3
s
x
− k4y. (5.13)
S therefore ‘feeds forward’, it directly activates X and Y and it activates Y indirectly via X. At
steady state, when the concentration of the signal S equals s, the concentration of X and Y are:
xs = k1sk2 and ys =
k2k3
k1k4
. Note that a change in s does not affect ys, y therefore displays ‘exact
adaptation’; the influence that s has on the synthesis rate of Y is compensated for by x. To
show that this system is capable of fold-change detection, we normalise the concentration with
respect to their basal, steady-state levels at reference concentration s,
Fs =
s¯
s
, Fx =
x
xs
, Fy =
y
ys
, (5.14)
with s¯ as the new value of s, applied when the system is at a steady state at the basal value, s,
when x = xs and y = ys. The dynamics of the fold changes in the concentration becomes,
d
dτ
Fx = Fs − Fx
k2
k4
d
dτ
Fy =
Fs
Fx
− Fy (5.15)
with τ = k2t. The fact that the concentration dynamics can be rewritten in terms of fold changes
indicates that the basal steady-state concentrations, at which the change in s is applied, do
not matter. The same fold change in s always give the same fold change in x and y regardless
of the basal levels xs and ys. The system therefore responds to fold changes rather than to
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absolute changes in concentrations. This system is therefore robust to undesired distorting
changes in basal concentrations, as they do not affect signaling outcome as long as the outcome
is considered normalized to the basal concentrations.
5.11 Outlook: appreciating how a GPCR plays a role in
the decision making machinery of a cell
Presently, we understand the basic principles of how single GPCRs integrate signals
and activate intracellular proteins in a biased, signal-combination dependent manner.
Combination of new techniques, such as G-protein FRET-sensors, structural methods
and mutant screens, will undoubtedly give deeper insights into single GPCR func-
tioning in the near future.
Systems-biology studies of signaling networks are indicating that the signaling does
not stop at the cell-surface receptors, much of the cellular signaling-capacities derive
from those networks. Activation/inactivation cycles of proteins, signaling cascades
and interwoven feedback and feedforward circuitry leads to counterintuitive, func-
tional signaling-dynamics that is best understood with mathematical models and
single-cell experiments. We therefore expect that the next developments in the
GPCR-field will move towards quantitative single-cell studies on the signaling conse-
quences of biased GPCR activation, using mathematical models for hypothesis
generation and data integration. Such studies can elucidate the interplay between the
receptors and the signal transduction machineries of the cell, this knowledge is of
great value for medical applications (as e.g. proposed by [268]).
In this review, we gave a glimpse of results obtained by systems biology of cellular
signaling. We discussed various network motifs of signaling pathways that have been
investigated with respect to their potential effects on signal outputs. For example,
we illustrated how ultra sensitivity arises and can result from cascade sensivity-
amplification. An important aspect was how feedbacks shapes signaling functions
in a cell, including oscillations and robustness. We emphasise that many of these
network-centered studies do not yet focus on GPCRs, even though those proteins
are often the network inputs. Thus, we hope that future studies will investigate
GPCR-signaling with systems approaches.
As more and more knowledge is gained about the crosstalk between membrane
receptors and their induced signaling pathways [290], we are forced to envision
signaling not as separated pathways, but as a network. A single receptor may then
play only a minor role in setting the behavior of the whole cell, rather it may be
that signal-integration by different receptors and intracellular wiring of protein-
protein interactions is decisive. This view of signal transduction has great potential
for the design and application of new (multi-target) therapeutics. The approach to
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combine mathematical models and to validate their predictions with experimental
data will enable new insights into the mechanisms of signal transduction and promises
innovative clinical applications.
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Figure 5.6: A network with an incoherent feed-forward loop can give rise to fold-change detec-
tion. Two identical fold-changes in the signal X, applied at two different of basal levels, give rise
to basal-level dependent dynamics of Y, whereas the dynamics of Z is basal-state independent (the
dashed and full lines overlap). Z therefore detects fold changes in X.
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CHAPTER6
General Discussion
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6.1 Multiplex signaling: is it the receptor, the network or
both?
How are cells able to discriminate and integrate the multitude of signals that they re-
ceive via their membrane receptors? Is this mostly done by the receptor themselves?
And, if so, how do receptors achieve signal integration (biased signaling)? Which
biochemical mechanisms lead to these phenomena? Or is the downstream signaling
network the major driver of signal integration, and do receptors only play a minor
role? Only by directly measuring signaling bias introduced by a receptor and com-
paring this to the bias that is observed at downstream signaling we can answer those
questions.
The central aim of this thesis is to investigate how and whether ligand bias occurs
at the receptor level, at the onset of cellular signaling when a GPCR activates a het-
erotrimeric G protein, the first cytosolic signal transduction event. I investigated this
research question using theoretical concepts and advanced fluorescence microscopy
techniques.
I first studied a conformation-equilibrium model of GPCRs (chapter 2) to address the
biochemical mechanism leading to receptor-level biased signaling. The model is an
extension of the concerted symmetry model of cooperative proteins introduced by
Monod, Wyman and Changeux. In our model, external signals induce two conforma-
tional changes. The first is a global conformation change, shifting the entire receptor
from an inactive to an active state. The second conformation change is a local confor-
mation change, involving conformation changes of the active state of the receptor;
such that multiple active conformations can co-occur, can shift in proportions, and ac-
tivate distinct intracellular signaling routes. The different active conformations are
differentially stabilized by different ligands. The model allows for the calculation of
the receptor fractions occurring in particular conformation states as function of the
ligand concentrations and ligand combinations. Biased signaling occurs when extra-
cellular ligands cause a shift in the ratios of active conformations. This is indeed what
we found. We therefore show that biochemistry allows for the occurrence of ligand
bias at the level of the receptor and that modifiers - for example, allosteric agonists -
can modulate the receptor bias. Several studies indicate this kind of conformational
flexibility of GPCRs [36, 70–73]. Improved structural methods, based on, for instance,
crystallography, will further extend our knowledge about the influence of orthosteric
and allosteric ligands on the receptor structure and its conformation equilibria[10,
291–293].
Additionally, I started experimental investigations. I focused on the human
glutamate-like, extracellular calcium sensing receptor, the CaSR. This receptor has a
surprisingly high capacity for multiplex signaling: it binds many external ligands,
both at orthosteric and allosteric sites and it is coupled to multiple intracellular
signaling pathways. CaSR is expressed in various tissues, performs different physio-
logical functions and seems to play divergent roles in cancer development [50]. I
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investigated the biasing effect of different agonists on CaSR-induced Gαq activation
(chapter 3). This study showed that time-resolved CaSR activity can be monitored by
a Gq FRET sensor in single cells. Thereby, we found similarities of the agonists’ ki-
netic properties described in the literature for downstream signaling [58, 59, 63, 168].
These similarities indirectly indicate a close coupling of Gαq activity with calcium mo-
bilization. We also observed differences in Gαq activity after stimulation with
polyamines compared to studies of calcium mobilization [174], indicating the ampli-
fying role of the signaling network. Based on our findings, I conclude that ligand bias
is partially established at the receptor level, and that the downstream signaling
network can modulate signaling biases occurring at the onset of cellular signaling.
My findings on partial ligand bias of the receptor are further supported by my second
set of experiments where I measured the simultaneous activation of Gαq activity and
the mobilization of intracellular calcium, (Ca2+)i upon CaSR activation (chapter 4).
Those measurements show for the first time the co-activation of two CaSR signaling
read-outs at different levels of the signaling cascade and in single cells. By taking the
following perspective,
signal(-s) CASR−−−→ Gq activation downstream signaling−−−−−−−−−−−−→ (Ca2+)i mobilization,
which I translate into a slight more abstract, generally-applicable, picture,
s
R(·)−−→ R(s) N(·)−−→ N(R(s)),
with ‘R(·)’ and ‘N(·)’ respectively denoting the receptor and network effects. Clearly,
if the network output, N, always has the same value for the same value of R then
downstream signaling is signal independent and biased signaling caused by network
effects does not occur. Plotting the (Ca2+)i vs Gαq for different signal combination of
the CaSR can therefore indicate the occurrence of network bias. If these plots vary
with the signal combinations then network bias occurs. Indications of such a
ligand-dependent variation have been observed in my co-activation study.
We expected to observe phenylalanine (PHE) as a signaling modifier of the Gαq
activity, as this impact of PHE has been already described on the basis of its effects on
intracellular calcium oscillations [57, 65, 164, 165, 179]. We did not detect significant
changes of Gαq activity upon PHE administration, when compared to stimulation
with (Ca2+)o alone (chapter 3). We did, however, observe effects of PHE on (Ca2+)i
mobilization (chapter 4). Perhaps our method is not sensitive enough to detect minor
changes at the G protein activation level. On the other hand, phosphorylations of
T888 in the cytoplasmic tail of the CaSR by PKC are known to be key regulators
of (Ca2+)i oscillations [63, 64]. Conformational changes of the CaSR induced by
amino acid binding might therefore alter the binding affinity of the kinase and/or
phosphatase and thereby additionally regulate (Ca2+)i dynamics, while G protein
activation remains unaffected. These observations further reinforce the importance of
the signaling network downstream of receptor activation.
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A better understanding of the mechanisms that lead to ligand bias will improve
the design of biasing ligands and help to develop improved drugs. Integration of
biological knowledge and experimental data with mathematical models should allow
for more mechanistic insights into how signaling network contribute to dynamic,
biased signaling. For signal transduction, many properties of recurrent network
motifs in signaling have been worked out theoretically and several of those have been
verified by experimentals (chapter 5). Regrettably, most of those studies focus on
signaling mechanisms associated with receptor tyrosine kinases [268, 294–298]. As
more and more (quantitative) data becomes available also in the GPCR field, systems
biology will provide a valuable tool to understand the highly dynamic processes of
signal transduction initiated by GPCRs.
6.2 Receptors are networks
The results presented in my thesis indicate that the receptor and the downstream
signaling network both contribute to biased signaling. The downstream signaling
network can amplify, attenuate or even shift biases that arise at the onset of signaling,
at the receptor level. In order to exploit and affect the occurrence of ligand bias in
clinical applications, both sources of bias need to be investigated.
Network interventions, in order to achieve for instance a change in biased signaling,
are particularly hard to predict. Blocking of a signaling route, due to a mutation or
the application of a drug, might, for instance, not result in the complete silencing of
this signal but can often be bypassed, due to the flexibility within a signaling network
as demonstrated by Klinger and coworkers [268].
Network approaches are possible, as we have nowadays a fairly good knowledge
of signaling pathways represented in form of network diagrams. We do not have
such representations for the allosteric interactions between binding sites on receptors,
even though those interactions underlie biased signaling by the receptor. Having
such a ‘network perspective’ on the functioning of GPCRs would be highly useful,
in addition it maps directly on the conformation-equilibrium model that I presented
in this thesis. A unified network-diagram of allosteric ligand-ligand interactions
would also allow for a concise summary of experimental knowledge on ligand-ligand
interactions and the localization of their binding sites in the 3D structure of the
protein. The same diagram building blocks could be used for different receptors to
unify the field and facilitate the exchange of information between scientists working
on different receptors. A similar endeavor for the depiction of metabolic, signaling,
and gene network has proven to be really useful in systems biology [299]. I will
shortly introduce my current ideas about such an approach.
Ligand effects on a single receptor can be summarized in a so-called "Black Box"
representation in which specifics about the signaling input, i.e. the ligand or combina-
tions of ligands, and the signaling output, i.e. the measured read-out, are
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summarized. This is visualized for some CaSR-specific ligands in figure 6.1. From
this knowledge, a graphical, more-mechanistic representation of established or pre-
dicted allosteric ligand-ligand interactions can be derived and depicted in "Grey Box"
diagrams (see figure 6.2 for illustration).
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dependency of Ca2+o [14]
PHE neutral; EC50 ~ 3.3 mM [1]
positive; transient oscillations with 
frequency ~1 per min [10]; left-shift 
of dose-response curve in presence 
of L-PHE [12]
positive, but small effect [11]
CaSR-ligand interactions
Figure 6.1: Examples of ligand combinations and their resulting signaling outputs exemplarily
for the CaSR. All knowledge about ligand combinations and their signaling effects for a specific
receptor can be represented in so-called "black boxes". The primary ligands are listed in the top row,
describing orthosteric ligands or ligands that were in the focus of a particular study, e.g. (Ca2+)o or
spermine in my titration experiments. Secondary ligands, that describe modifiers which were added
in addition to the main, primary stimulus, are listed in the left column. In this black box, the effects
of ligand-ligand interactions are summarized for three CaSR-signaling read-outs, Gαq activation,
(Ca2+)i mobilization and ERK phosphorylation. The corresponding references are indicated in the
table as numbers in squared brackets and listed below the table. The table can be extended for both
primary and secondary ligands, as well as signaling outputs.
Researchers from different fields have a different focus on the same receptor. While
a crystallographer sees the receptor from a structural perspective with focus on
the position and orientation of amino acids, molecular biologists or physiologists
are rather interested in the signaling of an active receptor and its outcome, and all
possible nuances in between. In the "Grey Box" approach, we distinguish between a
(extracellular) signal input level, which can also be shared between different domains
of the receptor (e.g. the Venus Flytrap and the transmembrane domain of glutamate-
like GPCRs) and a signal transduction level, at which the intracellular binding proteins
are activated by the receptor. Binding sites on both domains can have influence on
the information transduction of the receptor, usually measured with experimental
read-outs at the network/ signal output level (grey frame). From experiments it
is known that the combination of different binding partners influences their effect
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on the signaling capacity of the receptor, represented with arrowheads (activating,
positive influence) and bar headed arrows (inhibiting, negative effects). This general,
mechanistic representation of a GPCR can act as a summary of the known effects of
different ligands on the receptor and its underlying signaling network. Therefore, it
can be easily understood and exchanged between scientists of different fields.
In this way, a comprehensive overview of how (allosteric) ligands interact on a GPCR
and influence the signaling outcome can established. I think that this method is a
flexible and informative method that can be easily adjusted for different types of
receptors, and simplifies the exchange of knowledge between different receptor fields.
receptor function structure signaling
signal output
(protein modification,
gene regulation,
hormone secretion etc.)
domain 1 domain 2
RECEPTORRECEPTOR
domain 1 domain 2
P
signal 
transduction level
(intracellular molecule 
binding sites,
 e.g. G proteins, β-Arrestins)
signal
input level
(orthosteric and allosteric
 ligand binding sites) 
signalling network /
output level
P
cellular/physiologic perspectivereceptor perspective
Figure 6.2: Schematic overview of the ‘grey box’-approach. In this approach, three functional levels
of receptor and receptor signaling are distinguished: 1) The (extracellular) signal input level, possibly
shared between different domains of the receptor and depicted in blue. 2) The signal transduction
level, depicted in green.This is the interface between receptor and the signal transduction molecules.
3) In the gray box, the network / signal output level. Usually, experimental read-outs are obtained
at this level. This mechanistic representation of a GPCR summarizes the known effects of different
ligands and facilitate the exchange of knowledge between scientists of different fields. Chrystal
structure: human metabotropic glutamate receptor, adapted from [10].
6.3 The influence of the cellular context and
post-translational modifications on biased
signaling
We tend to think of information flow as directing from the outside to the inside of the
cell, as depicted in figure 1.1. In this view, it is indeed logical to decompose biased
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signaling into two independent components, the receptor and network contribution,
as they occur in sequence. However, a reverse flow has to be appreciated as well as
the network can affect the signaling characteristics of the receptor. Accordingly, the
receptor should be considered as a conduit [79] as intracellular molecules or processes
can alter receptor conformations and modify receptor-level biased signaling. Such a
‘biasing from inside’ has been shown for synthetic molecules acting on the intracellular
loops of GPCRs [86]. Further, the binding of intracellular adaptor molecules, besides
heterotrimeric G proteins and β-arrestins, might ‘prime’ the receptor for certain
extracellular agonists, by altering the ligand binding affinities. As a consequence, the
ligand-specificity and biasing-capacity of a receptor becomes cell-context dependent.
The same receptor can therefore induce different responses to the same signals in
different cells.
An extended version of the conformation-equilibrium model that I presented in
chapter 2 indeed indicates that biasing from the inside is a realistic possibility (un-
published results)∗. This we were able to show by incorporating the intracellular
binding of modulators to active receptor states. We included those binding effects in
the partition function, which ultimately determines all the distinct receptor fractions,
as presented for the monomeric partition function in equation 6.1.
zi,j = 1+
S
K1,i,j
+
S
K2,i,j
+
S2
αi,jK1,i,jK2,i,j
+
A
KA
S
αAK1,i,j
+
A
KA
S
αAK2,i,j
+
A
KAαA
S2
αi,jK1,i,jK2,i,j
(6.1)
with S being the ligand concentration, A being the adaptor concentration, KA, K1,i,j
and K2,i,j are the adaptor’s and binding sites’ dissociation constants, i = {r, t}, and
j = {1, 2}. αi,j and αA represent the effect of allosteric interaction between the
ligand binding sites and the adaptor, respectively. The investigation of this extended
model has shown that adaptors can (de-)sensitize the receptor for external agonists
dramatically, and that the relative abundance of adaptor proteins biases the signaling
efficacy of a receptor.
The implication of the receptor as a conduit could explain the cell- and tissue speci-
ficity observed for GPCRs. The multifaceted signaling and expression as well as the
diverse roles in physiology and disease of the CaSR could therefore be due to tissue
specific intracellular binding partners, in addition to G proteins and β-arrestins. Reg-
ulatory proteins of the 14-3-3 family have been shown to interact with the CaSR and
modifying its signaling behavior [300] indicating the role of CaSR-binding proteins.
Nevertheless, the general role of adaptors on the receptors’ conformation and their
impact on cell-type specificity needs to be further investigated.
∗M. Slagter, Bidirectional information transfer through transduction mechanisms perceived unidirectional: a
paradigm shift. This work has been carried out as a master thesis in 2013 under the supervision of F.J.
Bruggeman and S. Roth.
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As briefly discussed earlier, phosphorylations are common post-translational modifi-
cations of GPCRs that have major impact on signaling [4]. The CaSR, for example,
contains multiple serine and threonine residues that are phosphorylated by PKC and
other GRKs. Mathematical models indicate that multisite phosphorylations of signal-
ing proteins can promote ultrasensitive responses to inputs [175]. Thus, in principle,
double phosphorylations of GPCRs can cause all-or-nothing responses, rather than
gradual responses, of receptors, causing them to function as true ON/OFF switches.
These effects have also been shown by an extension of the biophysical model of
GPCR-conformation equilibria (unpublished results).
All of this suggests that GPCRs should be perceived as sophisticated regulatory
proteins capable of bidirectional signaling by integrating intra- and extracellular
information and as dynamic bifurcating inputs of cellular signaling. We certainly
need more combined theoretical and experimental investigations to elucidate the full
signaling capacities of GPCRs.
6.4 Conclusions and future perspectives
In summary, this thesis has demonstrated how advanced experimental tools and
theoretical considerations help to elucidate the onset and propagation of ligand
biased signaling. These investigations are a first step towards a deeper understanding
of the roles of receptors and signaling networks in biased signal transduction. I expect
that real-time fluorescence-based microscopy techniques, such as FRET, will have a
major impact on GPCR research in general and in ligand bias research in particular.
I investigated the biasing effect of different CaSR agonists on only one family of
Gα proteins.To gain further insights into the onset of bias at the receptor-G protein
level, the – ideally simultaneous – measurements of different G proteins in response
to receptor stimulation are required. Tools to study this could comprise sensors
consisting of different FRET-pairs in order to observe the activity of two (or more) G
proteins simultaneously and to quantify biased signaling at its onset. Moreover, this
concept may lead to a deeper understanding of specific biasing properties of receptor-
ligand combinations and might result in the identification of general mechanisms
leading to bias.
The roles of receptor and networks can be further disentangled by the concurrent
use of optical sensors for different signaling processes. Our results on simultaneous
measurement of Gαq and (Ca2+)i demonstrate that this kind of experiments are in
principle possible. Nevertheless, this approach requires careful testing of crosstalk
and other influences of the fluorescent probes on each other. Further, heterologous
expression levels of the sensors might be critical and require careful regulation. Stable
cell lines expressing the sensors in well-defined ratios would be a next step in these
applications.
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Discussion
Real-time microscopy provides detailed information about the dynamics of distant
players in the signal transduction cascade. The additional consideration of spatial in-
formation on distinct signaling processes would provide further insight on the impor-
tance of spatiotemporal component of the onset and propagation of bias. I would pro-
pose to investigate signaling in single cells and focus on cell-type-specific signaling
properties of GPCRs, possibly with a focus on binding proteins and phosphorylation
to characterize cell-context dependent signaling. Analysis of the influence of recep-
tor phosphorylations on signaling could reveal their impact on signaling bias, and
verify whether switch-like responses are indeed properties of GPCRs as predicted
by models. Systems biology approaches should be applied in order to identify and
understand basic mechanisms of biased signal transduction. The combination of ex-
perimental findings and theory, as done already for receptor tyrosine kinase initiated
signaling, may lead to a deeper, network-level understanding of signaling processes
and enable the targeted design and application of biasing drugs.
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